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ABSTRACT 
 
Gene therapy is a promising therapeutic approach for the treatment of inherited and 
acquired genetic disorders. Gemini surfactants are an emerging class of cationic lipids that has 
shown promising results in delivering genetic materials, particularly to the skin. The unique 
structure of the gemini surfactants imparts a design flexibility that permit the modulation of their 
physicochemical properties toward the enhancement of transfection efficiency. The behavior of 
gemini surfactants in complex biological systems may ultimately determine their efficiency and 
cytotoxicity. Correlating the biodistribution and biological fate of the nanoparticles to their 
chemical structure and physicochemical properties will inform the rational design process, 
resulting in the production of compounds with higher efficiency and reduced toxicity. In this 
research, a series of 22 novel peptide-modified gemini surfactants was evaluated. The aim of my 
research is to elucidate their structure-activity relationship and to determine their skin penetration 
behaviour.  
Transfection efficiency and cytotoxicity of the compounds were evaluated in murine 
keratinocytes and African green monkey kidney fibroblast cell lines. Physicochemical and 
structural properties of the nanoparticles were examined. Results revealed that the highest 
transfection efficiency and lowest cytotoxicity were associated with 16-7N(G-K)-16 gemini 
surfactant, showing an 8-fold increase in gene expression and a 20% increase in cell viability 
compared to the first-generation unsubstituted gemini surfactants. Furthermore, assessment of 
the contribution of the alkyl tail, in terms of length and saturation, indicated that compounds with 
hexadecyl tails were 5-10 fold more efficient than compounds with dodecyl and oleyl tails. 
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To track the level of localization of the gemini surfactants in the skin, mass spectrometric 
analytical strategies were developed. The tandem mass spectrometric (MS/MS) dissociation 
behavior of the compounds was evaluated. Diagnostic product ions were selected for accurate 
identification of the gemini surfactants in complex biological matrices. Such knowledge was 
utilized to develop rapid and simple flow injection analysis (FIA)‐MS/MS method for the 
quantification of three peptide-modified gemini surfactants ex vivo in skin and phosphate 
buffered saline. Results showed a more than 11% deposition in the skin with minimum 
penetration into the saline compartment, suggesting the suitability of the delivery system to be 
used for topical application.  
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CHAPTER 1 
Literature Review 
1.1. Introduction 
Gene therapy holds a promising future for the treatment of many acquired and inherited 
diseases. It is defined as the insertion of exogenous genetic material (DNA, RNA, mRNA) into 
cells in order to supplement a new gene, repair a defective gene or block gene overexpression [1]. 
The induced changes could be either transient or permanent in the targeted cells or tissues. The 
idea of using genes to modulate biochemical pathways was first introduced by Rogers in 1968 
when genetic material was inserted into Turkish tobacco seed using Tobacco mosaic virus [2]. 
However, gene therapy was pioneered by Friedmann and Roblin when they described the 
possible use of viruses in transferring genes to humans in 1972 [3].  
One of the key challenges for gene therapy is the development of effective and safe 
carrier systems. Since Friedmann and Roblin’s initial work, the development of gene delivery 
systems has attracted a great deal of attention from many research groups. Two methods of gene 
delivery are currently available: viral and non-viral vectors. Viral vectors are more efficient in 
transferring genes to cells; it has resulted in a few marketed gene therapy products such as 
Gendicine™ used for the treatment of head and neck squamous cell carcinoma, Glybera® for 
lipoprotein lipase deficiency and  Imlygic® (talimogene laherparepvec) approved by the FDA 
for the treatment of melanoma [4-6]. However, viral gene therapy suffers from major inherent 
drawbacks. In particular, safety concerns have been raised due to their propensity to generate a 
severe immune response. In 1999, the tragic death of an 18-year-old patient during clinical trials 
was the result of a massive immune response after the administration of adenovirus vector that 
encoded for the ornithine transcarbamylase gene [7]. In addition, viral vectors could cause 
2 
 
carcinogenesis such as the development of T-cell leukaemia in two patients who participated in a 
retrovirus-based gene therapy clinical trial to treat X-linked severe combined immunodeficiency 
syndrome (X-SCID) [8]. The cause of the adverse effect was the insertion of the retroviral vector 
that led to the deregulation of LMO-2 gene expression which in turn triggered T-cell 
proliferation [9, 10]. Another limitation of viral vectors is that they usually have a fixed size capsid 
so they are limited in the size of genes that can be encapsulated [7]. Non-viral methods, on the 
other hand, have the potential to address many of these limitations. They are considered safer 
alternatives since they tend to have lower immunogenicity than viral vectors. In addition, they 
have relatively unlimited DNA packaging capacity and are typically easier to produce than viral 
vectors. Non-viral methods employ diverse systems such as cationic lipids and polymers to 
compact the therapeutic DNA into nano-sized lipoplexes and polyplexes, respectively.  
This review summarizes the different barriers that non-viral systems must overcome to 
efficiently deliver the genetic material into the targeted site. In addition, it underlines prominent 
non-viral gene delivery systems with a focus on the cationic lipid-based gene delivery vectors. 
Finally, it highlights the potential use of lipid-based nanocarriers for skin gene delivery.    
1.2. Barriers to non-viral gene delivery systems  
Non-viral gene delivery systems have emerged as a promising modality to address the 
limitations of viral gene delivery vectors, particularly safety [11]. However, the use of non-viral 
based strategies has poorly translated into clinical success mainly due to their lower efficiency in 
delivering the genetic material compared to viral vectors [12]. One of the greatest challenges that 
impede the success of non-viral vectors is the variety of extracellular and intracellular delivery 
barriers [13]. These barriers are essential components of the human defense system, which prevent 
the entrance of foreign materials. A deep understanding of the biological barriers is an essential 
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requirement for the design of effective vectors capable of overcoming these delivery hurdles. 
The following section describes the main biological barriers faced by the non-viral gene delivery 
approach and discusses potential strategies for circumventing each barrier.  
1.2.1. Extracellular barriers 
Extracellular barriers include all immunological and physical hurdles that face the 
delivery system from the site of administration until the arrival to the target cell. Thus, the type 
of extracellular barriers encountered by the delivery vectors mainly depends on the route of 
administration. For example, intravenously administered vectors encounter the 
reticuloendothelial system which could rapidly remove the delivery vehicle from the blood 
circulation [14, 15]. Design strategies such as the attachment of polyethylene glycol (PEG) to 
lipoplexes and polyplexes was adopted to shield the vector from the extracellular environment 
and prolong the circulation time [16, 17]. For example, intravenously administered lipoplexes 
grafted with 15-mol % PEG showed a higher blood circulating concentration after 6 hours of 
administration [16]. However, PEGylated lipoplexes exhibited significantly lower transfection 
efficiency compared to the unmodified lipoplexes [16]. This was attributed to the impaired 
membrane interaction and reduced cellular uptake that resulted from vectors PEGylation:  “PEG 
dilemma” [18, 19]. Several attempts have been made to overcome this dilemma including the 
incorporation of a ceramide moiety into the PEGylated vectors [20]. Ceramide-PEG-coated 
vectors preferentially lose their shielding material near the desired delivery target, thus, they 
prolong the circulation time without reducing the transfection efficiency [20].  
Another major rate-limiting step for intravenously administered delivery systems is the 
passage through the endothelium of the blood vessels. The endothelium is composed of a 
monolayer of endothelial cells separated by small interendothelial spaces [21]. The size of the 
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interendothelial spaces is largely affected by the endothelial layer disease condition [21]. For 
example, under certain pathological conditions such as inflammation or cancer, the size of the 
interendothelial spaces increases permitting the escape of nanoparticles from the blood vessels. 
In addition, the size of interendothelial gaps is influenced by their anatomical location within the 
body. For instance, interendothelial spaces of the brain blood capillaries are about hundred times 
smaller than those in the liver [22]. Such a variation could be utilized as a targeting strategy for 
specific organ or disease condition.  
Once the delivery vectors have escaped the blood vessels, they must navigate through the 
dense extracellular matrix of the interstitial space. The extracellular matrix is a dynamic and 
complex milieu composed of a network of collagen, proteoglycans, glycosaminoglycans and 
microfibrilar elastins [23]. Similar to the endothelium, the integrity of the tissue varies depending 
on the disease condition and the anatomical location[23, 24]. Optimizing the physicochemical 
properties of the delivery system including particle size and surface charge could improve the 
passage through the extracellular matrix. For example, particle size of less than 200 nm was 
reported to show effective tumor accumulation [25].    
1.2.2. Cellular uptake  
The cell membrane represents the first barrier at the cellular level that hinders gene 
transfer. Typically, the cell internalizes macromolecules from the surrounding media by 
endocytosis [26]. The association of naked DNA with the cellular membrane is usually very low 
due to the electrostatic repulsion between the relatively high negative charge density of both the 
DNA and the cell membrane. Positively charged non-viral gene delivery vehicles can circumvent 
this problem by inducing electrostatic interaction with the negatively charged constituents of the 
plasma membrane such as heparan sulfate, proteoglycans and integrins [26-28].  Several studies 
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suggested that optimizing the surface charge of the non- viral gene delivery complexes enhances 
the efficiency of cellular entry [29, 30]. However, mainly non-specific interaction with cytoplasmic 
membranes was achieved.  
Efforts have been made to achieve cell-specific gene delivery by incorporating targeting 
ligands into the delivery vehicle such as the addition of cell penetrating peptides, a “Trojan horse 
approach” [31]. These peptides consist of 5–40 amino acids that can bind to specific receptors on 
the cell membrane to induce receptor-mediated endocytosis which is believed to be a more 
efficient internalization pathway for targeted gene delivery [32]. Promising results were attained 
in utilizing peptides such as HIV-1 trans-activating transcriptional (TAT) protein and Drosophila 
homeobox protein Antennapedia in non-viral gene delivery systems [31].  
Furthermore, the incorporation of monoclonal antibodies into the delivery vector has 
been used to promote cell-specific gene delivery [33, 34]. For example, Chiu et al. showed that 
polyethylenimine polyplexes conjugated with monoclonal antibody specific to human epidermal 
growth factor receptor-2 (HER2) showed up to a 20-fold increase in the level of gene expression 
compared to the non-derivatized polyplexes in the HER2 overexpressing cells.  On the other 
hand, no significant difference was observed in the HER2 low-expressing cell line indicating the 
success of the targeting approach [33].  
It is noteworthy that despite the success of techniques such as the coupling of cell 
penetrating peptides or monoclonal antibodies to the delivery vector in vitro, nonselective in vivo 
penetration has caused safety concerns [35]. Current focus is on the development of “smart” 
strategies to overcome such a problem [36].  
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1.2.3. Endosomal escape 
Once inside the cell, the DNA must escape from the endosomes to avoid lysosomal 
degradation [37]. As such, the ability of the delivery vectors to escape from the endosomal 
compartments is an essential characteristic of efficient gene delivery systems. Different escape 
mechanisms have been suggested including direct or induced endosomal membrane rupture [38]. 
Direct endosomal membrane disruption typically occurs as a result of the electrostatic 
interactions between the anionic endosomal lipid membrane and the positively charged gene 
carrier [39, 40]. 
Several strategies have been adopted to facilitate the release of the DNA from the 
endosomal compartments. For instance,  the incorporation of the fusogenic lipid 1, 2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) exhibited promising results in facilitating the 
endosomal escape due to its ability to undergo phase transition from the bilayer to the inverted 
hexagonal phase (HII) 
[41, 42]. Another approach involves the use of cationic polymers such as 
polyethyleneimine to mediate the “proton sponge” mechanism [38, 43]. These polymers have a 
high buffering capacity owing to the presence of several amino nitrogen groups that can undergo 
protonation upon endosomal acidification [43].  Protonation induces an extensive influx of ions 
into the endosomal compartments resulting in osmotic swelling and rupture of the endosomal 
membrane [43].  
Finally, the incorporation of pore-forming peptides is considered a common strategy to 
facilitate the release of DNA. Examples of these peptides are GALA and KALA; amphipathic 
peptides that were designed to mimic the membrane penetrating activity of viruses [44, 45]. They 
undergo conformational changes from a random coil to α-helix structure as a function of pH 
reduction, resulting in endosomal membrane disruption. Another common example is melittin, a 
7 
 
small cationic endosomolytic peptide that represents a major component of bee venom [46]. 
Melittin’s α-helix structure interacts with the lipid membrane forming toroidal pores [47]. In fact, 
the incorporation of melittin into a polyethyleneimine delivery system showed up to a 700-fold 
increase in the level of luciferase gene transfer [46]. Unfortunately, the cytotoxicity profile of the 
pore-forming peptides has limited the translation of such a methodology for in vivo applications 
[48].     
1.2.4. Nuclear localization 
For successful gene expression, transport of the DNA into the nucleus is required in order 
to allow access to the transcriptional machinery. The nuclear envelope represents the most 
formidable barrier for non-viral gene delivery. In fact, a study suggested that less than 1% of the 
DNA injected into the cytoplasm was able to reach the nucleus [49]. The passage of the DNA 
across the nuclear envelope is believed to take place through three possible routes: i) passive 
entry during mitosis, ii) passive diffusion through nuclear pores and iii) active traverse across the 
nuclear membrane [50].  
During mitosis, DNA can passively move into the nucleus due to the broken nuclear 
envelope. Thus, rapidly dividing cells are generally easier to transfect than quiescent cells [51]. 
Such attributes could be utilized as a targeting strategy for specific disease conditions like 
cancer. In fact, there are more than 1,415 ongoing clinical trials worldwide that are investigating 
the potential of cancer gene therapy [52]. Only small macromolecules with particle size of less 
than 50 kDa (∼9 nm) can passively diffuse through the nuclear membrane, however, larger 
macromolecules containing nuclear localization signal (NLS) can cross via active translocation 
[53, 54].  
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NLS is a targeting sequence consisting of a short chain of positively charged basic amino 
acids such as lysines or arginines that enables nuclear entry by interacting with surface proteins 
namely importin-α and importin-β [55]. Incorporating NLS into the genetic material or the carriers 
has been successfully used as a strategy to improve the nuclear import of non-viral gene delivery 
systems [56, 57]. Nevertheless, the NLS approach suffers from limitations, particularly the 
possibility of burying their localized signal in the therapeutic DNA due to their electrostatic 
interaction with the negatively charged phosphate groups [58]. In addition, successful outcomes 
were attained with linear DNA but not circular pDNA which is a better vector for sustained gene 
expression [58, 59]. New generations of specific NLSs are needed to lift this barrier in the 
development of efficient non-viral gene delivery vectors.  
1.3. Non-viral gene delivery systems 
1.3.1. Naked DNA 
The introduction of naked DNA into cells is considered the simplest and the safest non-
viral gene delivery method. The first in vivo study to transfer genes dates back to the 1990s when 
Jon A. Wolff et al directly injected plasmid DNA into mouse skeletal muscle [60]. Though the 
main purpose of the study was to evaluate cationic lipids as delivery agents, the level of gene 
expression without a vector was sufficient to consider direct injection for genetic vaccination [60]. 
Following that a series of experiments were conducted targeting different tissues such as skin, 
liver, kidney, lung and heart [61-64]. Successful attempts to directly inject naked DNA to the 
tumours in order to express antigens (cancer vaccine) were also reported [65]. Currently there are 
about 18 % of all clinical trials worldwide that utilize naked DNA [52]. DNA direct injection 
method yields high gene expression within tissues that is easily accessible, such as skin and 
muscles cells. The method of injection could determine the level of gene expression. Levy et al. 
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detected 200-fold higher gene expression with the use of an injection guided by intense 
illumination along the longitudinal axis of the mouse quadriceps muscle and parallel to the 
myofibers than with a perpendicular injection[66]. 
  Systemic injection of plasmid DNA showed a much lower level of gene expression 
compared to the viral or liposomal vectors [67, 68]. This is mainly due to the fact that naked DNA 
is more susceptible to degradation than encapsulated DNA. Unprotected DNA is degraded 
rapidly by the serum and the cytoplasmic nucleases which makes the technique not as effective 
for systemic applications as for targeting specific tissues[68]. The low level of gene expression 
and the need for a large amount of DNA are the main limitations for the use of naked DNA for 
gene therapy. To overcome these limitations, various physical methods such as electroporation, 
particle bombardment (gene gun), ultrasound induced pores (sonophoresis), magnetic field 
assisted transfection (magnetofection), and microinjection have been utilized to shuttle naked 
DNA into cells [69]. These methods circumvent extracellular and intracellular biological barriers 
and facilitate the transfer of genes leading to significant improvements in the delivery process 
(enhance the rate and the extent of gene delivery to targeted cells). However, the main drawback 
to all the physical methods is that they cause damage to the cell membrane. In addition, their 
efficiency in delivering genetic materials is still not adequate [69].  
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1.3.2. Lipid-based gene delivery system  
Lipid-based drug delivery systems have received increasing attention because of their 
ability to deliver a wide variety of drugs ranging from small molecules to biotechnology 
products. The idea of using lipids as a carrier for genetic materials was first proposed by Felgner 
and his colleagues in 1987 when they used N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA) and 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine 
(DOPE) to perform a DNA-transfection protocol [70]. Since that time, various generations of 
cationic lipids have been developed resulting in significant improvements in the in vitro and in 
vivo transgene delivery [71-73]. 
Cationic lipids are self-assembling amphiphilic compounds that possess two essential 
characteristics for gene delivery. Firstly, they have a cationic head group that interacts with the 
DNA’s anionic phosphate group condensing the DNA and shielding it from degradation by 
nucleases. Secondly, they have a lipid moiety as a fusogenic group that can facilitate penetration 
into the cell. Cationic lipids are responsible for the overall net positive charge of the lipoplex, 
which in turn will create an electrostatic interaction with the negative charge of the cell surface. 
Based on the chemical structure of the cationic head group, cationic lipids could be classified 
into the following categories: quaternary ammonium salt lipids, lipopolyamines, amidinium and 
guanidinium salt lipids and heterocyclic cationic lipids[71].  
A) Quaternary ammonium salt-based lipids 
Cationic lipids bearing quaternary ammonium are, by far, the most-studied class of 
cationic lipids. DOTMA (2,3-dioleyloxypropyl-1-trimethylammonium bromide) (Table 1.1) was 
the first compound in this family reported in Felgner's seminal paper [70]. Following that, a wide 
variety of structural modifications to the first compound increased exponentially resulting in 
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compounds that have higher transfection efficiency and/or lower toxicity. For example, 
replacement of the ether linkage with an ester linkage resulted in the formation of the 
biodegradable compound DOTAP (2-dioleoyl-3-trimethylammonium-propane) (Table 1.1) [74]. 
Furthermore, the replacement of the methyl group in DOTMA and DOTAP with a hydroxyethyl 
group producing DORIE (1,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide) and DORI 
(1,2-dioleoyloxypropyl-3-dimethyl-hydroxyethyl ammonium chloride) respectively, led to an 
improved transfection profile (Table 1.1) [75]. This indicates that the hydroxyl moiety plays an 
important role in the compound’s activity. Two mechanisms were proposed: 1) the hydroxyl 
group will form hydrogen bonds with DNA or the cellular membrane which will lead to a better 
compaction and subsequently better delivery process and 2) when the hydroxyl group forms 
hydrogen bonds with the cellular membrane and/or the DNA, the compounds containing the 
hydroxyl group remain in contact with the aqueous phase, maintaining the integrity of the bilayer 
structure and the stability of the complexes [75].  
In vitro transfection studies with COS-7 cells  showed that DORIE has a higher 
transfection efficiency than  DORI [75]. Felgner’s group conducted further structure activity 
relationship (SAR) studies on DORIE by modifying the alkyl tail length and the degree of 
unsaturation. DORIE (with C18:1 alkyl tails where C18:1= mono-unsaturated oleyl chain) was 
compared with compounds that have C14, C16 and C18 hydrophobic tails. 1,2-
dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE) (Table 1.1) , a 
C14 compound, was the most efficient [75]. It was suggested that the decreasing length of the 
alkyl chain was accompanied by reducing  phase transition temperature and bilayer stiffness 
which affects  both fusion with the cell membrane as well as endosomal escape; both of which 
are critical for effective gene transfer [75]. Due to  the high transfection efficiency and low 
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toxicity, DMRIE has been utilized in several clinical trials such as human basal cell carcinoma 
[76] , melanoma [77] and prostate cancer [78]; promising results were reported  in terms of 
efficiency and safety profile. Numerous other quaternary ammonium salt-based lipids were 
developed over the past three decades making this group the most widely used lipids in gene 
delivery. 
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Table 1.1. Chemical structure of quaternary ammonium salt-based lipids 
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B) Lipopolyamines 
The first attempt to introduce lipopolyamine compounds was pioneered by Behr, 
capitalizing on the ability of the naturally nucleus-occurring polyamines (spermine and 
spermidine) to efficiently compact DNA. Dioctadecyl-glycyl-carboxyspermine (DOGS) (Table 
1.2) was synthesized by attaching hydrophobic tails to spermine through a glycyl spacer [79, 80]. 
DOGS showed a high level of in vitro and in vivo gene expression without the use of a helper 
lipid [80]. Lipopolyamines are pro-cationic compounds (protonated at physiological pH), are more 
efficient than quaternary ammonium lipids in neutralizing the polyanionic phosphate backbone 
of the DNA resulting in better compaction [81]. Byk and his colleagues conducted an extensive 
SAR  evaluation by introducing step-by-step modification to the backbone of DOGS congeners 
[82]. The modifications included: using various geometrically differing polyamines; varying the 
geometry and the length of the linker; and changing the length of the lipid. Compound RPR-
120535 showed the highest transfection efficiency among the entire tested series (Table 1.2) [82]. 
RPR-120535 had a linear polar head group configuration which showed superior transfection 
efficiency to the branched, T-shaped and the globular head groups. Further investigations on this 
lead compound revealed that varying the length of the linker resulted in the same level of gene 
expression. However, varying the length of the hydrophobic tail showed that 18 carbon atoms 
was optimal for achieving the highest transfection efficiency compared to compounds with 12,13 
and 14 carbon atoms [82]. Enhanced transfection efficiency was justified by increasing the 
compound hydrophobicity, however, no conclusive explanation was provided [82]. 
The introduction of a class of lipopolyamines bearing a cholesterol moiety as a 
hydrophobic anchor was proposed by Gao et al introducing DC-Chol  (3B [N-(N', N'-
dirnethylaminoethane)-carbamoyl] cholesterol) (Table 1.2) [83]. DC-Chol was the first cationic 
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lipid to be used for clinical trials to treat cystic fibrosis [84]. In 1996 Lee et al introduced another 
polyamine cholesterol derivative named Lipid 67 (Table 1.2)  by connecting  cholesterol moiety 
to a spermine head group in a T-shape configuration [85]. Lipid 67 was tested in vivo for its ability 
to transfer a cystic fibrosis transmembrane conductance regulator (CFTR) cDNA as treatment of 
cystic fibrosis. The result showed that Lipid 67 was 100 times  more active than previously used 
cationic lipids [85]. A series of studies were conducted to optimize the safety and the stability of 
this lipid during aerosolisation [86, 87].  It was co-formulated with DOPE  to facilitate the 
endosomal escape of the genetic material and with a polyethylene glycol-containing lipid 
dimyristoyl phosphatidylethanolamine [(DMPE)-PEG5000] to stabilize the  formulation [86]. The 
administration of a single dose of this formulation with DNA encoding for CFTR to 35 patients 
suffering from cystic fibrosis during a phase I clinical trial was successful in achieving a high 
level of gene expression and restoring CFTR normal function [88-90]. More recently, a Phase II 
clinical trial has been launched to assess the safety and the efficacy of the lipid-mediated vector 
in multi-dose administration [91]. Lipopolyamines are more efficient in compacting DNA and 
their pH buffering ability facilitates the endosomal escape of DNA.  
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 Table 1.2. Chemical structure of Lipopolyamine 
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C) Amidinium and Guanidinium salts 
Instead of ammonium groups, this family of cationic lipids bears amidinium or 
guanidinum groups (Table 1.3). Amidinium or guanidinum groups possess several advantages 
over the amines. Firstly, they have a higher pKa, thus they protonate over a wide range of pH 
values. Secondly, they have higher affinity to bind to DNA because of their ability to form 
hydrogen bonds with the DNA phosphate group. Thirdly, they have good intrinsic 
biocompatibility [92]. Amidinium cationic lipids were first described by Ruysschaertet and his 
colleagues, when they introduced N-t-butyl-N’-tetradecyl-3-tetradecylaminopropionamidine 
(diC14-amidine) (Table 1.3) [93]. Transfection evaluation was conducted on Chinese hamster 
ovary cells and human erythroleukemic cells showing maximum gene level incorporation within 
the first hour of the treatment and low cytotoxicity was reported [93]. 
Lehn’s group was the first to introduce guanidinum cationic lipids, when they attached 
bis-guanidinium to cholesterol producing the two guanidinium-cholesterol derivatives BGTC, 
(3/3[N',N'-diguanidinoethyl-aminoethane) carbamoyl]cholesterol) and BGSC, (3P3[4N-(QN,8N-
diguanidino spermidine)-carbamoyl] cholesterol) (Table 1.3) [92]. A variety of mammalian cell 
lines were used to assess the transection efficiency of BGTC and BGSC, both compounds 
showed higher gene expression levels than Lipofectin®.  
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Table 1.3. Chemical structure of amidinium and guanidinium salt lipids. 
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D) Heterocyclic Cationic Lipids 
Heterocyclic cationic lipids have attracted the interest of several research groups since the 
type of the head group can profoundly affect the transfection efficiency. Different kinds of 
heterocyclic ring head groups have been utilized such as pyridinium [94-97], piperazine [98], 
morpholine [99] and imidazolinium [100]. However, compounds with pyridine, pyridinium head 
groups and their derivatives are the most widely used and their efficiency was comparable or 
even exceeds that of commercially available transfection agents [94-97]. Pyridinium cationic lipids 
were first introduced by Engberts and co-workers; they developed a series of compounds named 
synthetic amphiphile interaction (SAINT), (Table 1.4)  [94-97]. Intensive SAR assessment showed 
that SAINT with mono-unsaturated alkyl chains had transfection efficiency higher than that of 
the commercially available transfection agents [94].  
Another heterocyclic group is imidazolinium cationic lipids which were firstly discussed 
by Solodin et al.,  synthesizing three compounds that differ only in the length of the hydrophobic 
chains and the degree of unsaturation (C12, C14 and C18:1) [100]. Highest in vivo transfection 
efficiency was associated with the compound bearing the oleoyl chain, 1-[2-(9(Z)-
Octadecenoyloxy) ethyl]-2-(8(Z)-heptadecenyl)-3-(2-hydroxyethyl) midazolinium chloride 
(DOTIM), (Table 1.4). Currently, DOTIM is co-formulated with cholesterol and pDNA to be 
tested for its safety in a phase I clinical trial for the treatment of relapsed or refractory leukemia 
[101]. Heterocyclic cationic lipids in general show a potential of high transfection efficiency and 
low cytotoxicity due to delocalization of the positive charge on the aromatic ring that might 
improve the DNA compaction and facilitate endosomal escape.  
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Table 1.4. Chemical structure of Heterocyclic cationic lipids  
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1.3.3. Dicationic gemini surfactants  
The term “gemini surfactant” was coined by Menger in 1991 to describe a family of 
amphiphiles composed of two head groups (cationic, anionic, or neutral) and two hydrophobic 
tails covalently linked by a spacer (Figure 1.1) [102]. The unique molecular structure of gemini 
surfactants resulted in a number of superior properties compared to classical monomeric 
surfactants such as: 1) one or two orders of magnitude lower critical micelle concentrations 
(CMC) resulting in lower cytotoxicity, 2) lower Krafft temperature 3) higher efficiency in 
reducing surface tension and 4) enhanced wetting properties [102]. 
 
 
 
 
 
Figure 1.1. General structure of cationic gemini surfactant. 
Cationic gemini surfactants are of particular interest in gene therapy due to their ability to 
interact with the negatively charged phosphate groups of the nucleic acids through electrostatic 
interaction resulting in neutralizing, condensing and encapsulating the pDNA into nano-sized 
particles (Figure 1.2) [103]. The hydrophobic domains of the gemini surfactants, on the other hand, 
engage in cooperative hydrophobic interactions which stabilize the complexes during the 
delivery process [104]. Hydrogen and van der Waals interactions also participate in the 
condensation of the pDNA [104]. Neutral lipid vesicles, such as DOPE, is usually added to the 
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pDNA-gemini surfactant complexes due to its fusogenic properties, which facilitate cell 
penetration and endosomal escape (Figure 1.2) [42]. 
 
Figure 1.2. Schematic representation of the gemini surfactants-based gene delivery system 
shows the constituent part of the gemini surfactant-based lipoplexes. Cationic gemini surfactants 
interact with the negatively charged pDNA through electrostatic interaction and cooperative 
hydrophobic interaction of the alkyl tails. The complex is usually combined with a liposomal 
system such as DOPE to form lipoplexes. 
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The nature of the interaction between the nucleic acids and the gemini surfactants 
controls critical steps such as pDNA compaction and subsequent intracellular release [105]. The 
supramolecular arrangement of the gemini surfactants in a micellar dispersion will determine the 
structural arrangement of the pDNA-gemini surfactant complexes [106]. Gemini surfactants have 
the ability to self-assemble into a wide variety of aggregate structures depending on the 
proportion between the tail and head regions, depicted by the lipid packing parameter, P [107]. 
𝑃 = Ѵ/𝚊₀ɭ   
Where Ѵ is the volume of the hydrophobic chain, ɭ the length of the hydrophobic chain and 𝚊₀ is 
the surface area occupied by the head group. The P value gives an insight about the preferred 
curvature of the structure. For example an P value of 0.3 is typical for spherical micelle 
structure, a bilayer structure forms when P = 1, and P > 1 gives an inverted micellar organization 
[108]. Thus, P values can be rationally modified to form various aggregate structures by varying 
one or more of the following: 1) the head group size and valence, 2) the tail length and its degree 
of unsaturation, and 3) and the spacer length. 
1.3.3.1. Rational design 
Gemini surfactants’ unique structure offers virtually endless possibilities for structural 
modifications, allowing for a “fine-tuning” of their physicochemical characteristics which in turn 
can modulate transfection efficiency and cytotoxicity. Over the past quarter century, a large 
variety of gemini surfactants have been synthesized by combination of various head groups, 
spacer regions and hydrophobic domains. A detailed understanding of the role and impact of 
each structural modification is a fundamental step before any translation into clinical settings.  
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1.3.3.2.  Effect of head group and spacer 
The positively charged head group of the gemini surfactants is considered the main 
driving force for the electrostatic interaction with the negatively charged genetic material, which 
results in compacting the nucleic acid into nano-sized lipoplexes and shielding it from further 
degradation by enzymatic activity [108]. As such, the nature, size and charge density of the gemini 
surfactant head group greatly impacts the physicochemical characterization, toxicity and 
transfection efficiency of the delivery system [108-111].  
The spacer region of the gemini surfactants also plays a crucial role in determining the 
efficiency of the delivery system. It impacts the shape and size of the gemini surfactants 
affecting the self-assembly process and the CMC value [108-111]. In addition, the length and 
composition of the spacer greatly influence the binding of the gemini surfactant with the DNA 
[108-111]. The following section will briefly highlight the most commonly used cationic gemini 
surfactants’ head groups and spacer modifications, discussing their impact on the gene delivery 
process. 
A) Quaternary ammoniums head groups 
Cationic gemini surfactants bearing quaternary ammonium head groups are, by far, the 
most extensively studied class of gemini surfactants, mainly due to their ease of preparation and 
efficiency in compacting the genetic material [112]. They were first introduced in Menger’s 
seminal paper in 1991[102], after which a series of compounds have been synthesised and utilized 
in delivering genetic materials both in vitro and in vivo [109]. 
In our lab, we built on the basic structures of gemini surfactants with quaternary 
ammonium head groups and adopted a rational design approach by conducting component-by-
component testing, aimed at improving their ability to deliver DNA while minimizing toxicity. 
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The first generation is the cationic N, N-bis(dimethylalkyl)-α,ω-alkane-diammonium which is the 
simplest and the most frequently encountered family of gemini surfactants with the general 
formula [CmH2m+1(CH3)2N
+ (CH2)s N
+(CH3)2 CmH2m+1.2X
-], abbreviated as m-s-m, where m = the 
number of carbon atoms in the alkyl tails, s = the number of carbon atoms in the spacer and X = 
the counter ion (Table 1.5, group 1) [113, 114]. In the m-s-m family, modifications to the gemini 
surfactants' architecture by varying the length of the spacer (s = 2-16) induced significant 
differences in the level of the transfection efficiency. An in vitro transfection study in murine 
keratinocytes (PAM 212) revealed that compounds with s = 3 exhibited the highest level of gene 
expression and had a lower toxicity profile than the commercially available transfection agent, 
Lipofectamine PlusTM [113]. This was attributed to the distance between the two amine groups 
(0.49 nm) which is suitable for optimal electrostatic interactions with the two adjacent phosphate 
groups in the DNA backbone that have a distance of 0.34 nm [113]. Further elongation  in the 
spacer was accompanied by a decreasing trend in the transfection up to s = 8, after which the 
transfection efficiency increased gradually [113]. This was explained by the folding of the spacer 
into a U-shape as a function of spacer elongation resulting in a decrease in the distance between 
the two amine head groups especially with s = 12-16. In vivo topical application of the lead 
compound-based lipoplexes, 16-3-16, revealed a significant level of the transgene expression, 
demonstrating the promises of this family as effective non-viral gene delivery vectors [113, 115, 116].  
In light of the apparent importance of the distance between the two amine head groups in 
the interaction with the DNA, a second generation of gemini surfactants was proposed by 
inserting secondary or tertiary amine functional groups in the spacer region in an attempt to 
improve transfection. The gemini surfactants 12–7NH–12 ,12–7N(CH3)–12 , 12–5N(CH3)–12  
and 12-8N(CH3)-12 (Table 1.5, group 2) were evaluated in COS-7 cell-line 
[117]. Experimental 
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data showed that compounds with a three methylene (CH2- CH2- CH2) separation between 
adjacent nitrogen centers, such as 12–7NH–12 and 12–7N(CH3)–12 exhibited higher level of 
transfection compared to compounds separated with merely two methylene (CH2- CH2) moieties, 
12–5N(CH3)–12  and 12-8N(CH3)-12 [117]. The findings demonstrate the significance of optimal 
spacing between the nitrogen atoms within the spacer region [117]. In addition, 12–7NH–12 
exhibited higher level of gene expression with 9-fold increase compared to an unsubstituted 
gemini surfactant 12-3-12 and a 3-fold increase compared to the aza analog, 12–7N(CH3)–12. 
This was explained by the pH-dependent change in morphology arising from the protonated 
secondary amine functional group [117].   
In an attempt to enhance the transfection of the second generation gemini surfactants 
and reduce their cytotoxicity, a third generation of structures were designed in our laboratory, by 
coupling amino acids onto the N position of the spacer region of the 12-7NH-12 gemini 
surfactant [118]. Novel compounds with the general chemical formula C12H25(CH3)2N
+(CH2)3-
N(AA)-(CH2)3-N
+(CH3)2-C12H25 where AA= glycine, lysine, glycyl-lysine or, lysyl-lysine (Table 
1.5, group 3) were evaluated  in three different cell-lines, namely monkey kidney fibroblasts 
(COS-7), rabbit epithelial cells, and murine keratinocyte cells [118]. Results showed that the 
compounds substituted with either glycine or glycyl–lysine moieties had higher transfection 
efficiency compared to the unsubstituted compound, 12-7NH-12, in all the tested cell lines [118]. 
The insertion of amino acids provides additional terminal amino groups that contribute to: (i) 
enhanced binding to the cell membrane by forming additional hydrogen bonding, (ii) improved 
gemini surfactant-DNA electrostatic interactions due to the high pKa value of the terminal amines 
and (iii) induced liposomal fusion through a flip-flop mechanism due to the strong electrostatic 
interaction between the nanoparticles and the cell membrane [118, 119]. Additionally, cytotoxicity  
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of the third generation compounds was as low as the parent unsubstituted compound and 
significantly lower than commercial Lipofectamine PlusTM demonstrating the intrinsic 
biocompatibility of amino acids [119]. In order to assess their in vivo behavior, the glycyl-lysine 
substituted gemini surfactant-based lipoplexes was topically applied onto rabbit vaginal cavities, 
exhibiting higher transgene efficiency compared to the parent compound without visible toxicity 
[120].  
In order to capitalize on the potential of amino acid modified gemini surfactants as 
effective and safe gene delivery vectors, further modification to the third generation gemini 
surfactant structure is needed to augment their performance.  This research evaluates a new 
family of peptide-modified gemini surfactants having various structural modifications, hoping to 
establish a comprehensive structure-activity relationship. The long-term goal is to develop a 
model that could predict transfection efficiency of the gene delivery nanoparticles from the 
structural characterization/organization of these particles. This model might become a design 
tool for new delivery materials that have optimal delivery characteristics beyond existing gemini 
surfactants 
B)  Heterocyclic head group 
Heterocyclic chemical groups such as pyridinium, pyrolidinium and imidazolium were 
incorporated into the gemini surfactants as ‘softer’ charged systems than quaternary amines. This 
was attributed to the delocalization of the positive charge on several atoms of the heterocyclic 
head group [121]. As such, heterocyclic head groups can mediate for a balanced interaction with 
the nucleic acid accommodating for both processes of genetic material compaction and 
subsequent release [121, 122]. In addition, the lower charge density of the heterocyclic-based gemini 
surfactants minimized the repulsion between the adjacent gemini surfactants, resulting in lower 
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CMC compared to the ammonium-based gemini surfactants [121]. A low CMC value in gemini 
surfactants usually translates into higher transfection efficiency owing to the enhanced stability 
of the lipoplexes during the delivery process [123].  
Several generations of gemini surfactants with heterocyclic head-groups were introduced 
over the last two decades showing promising results [95, 121, 124, 125]. The impact of varying the 
spacer length on the transfection efficiency was more pronounced compared to the gemini 
surfactants bearing quaternary ammonium head groups. This was linked to the larger steric 
demand of the heterocyclic head groups relative to quaternary ammonium head groups. Engberts 
et al were the first to synthesize pyridinium gemini surfactants with four hydrophobic chains 
varying the length of the aliphatic spacer (s = 3, 4 and 5 ) (Table 1.5, group 4) [95]. Transfection 
studies conducted on the COS-7 cell-line revealed that the compound with spacing s = 4 
exhibited the highest transfection efficiency compared with the shorter s = 3 or longer s = 5 
spacers, however, no clear explanation was presented [95]. In another study, pyridinium cationic 
gemini surfactants having two aliphatic chains and various spacer lengths (s = 3, 4, 8 and 12) 
(Table 1.5, group 5) were evaluated in a human rhabdomyosarcoma cell line [124]. Similar to past 
observations [95], gemini surfactants with s = 4 exhibited the highest transfection efficiency 
among the tested compounds [124]. It was suggested that a spacer of 4 carbons allowed the 
compound to act like molecular tongs gripping the basic groups near each other, resulting in 
efficient compaction of the DNA [124].  
Unlike quaternary ammonium head group gemini surfactants,[117] the insertion of 
secondary amine functional groups in the spacer region did not translate into an increase in the 
transfection efficiency (Table 1.5, group 6) [126]. This was explained by the strong interaction 
with the DNA that impedes its release upon cellular entry. The authors tested this theory by 
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assessing the transfection activity of the gemini surfactants’ Boc-protected synthetic precursors 
(Table 1.5, group 7) [126]. Results supported the hypothesis revealing a five-fold increase in the 
transfection efficiency in the Boc-protected precursor-based lipoplexes [126].   
C) Glycosylated head groups 
The replacement of the head group region with acyclic carbohydrate moieties such as 
glucose and mannose resulted in the production of what is known as the sugar-based gemini 
surfactants [127]. Since sugars are nontoxic, biodegradable materials, less cytotoxicity is expected 
for sugar-based gemini surfactants.  In addition, some mono-carbohydrates, such as mannose and 
galactose have been used as a targeting ligand for specific tissues and cells. For example, 
mannose-containing lipoplexes were efficiently recognized by mannose receptors expressed in 
the liver and macrophages exhibiting higher gene expression both in vitro and in vivo [128].  
Engberts et al. were the first to synthesize sugar-based gemini surfactants and explore 
their structure activity relationship by examining the effects of the head group size, carbohydrate 
stereochemistry as well as the length and nature of the spacer region (Table 1.5, group 8) [129, 130]. 
Results suggested that neither variations in the head group nor the spacer significantly impacted 
the level of transfection efficiency [130]. However, the use of an aliphatic chain spacer was 
remarkably more toxic than the use of a more hydrophilic spacer such as ethylene oxide [130].  
Sugar-based gemini surfactants adopted a pH-dependent aggregation behavior in an 
endosome simulated environment [131-133]. Upon gradual acidification, sugar-based gemini 
surfactant lipoplexes exhibited different phase behaviors, namely lamellar phase and inverted 
hexagonal phase [131, 133]. Adopting such a phase transition can assist in the escape of the vector 
from the late endosomal compartment and the possible release of the DNA cargo.  
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D) Amino acids head groups 
The incorporation of amino acids into the gemini surfactant head groups was aimed at 
producing lipoamino acids mimicking compounds with biocompatible and biodegradable 
features [134, 135]. Both basic (e.g. lysine) and aromatic (e.g. serine) amino acids were successfully 
utilized in delivering genetic materials showing a reduced cytotoxicity [134-137]. In addition to the 
fact that amino acids are naturally-occurring non-toxic compounds, they possess multifunctional 
properties, such as the presence of a chiral center in the amino acid. The chirality induces 
changes in the molecular orientation, allowing the formation of a wide variety of aggregate 
structures [138]. Furthermore, amino acids are pH sensitive motifs that respond to the pH drop in 
the endosomal compartment resulting in the release of the encapsulated genetic material, 
resulting in higher transfection efficiency [139].  
Varying the spacer length and the nature of the amino acid head group-gemini surfactants 
did not translate into major differences in transfection efficiency.  For example, experimental 
data of gemini surfactants composed of two N-acyl-lysines linked through a di-amine spacer 
(Table 1.5, group 9) revealed no changes in the transfection efficiency upon changing the spacer 
length [134]. This could be attributed to the distance between the cationic charges and the spacer 
which led to a negligible role for the spacer (Table 1.5, group 9) [134].  
The nature of the linkage (amine, amide and ester) between the spacer and the head 
groups was also evaluated in a series of serine-based gemini surfactants (Table 1.5, group 10) 
[137]. Transfection studies exhibited contradicting results between the tested cell-lines: human 
embryonic kidney cells and human epithelial cervical carcinoma cell line, which prevent drawing 
a solid conclusion [137]. However, it was suggested that the C–O bond in the ester series made the 
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spacer more flexible which resulted in optimized interaction with the DNA and lowered 
cytotoxicity [137].  
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Table 1.5. Chemical structure of gemini surfactants used as gene delivery vectors  
 
1.  Quaternary 
ammonium 
gemini 
surfactants  
(1st generation) 
 
 
 
2.  Quaternary 
ammonium 
gemini 
surfactants  
(2nd 
generation) 
 
 
3. Quaternary 
ammonium 
gemini 
surfactants  
(3rd generation) 
N
+
N
+
N
CH3
CH3
CH3
CH3
CH3
CH3
R
R=  Glycine : 12-7N(Gly)-12
 Lycine: 12-7N(Lys)-12
 Histidine: 12-7N(His)-12
 Glycyl-Lysine: 12-7N(Gly-Lys)-12
 Lysyl-Lysine: 12-7N(Lys-Lys)-12
 Glycyl-Glycine: 12-7N(Gly-Gly)-12
 
4. Pyridinium 
gemini 
surfactants 
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5.  Pyridinium 
gemini 
surfactants 
 
6.  Pyridinium 
gemini 
surfactants 
 
7.  Pyridinium 
gemini 
surfactants 
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8. 
Carbohydrate 
based gemini 
surfactants  
 
9. Amino acid 
gemini 
surfactants  
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10. Amino acid 
gemini 
surfactants 
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1.3.3.3.  Effect of the hydrophobic tail  
The hydrophobic domain of gemini surfactants impacts their interactions with the 
hydrophobic domain of the DNA.  It also affects the aggregation behaviour, shape of the 
supramolecular assembly and membrane fluidity. The following section briefly explores the most 
common structural variation of the hydrophobic domain of gemini surfactants and their influence 
on biological activity.  
A) Aliphatic Tail length  
An aliphatic tail is, by far, the most widely used hydrophobic domain in gemini 
surfactant-based gene carriers. The length of the alkyl tail was found to significantly alter the 
physicochemical characteristics of gemini surfactants, affecting their efficacy to deliver the 
genetic material [113, 136, 140, 141]. Several studies have suggested that an increase in the tail length 
could be translated into superior transfection efficiency [136, 140]. Since the cooperative 
hydrophobic interaction between the tail groups plays a key role in the interaction with the 
nucleic acid, increasing the alkyl tail length (higher hydrophobicity) produced a stronger DNA 
interaction [142, 143]. In fact, Matulis et al revealed that the addition of a methylene group in the 
aliphatic lipid chain led to an increase of the lipid-DNA binding constant by 4 fold [144]. In 
addition, alkyl tail elongation is associated with decrease in the aggregation properties and the 
CMC [145], resulting in a higher tendency of gemini surfactants to self-assemble with enhanced 
stability [146].  
It should be noted that increasing the alkyl tail length may have negative consequences. 
Longer chains will elevate the micelles critical temperature (Krafft temperature) which cause the 
supramolecular assemblies to become stiffer at physiological temperature [147]. This will 
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eventually interfere with the lipid mixing at the cellular membrane affecting both cellular uptake 
and endosomal escape. In addition, further elongation in the alkyl tail might produce a larger 
particle size which could affect critical steps, such as the route of cellular entry, rate of cellular 
uptake, and intracellular fate [121, 148, 149].  
Although several studies have attempted to identify the optimal alkyl tail length, a 
definitive conclusion is rarely obtained due to the complex interplay between the head group, the 
spacer region and the nature of the tail that is specific to each series of gemini surfactants. 
Nevertheless, high transfection efficacy was usually achieved when the tail length falls within 
the range of 12 to 18C [109]. 
B)  Degree of unsaturation and stereochemistry 
The use of unsaturated hydrocarbon tails is a common structural modification that has 
been extensively assessed in the literature to optimize the transfection efficiency of gemini 
surfactants. The the introduction of unsaturation (double and triple bond) in the surfactants tails 
resulted in an increased CMC compared to the saturated equivalents [150]. In addition, it lowered 
the Krafft temperature below the physiological temperature resulting in enhanced susceptibility 
of the nano-assemblies to morphological changes at physiological temperature, which in turn 
will ease the process of lipid mixing (membrane fusion) during endocytoses [151]. Thus, 
unsaturation of the alkyl tail can be used as a strategy to overcome the stiffness of the 
supramolecular assemblies that occurs at physiological temperature with tail elongation. 
Membrane fluidity is an essential requirement for successful gene transfer as it greatly 
impacts critical steps such as membrane fusion and endosomal escape [152]. Unsaturated 
hydrophobic tails are known to have higher membrane fluidity than saturated ones [153, 154]. This 
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is mainly linked to the geometrical characteristics of the unsaturated bond that hamper the 
packing of lipids at the molecular level inducing a looser packing arrangement.  
The stereochemical arrangement of the unsaturated hydrophobic tails is another important 
factor in determining the transfection efficiency of the lipid-based gene delivery systems [155]. 
There is an apparent debate in the literature on whether trans or cis configuration is more 
favorable for higher transfection, however, the overwhelming majority of evidence showed that 
cis orientation is a better choice for higher transfection [129, 140]. A cis-configured double bond is 
expected to hamper the lipid packing more than a trans-configured bond, resulting in a higher 
CMC value [150].  
The position of the double bond or the triple bond in the alkyl chain is an additional 
parameter that should be considered when the effect of unsaturation is evaluated. The position of 
the double bond can affect the CMC and the lipid packing arrangement within the 
supramolecular assembly [150]. For example, unsaturation adjacent to the head group or at the end 
of the alkyl chain has a smaller effect on the aggregation properties than a double or triple bond 
in the middle of the alkyl tail. This could be attributed to the lesser impact in hampering the 
packing of the lipids when the unsaturation is positioned around the extremities [150]. Despite the 
added advantages of unsaturation via decreasing the compounds’ melting point and increasing 
solubility, the existence of unsaturation makes the compound more susceptible to oxidation 
reducing stability during storage [156]. 
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C) Asymmetry   
The above sections focused on the most commonly used gemini surfactants, namely 
symmetrical compounds. The last decade, however, has witnessed a growing interest in the use 
of asymmetrical gemini surfactants, m-s-n where m ≠ n [157-159]. Thermodynamic studies reported 
no major differences in the aggregation behaviour when the number of m + n is equal to the total 
carbons number in the tails of the corresponding symmetrical analogs [157, 158]. However, in 
compounds where m was fixed but n varied, resulting in different degrees of asymmetry, the 
CMC was decreased and the micellization process was significantly altered [160]. In order to 
assess how such results could affect the DNA complexation, a series of gemini surfactants with 
different degrees of asymmetry have been synthesized. A weaker interaction with the nucleic 
acid and gemini surfactants was attained with higher degree of asymmetry due to disruption in 
the intermolecular hydrophobic interactions [159]. 
1.4. Topical lipid-based gene therapy 
1.4.1. Skin as target organ for gene delivery  
Topical application of genetic materials into the skin is an attractive method for gene 
delivery because of the numerous advantages over other routes of delivery. It is a pain-free, 
convenient and easy to administer method, which could enhance patient compliance and reduce 
the need for costly health care services. The skin is a highly accessible organ that provides an 
ideal site for gene administration due to the potential for visual monitoring of the treated area and 
timely intervention if unwanted side effects appeared [161]. In addition, skin represents an 
excellent site for the induction of adaptive immune responses since it is rich in potent antigen 
presenting cells [162]. As such, DNA-immunization is a highly promising application of topical 
gene delivery. Despite all the advantages associated with the use of skin as a target organ, it 
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represents a formidable barrier to the penetration of drugs. Thus understanding the skin structure 
is a fundamental step toward the design of efficient delivery system. 
Skin is the largest organ of the human body with a surface area of about 1.7 m2 
corresponding to 10% of the total body weight of an average adult. It consists of three 
anatomically distinct layers: the epidermis, dermis and hypodermis in addition to a number of 
additional features such as hair follicles, sweat glands and sebaceous glands [163] (Figure 1.3). 
More than 90 % of the epidermis is keratinocytes alongside other cell types such as melanocytes, 
Langerhans cells and Merkel cells [163]. It is comprised of four distinct layers: the stratum 
corneum, stratum granulosum, stratum spinosum and stratum germinativum [163]. The stratum 
corneum (SC) (or horny layer) is the outermost layer of the epidermis and it represents the rate-
limiting step for the penetration of drugs through the skin [164]. It consists of protein-rich 
corneocytes packed within an extracellular lipid matrix forming a "brick and mortar" 
arrangement. The thickness of the SC is dependent on the anatomical site, age, sex and disease 
status [165]. The stratum granulosum is the layer below the SC; it is also referred to as the granular 
layer due to the presence of three layers of granular cells which are characterized by the presence 
of intracellular keratohyalin granules in the cytoplasm [163]. Below the stratum granulosum is the 
stratum spinosum or prickle cell layer which consists of two to six rows of polygonal shaped 
keratinocytes [163]. The stratum germinativum (basal layer) is the innermost layer of the 
epidermis that is the main residence of melanocytes, Langerhans cells and Merkel cells within 
the epidermis in addition to mitotically active columnar shape keratinocytes [163].  
The epidermis binds tightly to the dermis through the dermal-epidermal junction 
membrane which provides adequate mechanical support to the epidermis and serves as selective 
barrier to regulate molecular and cellular exchanges between the two layers. The dermis is the 
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connective tissue bulk component of the skin; it is comprised of cells (mainly fibroblasts), 
fibrous proteins (75% collagen) and aqueous ground substances [163]. The thickness of the dermal 
layer is mainly dependent on the body region providing the required pliability, elasticity, and 
tensile strength to the skin and protecting the body from external mechanical injuries. The 
hypodermis (subcutis) is a fatty tissue that represents the innermost layer of the skin [163]. It is 
composed mainly of adiopocytes and plays an important role in maintaining body temperature.  
Drug molecules penetrate the skin layers through two main routes: transepidermal and 
transappendageal [166]. The permeating molecule can cross the skin by either one of the routes or 
a combination of both pathways, depending on its physicochemical properties. Transepidermal 
routes transport drug molecules across the SC using transcellular (through the corneocytes) 
and/or intracellular pathways (through intercellular lipid domains) ]164[ (Figure 1.3). On the other 
hand, transappendageal routes (shunt routes), transport drugs via sweat gland ducts, hair follicles 
and associated sebaceous glands [164]. In theory, the relatively large size of the sweat glands pores 
and hair follicles opening can make the penetration of large genetic material possible. However, 
the appendages cover only 0.1% – 1% of the total skin surface indicating the insignificance of 
this route. In addition, natural secretions (sweat and sebum) can hamper drug penetration. As 
such, it is important to understand the particularities of these routes in the drug design and 
delivery process. It is also critical to recognize the limitations of dermal drug delivery in order to 
tailor delivery systems that can overcome these limitations. 
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Figure 1.3. Diagrammatic cross section of human skin showing the different cell layers, 
appendages and possible routes of particle penetration. Reprinted from the European Journal of 
Pharmaceutical Sciences, Vol 43, Lipid-mediated gene delivery to the skin, P 199-211, ©2011, 
with permission from Elsevier. 
 
1.4.2. Barriers for topical gene therapy  
The stratum corneum (SC) is the main physical barrier of the skin that hinders both 
topical and transdermal drug delivery. This could be attributed to its lipid-rich nature and unique 
chemical arrangement embodied by the brick and mortar model. In addition, the SC high turn-
over rate, acidity and the presence of enzymatic activity provide additional restriction to the 
delivery process [165]. The physicochemical properties of the candidate drug such as lipophilicity, 
size, surface charge, pKa and partitioning coefficient govern the diffusion into or through the 
skin [164]. For example, uncharged lipophilic drugs with a molecular weight less than 500 Dalton 
are believed to penetrate the skin passively [167]. Furthermore, the concentration of the drug, site 
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of application, disease state of the skin, age and the application method can determine the 
amount of the drugs that penetrate the SC. Macromolecules, such as the high molecular weight 
negatively charged DNA do not pass the epidermis layer. Thus, active strategies as efficient 
delivery systems need to be employed.  
1.4.3. Lipid-based carriers for skin gene delivery  
In recent years, there has been an increased interest in examining the potential of lipid 
vesicles as carriers for skin gene delivery. Several types of lipid vesicles have emerged such as 
classical liposomes, cationic liposomes, niosomes, Transfersomes®, and others. Phospholipids 
are the main constituent of classical liposomes that offer numerous advantages for skin gene 
delivery. The chemical composition of phospholipids is similar to the composition of skin lipids 
and cell membrane [168]. As such, phospholipid-based liposomes can fuse with the epidermal 
lipids, destabilizing the lipid matrix and enhancing drug penetration[169]. In addition, most 
phospholipids are non-toxic and biodegradable minimizing the possibility of side effects [170]. 
Cholesterol might be added to classical liposomes to enhance bilayer characteristics. It increases 
the membrane microviscosity, reducing permeability to water soluble molecules [171]. This in turn 
enhances the rigidity and stability of the vesicles [171].  
The transappendageal follicular pathway is the main route of gene delivery with 
classical liposomes; however, conflicting results have suggested that the transepidermal pathway 
may also be significantly involved [172]. Although classical liposomes have been widely 
investigated for their potential application in topical gene therapy [173], the level of gene delivery 
has not been satisfactory. Combinations with other delivery enhancing strategies that disturb the 
SC are needed. Thus, the emergence of new delivery systems that achieve a high level of gene 
expression is necessary, as outlined below. 
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The addition of an edge activator to phospholipids led to the formation of highly elastic 
deformable vesicles named Transfersomes® [174]. An edge activator is a single chain surfactant 
that is capable of destabilizing the lipid bilayer. It increases the vesicle deformability and 
elasticity by decreasing the interfacial tension [175]. Therefore, improved penetration through the 
intercellular lipids of the SC is achieved. Different types of edge activators have been introduced 
such as sodium cholate, sodium deoxycholate, Tween 80, Tween 20 and Span 80[173]. The type of 
the edge activator plays a crucial part in determining the extent of transdermal absorption. For 
example the use of cholate-based Transfersomes® showed the best results in topical DNA 
delivery compared to other edge activators [173]. 
In order to ameliorate the efficiency of the previously described vascular systems, 
niosomes vascular system was first introduced by L’Oreal as a drug carrier for cosmetic 
applications[176]. Niosomes  are composed of single-chain synthetic non-ionic surfactants such as 
diacylglycerides, saccharose diesters, polyoxyethylene alkyl ethers or polyoxyethylene alkyl 
esters with cholesterol [173]. Although niosomes appear to have the same physical properties as 
liposomes, niosomes showed better chemical stability and enhanced penetration into the skin. 
The surfactants’ solubilization properties improve the mixing of niosomes with skin lipids 
causing an alteration in the structure of the SC  in the intercellular layers which in turn enhances 
the penetration through the skin [177]. 
Cationic lipids are another category of lipid-based carriers that has been widely 
investigated as a non-viral gene delivery system for skin gene therapy. Through their positive 
charge, they induce an electrostatic interaction with negatively charged DNA leading to the 
formation of nano-sized lipoplexes that shield the DNA from enzymatic degradation. In addition, 
charge-mediated interactions with the skin surface have a crucial role in the passive delivery 
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across the skin [178]. Cationic lipids have the ability to passively target tumors taking advantage 
of the leaky tumor vasculature, hence increasing gene delivery to the target cancerous tissue. 
Furthermore, cationic lipids can act as an adjuvant for immunotherapy as they are preferentially 
taken up by immune cells [179]. The first in vivo lipid-mediated gene transfer study into the skin 
of a living animal model was conducted by Alexander and Akhurst in 1995 [180]. The cationic 
lipid DOTAP was complexed with pDNA encoding for β-galactosidase at a ratio of 1:1.6 (w/w). 
Rapid gene expression was achieved (after 6 h) in the hair follicle, epidermis and also in the 
deeper layers of the dermis and lasted up to 48 hours [180]. The level of gene expression was 
dependent on the phase of hair cycle growth indicating the importance of  transfollicular routes 
in lipid-based DNA delivery [180]. Since then, the use of cationic lipids has captured increased 
interest as an important component in topical gene delivery. 
The incorporation of cationic lipids into other vascular systems such as niosomes or 
Transfersomes® alters the charge of these vascular systems resulting in the formation of cationic 
niosomes and cationic Transfersomes® vesicles. Cationic niosomes or Transfersomes® take 
advantage of both systems producing carriers that are more efficient and more tailored for gene 
delivery. Kim et al. investigated the ability of cationic Transfersomes® constructed from 
DOTAP and sodium cholate to transfect intact hair-removed dorsal skin of mice with pDNA 
encoding for green fluorescent protein (GFP) [181]. GFP expression was detected in some organs 
such as the liver and the lungs up to 6 days, demonstrating a promising approach for non-
invasive gene delivery. In addition, cationic Transfersomes® composed of the cationic lipid 
DOTMA and sodium deoxycholate were employed for topical vaccination against hepatitis B in  
Balb/c mice [182]. A high immune response was provoked producing a serum antibody titer and 
endogenous cytokine levels comparable with those produced by intramuscular injection of 
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recombinant hepatitis B surface antigen (HBsAg) [182].  More recently, cationic niosomes made 
of dimethyl dioctadecyl ammonium bromide (DDAB), Tween 61 and cholesterol were loaded 
with pDNA encoding human tyrosinase and evaluated for their potential as drug carriers for 
topical vitiligo therapy [183]. Transdermal absorption through rat skin was conducted using Franz 
diffusion cells demonstrating four-fold higher tyrosinase activity than the free plasmid [183].  
The use of cationic gemini surfactant-based lipoplexes for skin gene delivery was firstly 
conducted by Badea et al. to treat scleroderma [115]. Cationic gemini surfactants N, N'-
bis(dimethylhexadecyl)-1,3-propanediammonium dibromide (designated as 16-3-16) was 
formulated with pDNA encoding for IFN-γ in the presence of DOPE, DPPC and penetration 
enhancer and administrated into IFN-γ-deficient mice. A three-fold increase in transgene 
expression was achieved in the animals treated with gemini surfactant-based lipoplexes 
compared to animals treated with a plasmid DNA solution indicating the promise associated with 
the use of gemini surfactants [115]. This research will capitalize on the use of a new generation of 
dicationic gemini surfactants: peptide-modified gemini surfactants as potential carriers for skin 
gene delivery.  
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1.5. Biological fate of topical lipid-based gene carrier 
Upon topical application, lipid-based nanoparticles distribute within various tissues and 
cellular components [115, 180, 181]. As of yet, the ultimate fate of the building constituents of the 
lipid-based nanoparticles has not been fully understood. Many questions remain unanswered 
regarding the degradation profile of nanoparticles after releasing their therapeutic cargo 
including the formation of metabolic breakdown by-products, some of which may be toxic. 
Correlating the biodistribution and the biological fate of the nanoparticles to their chemical 
structure and physicochemical properties will provide insights into the rational design process to 
produce lipid-based gene carriers with higher efficiency and reduced toxicity.  
Fluorescently labeled and radiolabeled carriers have been widely utilized in tracking the 
fate and distribution of lipid-based nanoparticles [174, 184, 185] . For example, Cevc and Blume used 
radioactive 3H-DPPC to follow the fate of dermally applied lipids after both occlusive and non-
occlusive application [174]. Two kinds of vesicles systems; classical liposomes and transfersomes, 
were applied onto intact mouse skin to investigate the influence of lipid composition on 
biodistribution. Results showed that with the use of liposomes or occluded transfersomes, up to 
25% of the total dose was associated with the SC and a few percent was localized in the deeper 
epidermal layers [174]. However, the use of transfersomes under non-occlusive conditions resulted 
in the detection of 30±10% of the applied lipids in the subdermis and up to 6–8% in the blood 
[174]. These results indicate the importance of both the method of the application and the 
liposomal composition on the nanoparticles biodistribution. Similar to radiolabeling, 
fluorescently labeled lipid-vesicle biodistribution was monitored using confocal laser scanning 
microscopy after topical application onto intact murine skin [185]. Results confirm the penetration 
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of the liposomes through the skin to the systemic circulation, indicting the feasibility of using 
fluorescent labelling in tracking lipid based carriers [185]. 
Despite promising results, the use of fluorescent and radioactive labeling could have a 
considerable effect on the pharmacokinetic profile by altering the physicochemical properties of 
the delivery system [186]. A research group in Belgium has recently conducted a detailed study on 
the effect of fluorescent labeling density on the intracellular trafficking of lipid-based DNA 
delivery systems. It was shown that with higher labeling densities, the affinity of pDNA for 
lipids increased, influencing the dissociation of DNA from lipoplexes which may alter the 
endosomal escape and consequently reduce the transfection efficiency [186]. In addition, labeling 
strategies are limited to qualitative and semi-quantitative assessment of the biodistribution of 
lipid-based nanoparticles [184, 187]. As such, there is a sense of urgency to use more reliable 
techniques to monitor the fate and biodistribution of the gene carriers within biological matrices.  
Mass spectrometry (MS) is a powerful analytical tool that is used for both quantitative 
and qualitative applications [188-191]. It is widely applied in the field of pharmaceutical research 
due to its sensitivity, accuracy, and high throughput capability [192-194]. The presence of two 
permanently charged quaternary ammonium groups and the lack of a chromophore or 
fluorophore on the gemini surfactants make MS the technique of choice for the identification and 
quantification of gemini surfactants. In our lab, MS was used to study the fragmentation 
mechanism of different families of diquaternary ammonium gemini surfactants and to establish 
universal tandem mass spectrometric (MS/MS) fingerprints for accurate identification of gemini 
surfactants within complex biological matrices [195-198]. Furthermore, liquid chromatography 
tandem mass spectrometry (LC–MS/MS) methods were developed for the quantification of first 
and second generations gemini surfactants within PAM212 murine keratinocytes to determine 
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the rate of cellular uptake and removal [199-201]. Ongoing research includes the identification and 
quantification of two structurally distinct gemini surfactants within transfected PAM212 
keratinocytes that possess distinct cytotoxicity profiles. MS will be employed to investigate the 
subcellular localization and to detect and quantify any potential metabolites in order to establish 
structure–toxicity correlations, which will give insights into the rational design process.  
In this research, MS will be utilized to detect and quantify topically applied 
diquaternary ammonium gemini surfactants in an ex-vivo skin model of CD1 mice and a 
biologically relevant buffer to assess their cutaneous deposition and penetration behaviour.  
Understanding the MS/MS fragmentation behavior will be required for the development of 
multiple reaction monitoring (MRM) FIA–MS/MS method.  The method can be used in the 
future to track the fate and biodistribution of gemini surfactants. Such knowledge is needed to 
guide the development of effective gene delivery system.  
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1.6. Rationale  
Gene therapy is a promising therapeutic approach predicated on the intentional 
modulation of gene expression in cells to treat genetic disorders, both inherited and acquired. 
Current focus is on the design of “intelligent” nanoparticles that respond to stimuli and carry 
their cargo to the targeted site, increasing gene transfer into the cells and promoting gene 
expression – the ultimate goal of gene therapy. However, one of the major hurdles for the 
successful application of gene therapy is the effective delivery of genetic material into the 
targeted cells. Gemini surfactants are a group of cationic lipids able to form nanoparticles with 
nucleic acids of a certain size and morphology and deliver the encapsulated materials to target 
tissues. They are composed of two head groups attached to their hydrocarbon tails and connected 
by a spacer. Altering the chemical structure of the gemini surfactants was shown to have a 
dramatic impact on the physicochemical properties of the gene-gemini surfactant lipoplexes, 
affecting the transfection efficiency of the delivery vector. As such, a series of 22 new 
derivatives have been synthesized having 12-18:1C hydrocarbon tails and spacer group 
substitutions ranging from dipeptide-substituted compounds to oligo-peptides. This research 
evaluates the impact of the structural variations of the peptide-modified gemini surfactant 
nanoparticles on their physicochemical properties and transfection efficiency. 
A major application of gemini surfactants is topical gene delivery.  Topical gene delivery 
is a convenient and easy to administer route, particularly for wound healing, DNA-
immunization, melanoma treatment and vitiligo. In this research, topical formulation of peptide 
modified gemini surfactants is assessed ex vivo for their dermal penetration ability. The aim 
beyond this project is to develop targeted delivery for the treatment of melanoma. 
While extensive research is being done to monitor the biodistribution of the active 
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therapeutic agent, the ultimate fate of lipid-based carriers has not been fully understood. Many 
questions remain unanswered regarding the degradation profile of the building constituents of 
nanoparticles after releasing their therapeutic cargo including the formation of breakdown by-
products, some of which may be toxic. Correlating the biodistribution and the biological fate of 
the nanoparticles to their chemical structure and physicochemical properties will guide future 
formulation decision, resulting in the production of lipid-based gene carriers with higher 
efficiency and reduced toxicity. Herein, mass spectrometry (MS) is employed to detect and 
quantify topically applied gemini surfactants in skin tissue of an animal model in order to 
determine their behavior in complex biological environment. 
The long-term possible outcomes of this research are to develop a model that could be 
used to predict the in vivo distribution and transfection efficiency of the gene delivery 
nanoparticles. Such a model might become a design tool for new delivery materials that have 
optimal bio-distribution and delivery characteristics beyond gemini surfactants.   
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1.7. Research Hypothesis 
1.7.1. Optimization of the DNA binding properties of novel peptide-modified gemini 
surfactant- based gene delivery systems will result in more efficient and less toxic dermal 
gene delivery system compared to the unsubstituted gemini surfactants. 
1.7.2.  The distribution of diquaternary ammonium gemini surfactants will be confined to the 
skin layers.  
1.8. Research Objectives 
1.8.1. Hypothesis #1:  
 To develop and characterize novel peptide-modified gemini surfactant-based gene delivery 
systems for in vitro and ex vivo applications. 
Specific aims: 
 To assess the physicochemical and structural properties of novel peptide-modified gemini 
surfactant-based gene delivery systems. 
A. To study the MS/MS fragmentation behavior of the peptide-modified gemini 
surfactants (hydrocarbon-peptide-substituted). 
B. To identify the supramolecular arrangement of peptide-modified lipoplex 
formulations using small angle X-ray scattering technique. 
C. To conduct size and zeta potential measurements for the lipoplex formulations.  
 To evaluate the efficiency of peptide-modified gemini surfactants lipoplex formulations in 
delivering genetic materials in vitro. 
 To determine the in vitro cytotoxicity of the peptide-modified gemini surfactants lipoplex 
formulations. 
53 
 
 To evaluate the skin permeation efficiency of the lead compounds of peptide-modified 
gemini surfactants lipoplex formulations ex vivo. 
 To examine the relationship between the physicochemical properties of the delivery agent 
and their in vitro transfection efficiency and ex vivo permeation efficiency (structure activity 
relationship). 
1.8.2. Hypothesis #2: 
 To develop flow injection analysis -tandem mass spectrometry (FIA–MS/MS) methods 
for the determination of novel peptide-modified gemini surfactants within complex 
biological matrices. 
 To detect and quantify the lead compounds of peptide-modified gemini surfactants in 
skin tissues as well as in phosphate buffered saline (PBS): a biologically relevant buffer. 
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Transitioning rationale: 
Literature review provided evidence about the potential of gemini surfactants as a gene delivery 
vector. Modifications to the gemini surfactants’ molecular structure may significantly affect the 
efficiency of the delivery system. Previous research revealed that the insertion of amino acids 
into the gemini surfactants’ spacer resulted in the production of compounds with enhanced 
transfection efficiency and reduced cytotoxicity.  This chapter aims at evaluating the impact of 
altering the hydrophobic tails of gemini surfactants on the physicochemical characteristics and 
biological activity.  
Contribution statement: 
Mays Al-Dulaymi contributed to this manuscript by designing the study, performing 
experiments, data acquisition, data analysis and manuscript writing except the chemical synthesis 
part. Dr. Jackson Chitanda synthesized the gemini surfactants used in this work. Drs. Grochulski 
and Badea performed the onsite SAXS measurements. 
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2.1. Abstract 
The aim of this work was to elucidate the structure-activity relationship of new peptide-modified 
gemini surfactant-based carriers. Glycyl-lysine modified gemini surfactants that differ in the 
length and degree of unsaturation of their alkyl tail were used to engineer DNA nano-assemblies. 
To probe the optimal nitrogen to phosphate (N/P) ratio in the presence of helper lipid, in vitro 
gene expression and cell toxicity measurements were carried out. Characterization of the nano-
assemblies was accomplished by measuring the particle size and surface charge. Morphological 
characteristics and lipid organization were studied by small angle X-ray scattering technique. 
Lipid monolayers were studied using a Langmuir-Blodgett trough. The highest activity of glycyl-
lysine modified gemini surfactants was observed with the 16-carbon tail compound at 2.5 N/P 
ratio, showing a 5 to 10-fold increase in the level of reporter protein compared to the 12 and 18:1 
carbon-tail compounds. This ratio is significantly lower compared to the previously studied 
gemini surfactants with alkyl or amino- spacers. In addition, the 16-carbon tail compound 
exhibited the highest cell viability (85%). This high efficiency is attributed to the lowest critical 
micelle concentration of the 16-tail gemini surfactant and a balanced packing of the 
nanoparticles by mixing a saturated and unsaturated lipid together. At the optimal N/P ratio, all 
nanoparticles exhibited an inverted hexagonal lipid assembly. The results showed that the length 
and nature of the tail of the gemini surfactants play an important role in determining the 
transgene efficiency of the delivery system. Moreover, the interplay between the head group and 
the nature of tail is specific to each series, thus in the process of rational design the contribution 
of the latter should be assessed in the appropriate context.  
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2.2. Introduction 
Over the past quarter century, gene delivery has attracted significant interest due to the 
potential of gene therapy to treat both genetic and acquired diseases. However, one of the major 
hurdles for the successful application remains the effective delivery of genetic material into the 
targeted cells. Currently, there are two main categories of gene therapy vectors: viral and non-
viral. Viruses are the most effective vectors for gene therapy; however, they suffer from major 
drawbacks particularly their propensity to trigger immune response and mutagenic toxicity [1]. 
Non-viral methods, on the other hand, are considered safer alternatives, which can be prepared, 
easily in large quantities and at lower cost. Although numerous non-viral methods of delivery are 
currently available, the use of cationic lipids is the most prominent[2]. They have the ability to 
compact the negatively charged DNA through electrostatic interaction forming nano-sized 
lipoplexes as a delivery vehicle [3-5]. One special family of cationic lipids is the quaternary 
ammonium gemini surfactants [6], which have shown promising results in delivering DNA. 
Gemini surfactants are composed of two head groups attached to their hydrocarbon tails and 
connected by a spacer. Compared to classic monomeric surfactants, gemini surfactants possess a 
number of superior properties such as one to two orders of magnitude lower critical micelle 
concentration (CMC), lower Krafft temperature, and greater ability to reduce surface tension. 
The structure of the gemini surfactants plays an essential role in determining the 
supramolecular arrangement into nanoparticles; hence, will have direct effects on the 
cytotoxicity and the gene delivery efficiency. Our research strategy follows a rational design 
approach to develop novel families of gemini surfactants and conduct component-by-component 
tests aimed at producing compounds with superior transgene efficiency and minimum 
cytotoxicity. As a starting point, the simplest family of gemini surfactants with aliphatic spacer, 
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was extensively studied [7-11]. Modifications to the gemini surfactants' architecture by varying the 
length of the hydrophobic tail and/or the spacer were found to have a significant impact  on the 
morphology of the lipid/DNA nanoparticles (lipoplexes) and their transfection efficiency [8, 9]. In 
an attempt to form intelligent nanoparticles that respond to environmental stimuli, pH-sensitive 
gemini surfactants were also synthesized by inserting an amino group into the spacer [12]. Among 
the series, 12-7NH-12 showed superior transfection efficiency and adopted various morphologies 
which may have facilitated membrane fusion, aiding the release of the DNA within the cell. In 
order to achieve a more balanced binding and release of the genetic material, a third generation 
was conceived by coupling amino acids or peptides into the N position of the spacer of 12-7NH-
12. The insertion of amino acids that provided additional terminal amino groups resulted in: (i) 
enhanced binding to the cell membrane by forming hydrogen bonds, (ii) improved gemini 
surfactant-DNA electrostatic interaction due to the high pKa value of the terminal amines and (iii) 
induced liposomal fusion through a flip-flop mechanism due to the strong electrostatic 
interaction between the nanoparticles and the cell membrane [13, 14]. The glycyl-lysine substituted 
gemini surfactant yielded lipoplexes with enhanced transfection efficiency showing a 
significantly higher gene expression compared to the unsubstituted parent compound without 
increasing cytotoxicity [13, 14].  
In this work, further investigations of the glycyl-lysine substituted gemini surfactants was 
carried out by examining the effect of the length of the alkyl tail and the degree of unsaturation 
on the assembly of the nanoparticles and, subsequently, the impact on their transfection 
efficiency and cytotoxicity. Three glycyl-lysine substituted compounds having dodecyl, 
hexadecyl and oleyl tails (Figure 2.1A) were complexed with pDNA and the transfection 
efficiency of the lipoplexes was tested in vitro. Small-angle X-ray scattering (SAXS) 
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measurements were carried out in order to probe the morphology of the lipoplexes and to 
correlate with their transfection efficiency. The ultimate goal of this study is to enrich the 
understanding of the structure-activity relationship of the gemini surfactants and to provide 
fundamental information for the bottom-up design of gemini surfactant-based gene delivery 
systems.   
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Figure 2.1. Chemical structure of (A) the tested cationic gemini surfactants and (B) helper lipid 
DOPE 
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2.3. Materials and methods  
2.3.1. Synthesis of glycyl-lysine modified gemini surfactants 
The synthesis of three dipeptide cationic gemini lipids, designated as m-7N(G-K)-m (G = 
glycine and K = lysine) where m is the alkyl tail carbon chain length, m = 12, 16 and 18:1 (18:1 
= mono-unsaturated oleyl chain), is illustrated in Scheme 1. Unless otherwise stated, all reactions 
were performed under N2 atmosphere using standard Schlenk techniques. Boc-gly-OH (99%), O-
(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 98%), bis-
boc-lysine (99%),and N-diisopropylethylamine (DIPEA, 99.8%) were obtained from Chem-
Impex International Inc. Dry dimethylformamide (DMF, ≥99.5%, kept over molecular sieves), 
3,3’-iminobis(N,N-dimethyl-propylamine) (97%), iodohexadecane (95%, stabilized with copper) 
and 4M HCl (in dioxane) were purchased from Sigma-Aldrich. HPLC grade methanol and 
iodododecane (98%, stabilized with copper) were purchased from Alfa Aesar, while anhydrous 
ACS grade granular Na2SO4 and ACS grade NaHCO3 powder were acquired from EMD 
chemical company. Oleylbromide was prepared from oleyl alcohol (97%, Acros Organics) using 
triphenylphosphine dibromide (96%, Aldrich) as previously described [15]. All chemicals were 
used without any further purification. Mass Spectra were obtained by using a QSTARXL MS/MS 
System. 1H NMR spectra, in either CDCl3 or dimethylsulfoxide (DMSO)-d6, were recorded by 
using a Bruker 500 MHz Avance spectrometer. Chemical shifts, δ, are reported in ppm, 
referenced to the residual 1H and 13C (CDCl3 at 7.26, 77.23 and DMSO-d6 at 2.50, 39.58), 
respectively.  
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Scheme 2.1. Synthesis of glycyl-lysine gemini surfactants having different carbon tail lengths 
and functionalities. Step (1): Boc-glycine, HATU, DIPEA, DMF, 18 h. Step (2): iodododecane, 
iodohexadecane or oleybromide, DMF, 18 h. Step (3): 4M HCl, dichloromethane, 2 h. Step (4a): 
bis-boc-lysine, HATU, DIPEA, DMF, 18 h (4b) 4M HCl, dichloromethane, 2 h.  
 
Briefly, in step (1) boc-glycine (1.00 g, 0.0457 mmol), HATU (2.480 g, 6.54 x 10-3 mol) 
and DIPEA (2.1 mL, 5.944 x 10-3 mol, 2eq.) were sequentially placed in a 100 mL Schlenk flask 
containing 20 mL DMF and stirred under an inert atmosphere for 15 min to give a pale-yellow 
and later a dark-red mixture. 3,3’-iminobis (N, N-dimethyl-propylamine (4.00 g, 0.0467 mmol, 1 
eq.) was then added and the reaction mixture was stirred for 18 h. DMF was removed under high 
vacuum. To the residue, 100 mL dichloromethane (DCM) was added and then solvent extracted 
with saturated sodium bicarbonate (5 x 100 mL). The combined aqueous layers were further 
extracted with DCM (5 x 100 mL). Organic layers were combined and dried over anhydrous 
sodium sulfate. Excess DCM was removed under vacuum to give a reddish oily desired 
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compound that was confirmed by 1H-NMR. This was further purified by washing with 
chloroform; the desired compound is soluble in chloroform (69%). 
In step (2), the product of step (1) was reacted with the respective alkyl and alkene halide 
compounds (C12, C16 or C18:1) in a 1 to 2 ratio, respectively. For C12 and C16 alkyl tails, the 
mixture was stirred at ambient temperature overnight in DMF and the C18:1 tail was stirred at 80 
°C for 2 days in DMF. After the removal of excess solvent; the residue was washed by 
decantation using diethyl ether and thereafter with pentane. The red substance was dried under 
high vacuum. Proton NMR was consistent with the expected spectra of the desired compounds.  
In step (3), Boc de-protection was carried out by dissolving the boc containing products 
of step (2) in 20 mL dry DCM and adding 10 mole equivalents of HCl (4M in dioxane). After 
stirring for 2 h, excess solvent was removed and the residue was washed by decantation with 
diethyl ether. Finally, DCM was added to dissolve the compound and then it was precipitated by 
using diethyl ether. This was repeated three times before the sample was dried under high 
vacuum.  
In Step (4a), bis-boc-lysine, HATU and DIPEA were sequentially placed in a 100 mL 
Schlenk flask containing 20 ml DMF at inert atmosphere to give a pale-yellow and later to a 
dark-red mixture. After stirring for 15 min, the product from step (3) was added. DMF was 
removed under high vacuum after stirring for 18 h. To the residue, 100 mL DCM was added and 
then extracted with saturated sodium bicarbonate (5 x 100 mL). The extracted organic layer were 
dried over anhydrous sodium sulfate, and then concentrated under vacuum to give the reddish 
oily compound. The final step (step (4b)) is the boc deprotection step as described in step (3). 
The final products had a yellowish to orange color. The counter ion exchange reaction, from 
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either bromide or iodide to chloride counter ion, was achieved during the two de-protection steps 
(addition of excess HCl). 
All steps were verified by 1H NMR spectroscopy and were consistent with the expected 
spectrum for desired compounds. 
12-N(GK)-12: 1H NMR (500 MHz, DMSO-d6): δ  8.97 (m) 1H (NH3-CH(-CH2-)-C=O; 8.46 (m) 
3H (-NH3), 8.30 (m) 3H (-NH3); 4.12 (d) 1H; 4.04 (d) 1H (-NH-CH2-C=O-); 3.90 (m) 1H (-NH-
CH2-C=O-); 3.33 (m) 12H; 3.07 (s) 6H (-N(CH3)2); 3.04 (s) 6H (-N(CH3)2); 2.71 (m) 2H; 2.01 
(m) 2H; 1.91 (m) 2H, 1.70 (m) 2H; 1.65-1.60 (m) 6H; 1.45 (m) 2H; 1.24 (m) 36H; 0.84 (t) 6H (-
CH3). MS-TOF (m/z); Calculated for C42H90N6O2
2+; expected 355.3557, found 355.3571 
16-N(GK)-16: 1H NMR (500 MHz, DMSO-d6): δ = 8.93 (m) 1H (NH3-CH(-CH2-)-C=O-); 8.44 
(m) 3H (-NH3), 8.27 (m) 3H (-NH3); 4.15 (d) 1H (-NH-CH2-C=O-); 4.04 (d) 1H (-NH-CH2-
C=O-); 3.90 (m) 1H; 3.33 (m) 12H; 3.04(s) 6H (-N(CH3)2); 3.04 (s) 6H (-N(CH3)2); 2.72 (m) 4H; 
2.01 (m) 2H; 1.91 (m) 2H, 1.77 (m) 2H; 1.68-1.59 (m) 6H; 1.45 (m) 2H; 1.23 (m) 50H; 0.84 (t) 
6H (-CH3).
 MS-TOF (m/z); Calculated for C50H106N6O2
2+; expected 411.4183, found 411.4094 
18-N(GK)-18: 1H NMR (500 MHz, DMSO-d6): δ 8.88 (m) 1H (NH3-CH(-CH2-)-C=O-); 8.37 
(m) 3H (-NH3), 8.17 (m) 3H (-NH3); 5.32 (m) 4H (-CH=CH-); 4.12 (d) 1H (-NH-CH2-C=O-); 
4.05 (d) 1H (-NH-CH2-C=O-), 3.90 (m) 1H; 3.40-3.25 (m) 12H; 3.04(s) 6H (-N(CH3)2); 3.02 (s) 
6H (-N(CH3)2); 2.72 (m) 4H; 1.94 (m) 8H; 1.91 (m) 2H, 1.77 (m) 2H; 1.68-1.59 (m) 8H; 1.45 
(m) 2H; 1.23 (m) 42H; 0.84 (t) 6H (-CH3).
 MS-TOF (m/z); Calculated for C54H110N6O2
2+; 
expected 437.4340, found 437.4334.   
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2.3.2. Formulations  
The plasmid pGT.IFN-GFP (pDNA), encoding for murine interferon gamma (IFN-γ) and 
green fluorescent protein (GFP) was utilized in this work [8]. QIAGEN Plasmid Giga Kit 
(Mississauga, ON, Canada) was used to isolate and purify the plasmid DNA according to the 
manufacturer’s instructions. The gemini lipids were combined with pDNA at six different 
nitrogen (cationic) to phosphate (anionic) charge ratios (N/P) of 1, 2.5, 5, 10, 15 and 20 in the 
presence of a fixed amount of a helper lipid, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine 
(DOPE) (Avanti Polar Lipids Inc., Alabaster, USA). (Figure 2.1B), at a final concentration of 
1mM to create pDNA / gemini lipid / helper lipid (P/G/L) nanoparticles.  An appropriate amount 
of 3mM aqueous solutions of gemini was added to 200 µg/mL pDNA and incubated for 20 
minutes at room temperature (P/G complex). 1 mM DOPE was prepared as described previously 
[9] and added to P/G complexes to form the final nanoparticles (P/G/L).   
2.3.3. Cell culture and in vitro transfection study  
COS-7 African green monkey kidney fibroblasts cell line (ATCC, CRL-1651) were 
grown to 80% confluency in 75-cm2 tissue culture flasks in Dulbecco's modified Eagle's medium 
(DMEM) obtained from ATCC (Manassas, VA USA) supplemented with 10% (vol/vol) fetal 
bovine serum and 1% (vol/vol) antibiotic antimycotic agents and incubated at 37 °C with 5% 
CO2. One day prior to transfection, 96-well tissue culture plates (Falcon, BD Mississauga, ON, 
Canada) were seeded with the cells at a density of 1×104 cells/well. The supplemented DMEM 
was replaced with DMEM one hour prior to transfection. Cells were transfected with 0.2 μg/well 
pDNA and incubated at 37 °C in CO2 for 5 h. Lipofectamine Plus reagent (Invitrogen Life 
Technologies) was used as a positive control according to the manufacturer’s protocol. The 
transfection mixture was replaced by supplemented DMEM after 5 h. Supernatants were 
collected at 24 and 48 h and replaced with fresh medium. The collected supernatants were stored 
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at - 20 °C. The results presented are the average of three plates of quadruplicate wells. 
2.3.4. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was carried out to measure the level of interferon gamma using flat bottom 96-
well plates (Immulon 2, Greiner Labortechnik, Germany) according to the BD Pharmingen 
protocol. A standard IFN-γ curve was created using recombinant mouse IFN-γ standard (BD 
Biosciences, Mississauga, ON, Canada) to calculate the concentration of the secreted IFN-γ.  
2.3.5. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
MTT assay was performed to examine the cytotoxicity of the peptide-substituted gemini 
surfactants in the COS-7 cell-line. Three 96-well cell culture plates were seeded with cells at a 
density of 1×104 cells/well and treated with the P/G/L nanoparticles. Plates were incubated for 5 
h at 37 °C with 5% CO2 before replacing the old media with fresh media as described in the 
transfection section. Cell toxicity was evaluated 48 h after treatment. Lipofectamine, a 
commercial transfection agent, was used as a positive control. A sterile solution of 5 mg/mL of 
MTT (Invitrogen, U.S.A.) in phosphate buffered saline (PBS) was prepared, mixed with 
supplemented media, then added to the cells and incubated for 3 h. The supplemented media was 
removed and the formed, purple formazan crystal was dissolved in dimethyl sulfoxide 
(spectroscopy grade, Sigma-Aldrich, ON, Canada) and the plates incubated at 37 °C for 10 m. 
Absorbance was measured at 550 nm using a microplate reader (BioTek® Microplate Synergy 
HT, VT, U.S.A.). The results are the average of three plates (treated with individually prepared 
formulations of quadruplicate wells) and the cytotoxicity is expressed as a percentage of the non-
transfected control cells ± standard deviation.  
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2.3.6. Size and ζ-potential measurements 
Size and ζ-potential measurements for the three lipids at six N/P ratios were performed 
by using a Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK). An MPT-
2 autotitrator was connected to the Zetasizer Nano ZS to measure size and ζ-potential of 16-
7N(G-K)-16 at N/P =10 as a function of pH. A 9 mL aliquot of sample was placed in the titration 
cell of the autotitrator and titrated with 0.1 M HCl over the desired pH range using 0.2–0.5 pH 
unit increments. Samples were prepared as described in the formulation section and each sample 
was measured three times and the results reported are the average of the three readings ± 
standard deviation. 
2.3.7. SAXS measurements 
The formulations were prepared as for the transfection study using ten times higher 
concentrations. The SAXS experiments were performed at the BL4-2 beam line at Stanford 
Synchrotron Radiation Lightsource (SSRL, Stanford, USA) using a wavelength of 1.1271 Å 
(11KeV energy). The scattered X-ray was detected on MAR225-HE (225 mm x 225 mm (3072 x 
3072 pixels, pixel size 73.24 μm) at 20s exposure time and at sample to detector distance of 
1.1m. The SAXS detector was calibrated with silver behenate. GSASII software was used to plot 
diffraction intensity versus 2θ (where θ is the diffraction angle) or the scattering vector (𝑞 =
4𝜋
𝜆
sin 𝜃 ) by radial integration of the 2D patterns.  
2.3.8. Langmuir Studies 
The Langmuir-Blodgett technique was utilized to determine the surface area occupied by 
the gemini surfactant head group. Surface pressure-mean molecular area isotherms were 
collected using a Langmuir minitrough (KSV, Helsinki, Finland) equipped with a Wilhelmy 
plate balance. The trough was filled with ultrapure water (Millipore, resistivity 18 MΩ·cm) as a 
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subphase and the temperature was maintained at 22 °C. Stock solutions of the three gemini lipids 
or DOPE were prepared at a concentration of 1 mM of lipid in chloroform. 30 μL of the stock 
solution was spread dropwise on the surface of the subphase with a Hamilton syringe. The 
solvent was allowed to evaporate for 10 min before the monolayer was compressed at a speed of 
20 mm·min−1. 
2.3.9. Structure calculations  
An estimate of the length of the hydrocarbon tails was attained by using Avogadro 
software [16]. Volume calculations were conducted with Gaussian09 software, revision C.01 [17]. 
The geometry was optimized on the B3LYP level of theory with 6-311+G(d,p) basis set. 
Optimized structures were confirmed using harmonic frequency calculations. Volumes for the 
optimized structure were calculated using united atom radii. 
2.3.10. Statistical analysis 
Statistical analyses were performed using SPSS software (Version 23.0). Results 
expressed as the average of n ≥ 3 ± SD. One-way analysis of variance (ANOVA, 
Scheffé/Dunnett’s post hoc tests) were used for statistical analyses. Significant differences were 
considered at p<0.05 level. 
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2.4. Results and Discussion 
2.4.1. Evaluation of the in vitro transfection activity  
One of the purposes of the study was to investigate the effect of structure on the level of gene 
expression. The tested compounds, 12-7N(G-K)-12, 16-7N(G-K)-16 and 18:1-7N(G-K)-18:1 
varied in the length of their hydrophobic tails and the degree of unsaturation within the carbon 
tails. P/G/Ls of the gemini lipid 16-7N(G-K)-16 showed the highest transfection efficiency 
compared to 12-7N(G-K)-12 and 18:1-7N(G-K)-18:1 at all N/P ratios (Figure 2.2). The 
interaction of pDNA with cationic amphiphiles plays a key role in the delivery of genetic 
material. Lipoplex formation results mainly from the electrostatic interaction between the 
negative phosphate group in the DNA backbone and the positive cationic lipid head group(s), in 
addition to the cooperative hydrophobic interaction between the tail groups of the cationic lipid 
[18]. By increasing the length of the alkyl tail, there is an increase in the compound’s 
hydrophobicity resulting in better interaction with the DNA [19, 20]. Matulis et al showed that 
addition of a methylene group in the aliphatic lipid chain increases the lipid-DNA binding 
constant by 4 fold [18]. 
At N/P of 1 (Figure 2.2), a low level of protein expression was detected in cells treated with 16-
7N(G-K)-16 nanoparticles (1.6 ±1 ng INF-γ /104 cells) while none was detected for 12-7N(G-K)-
12 and 18:1-7N(G-K)-18:1 nanoparticles. For all three gemini surfactants, increasing the N/P 
ratio was associated with an elevation in the level of protein expression reaching a maximum at 
an N/P value of 2.5 followed by a decreasing trend illustrating a bell-shaped disposition, 
especially for 16-7N(G-K)-16 (Figure 2.2). At the most efficient charge ratio (2.5 N/P), 16-
7N(G-K)-16 gemini lipid showed the highest transfection efficiency (11.7± 0.8 ng INF-γ /104 
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cells ) with more than a 10 fold and 5 fold  increase in the level of INF-γ compared to 18:1-
7N(G-K)-18:1  and 12-7N(G-K)-12, respectively. A significant decrease in the level of protein 
expression was observed at N/P ratios above 5 becoming undetectable for all the tested 
compounds at a charge ratio of 20. This could be explained by the very strong DNA compaction 
that could hinder the release of the DNA from the carrier.   
Interestingly, the optimal N/P ratio of 2.5 was considerably lower compared to previous 
generations of gemini lipids, which showed maximum efficiency at N/P = 10 [8, 21]. This can be 
attributed to the fact that the glycyl-lysine substituted gemini surfactants have a greater number 
of terminal amino groups that can undergo protonation with decreasing pH, leading to an 
increase in the positive charge of the glycyl-lysine substituted compounds. As a result, fewer 
gemini surfactant molecules are required to neutralize and compact the DNA compared to the 
previous generations of gemini surfactants.  Furthermore, the substitution with glycyl-lysine 
moieties in the spacer renders a conformational flexibility to the gemini surfactants and offers a 
balanced binding with the DNA, adequate to avoid enzymatic degradation and to maintain 
intracellular release [14].  Moreover, in the previously studied m-3-m series, there was only a 50% 
increase in gene delivery efficiency from the 12-tail to the 16-tail gemini [8], while in this new 
series there was a 5-fold increase between the 12 and the 16-tail peptide substituted gemini 
surfactants, demonstrating significantly better efficiency. 
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Figure 2.2. In vitro transfection of COS-7 cells comparing the level of IFN-γ expression of the 
three gemini surfactants after 48 h of treatment. Results are the average of three plates of 
quadruplicate wells, error bars represent standard deviation. * Indicates significant at p < 0.05. 
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2.4.2. Assessment of cell viability 
The toxicity of the P/G/L nanoparticles prepared with the three gemini surfactants was evaluated 
in COS-7 cell line after 48 h of treatment (Figure 2.3). P/G/Ls of the 16-7N(G-K)-16 exhibited 
the highest cell viability, 67-85%, at all the N/P ratios studied followed by 12-7N(G-K)-12, 36-
77%, and 18:1-7N(G-K)-18:1 with 23-67% of the cells being viable (Figure 2.3). It is worth 
noting that at the optimal ratio, P/G/Ls of the 16-7N(G-K)-16 showed a significantly lower 
toxicity (more than 80% cell viability, p<0.05) compared to a commercially available 
transfection agent (approximately 50 % viability) (Figure S1, Appendix I). Above the optimal 
N/P ratios there was a trend of dose-dependent increase of cytotoxicity for all compounds. Since 
at lower N/P ratios the concentration of gemini surfactants was lower, it was expected to show 
less toxicity. It was reported that after the neutralization of DNA with cationic surfactant, no 
more surfactant will bind to the lipoplex. As such, excess surfactant will remain in the 
supernatant as free micelles [22, 23]. Thus at higher N/P ratios, the toxicity could be triggered by 
the excess free surfactant. 
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Figure 2.3. Evaluation of COS-7 cell viability at six different N/P ratios of the three gemini 
surfactants using MTT assay after 48 h of treatment. Results are the average of three plates of 
quadruplicate wells, error bars represent standard deviation. 
 
2.4.3. Physicochemical characterization of the lipid-based gene delivery system 
2.4.3.1. Determination of the critical micelle concentration (CMC) 
Increasing the length of the alkyl chain from C12 to C16 was accompanied by a significant 
decrease in the critical micelle concentration (CMC) from 3.72 to 0.155 mM, while the 
compound with mono-unsaturated oleyl chains exhibited a slight but definite increase in CMC 
value (0.178 mM) compared to the C16 gemini. The behaviour of the C16 and C12 gemini is in 
agreement with previously observed behaviour of the diquaternary ammonium gemini 
surfactants [24]. Kuiper et al. showed that the introduction of a double bond, especially cis-
oriented, increases the CMC of the compound compared to the corresponding saturated analogue 
[25]. This was attributed to (i) decrease in hydrophobicity as the hydrophobic fragmental constant 
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for the double bond is 0.63 while for the single bond it is 1.476, (ii) decrease in the tail length as 
the carbon-carbon double bond is shorter than the single bond, and (iii) the hindered ability of 
the alkyl chain to pack in the core of the micelle due to the  less flexible unsaturated tails [25]. In 
addition, cis-oriented bond drives the carbon chain to turn back on itself, making the extension 
shorter compared to the fully extended tail. The lowest CMC for the 16-7NGK-16 surfactant 
indicates that this surfactant has the highest propensity for supramolecular assembly. 
The CMC has been shown to correlate with transfection efficiency. Dauty et al. found that in 
dimerized surfactants, a low CMC was accompanied by higher transfection efficiency compared 
to monovalent counterparts as they increased the stability of the lipoplexes during the delivery 
process [26]. Similarly, the P/L/G nanoparticles of the 16-7N(G-K)-16 gemini surfactant having 
the lowest CMC showed the highest transfection ability in the series studied in this work. Based 
on this hypothesis, the 18:1-7N(G-K)-18:1 should show higher transfection efficiency compared 
to 12-7N(G-K)-12 as it has a lower CMC (0.178 mM). However, the 18:1-7N(G-K)-18:1 showed 
the lowest transfection efficiency at all charge ratios (Figure 2.2). This is in agreement with our 
previous results for the parent compound m-7NH-m [21],  which can be attributed to the loose 
packing arrangement that might result from mixing two unsaturated lipids (18:1-7N(G-K)-18:1 
and DOPE) to form the P/G/L nanoparticles.[27] The looser packing might be due to the presence 
of the double bond that confers less flexibility to the molecule compared to the fully saturated 
tails of 12-7N(G-K)-12 and 16-7N(G-K)-16. Formulations prepared by mixing a saturated and 
unsaturated lipid together resulted in the highest transfection efficiency compared to 
formulations prepared from mixing either two saturated lipids or two unsaturated lipids together 
[27].  
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2.4.3.2. Determination of size and ζ-potential 
In order to correlate the gene delivery efficiency to the physicochemical properties of the P/L/G 
nanoparticles, size and zeta potential measurements of the three compounds at six N/P ratios 
were carried out. The nanoparticles showed a range of particle sizes between 70 and 900 nm. At 
the optimal N/P ratios of 2.5, no significant differences were observed between nanoparticles 
containing gemini compounds with the 12 carbon tail or the 16 carbon tail (77±2 nm and 81±3 
nm, respectively), whereas the P/L/Gs with the 18-carbon mono-unsaturated oleyl tails showed a 
relatively larger particle size of 206±6 nm. This trend is in agreement with size measurements of 
previous generations of gemini surfactants [21] and correlates with the loose packing theory[27].   
Similar to previous generations [28], the particle size of the lipoplexes decreased with increasing 
N/P ratio, implying the importance of charge ratio in determining the particle size. For example, 
at N/P=1 the particle size of all tested compounds was either very large [650 nm for 16-7N(G-
K)-16 and 900 nm for 18:1-7N(G-K)-18:1] or outside of the measurable range of 10-6000nm for 
the 12-7N (G-K)-12, showing visible precipitation, while at a N/P ratio of 20 the particle size of 
the investigated compounds ranged between 54 and 61 nm (Figure 2.4A). Increasing the N/P 
ratio results in increased electrostatic interaction events between the gemini surfactants and the 
DNA, thus a better DNA compaction.  
The size of the DNA lipoplexes impacts the route of cellular entry, efficiency of cellular uptake,  
cytotoxicity,  and intracellular fate [29, 30]. Mammalian cells adopt a variety of endocytic 
pathways, the most common being clathrin-mediated endocytosis, caveolae-mediated 
endocytosis and clathrin- and caveolin-independent endocytosis [31, 32].  The size of endocytic 
vesicles formed during the endocytic processes varies with the specific pathway. For example, 
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the size of vesicles involved in clathrin-mediated endocytosis is in the rage of 120-200 nm, while 
in caveolae mediated endocytosis it is about 60–80 nm [31, 32]. The particle size of the lipoplexes 
of the best performing gemini surfactant, 16-7N(G-K)-16 at its optimal N/P ratio, N/P = 2.5, was 
81 ± 3 nm which was suitable for efficient cellular uptake. In previous work, we showed that the 
uptake of lipoplexes formulated with 12-7N(G-K)-12 in cotton tail rabbit epithelial cells took 
place via both clathrin- and caveolae-mediated endocytosis [33]. Prabha et al. investigated the 
effect of particle size of nanoparticles formulated from poly (D, L-lactide-co-glycolide) on the 
level of gene expression in COS-7 cells. Small nanoparticles of  70 nm showed a 27-fold higher 
transfection than the large-sized nanoparticles  of 200 nm [30]. This result could be one of the 
reasons in the present work for the low level of protein expression found with lipoplexes 
formulated with 18:1-7N(G-K)-18:1 having particle size of 206 ± 6 nm at N/P = 2.5, compared 
to lipoplexes formulated with 16-7N(G-K)-16 having particle size of 81 ± 3 nm, despite their 
close CMC values. 
The nanoparticles reported herein also showed a wide range in zeta potential values, -8 to +94 
mV (Figure 2.4B). All three compounds at N/P ratio of 1 exhibited negative zeta potentials (-8 to 
-0.64 mV), suggesting insufficient DNA charge neutralization and possibly inefficient 
compaction, indicated by the large particle size. All these factors explain the low level of gene 
expression at an N/P ratio of 1. The charge neutralization of the particles occurred at N/P ratios 
<2.5. For all three compounds, the zeta potential increased upon increasing the N/P ratio 
reaching their maximum value at N/P= 20; +25 mV for 12-7N(G-K)-12, +50 mV for 16-7N 
(GK)-16 and +37 mV for 18:1-7N (GK)-18:1 (Figure 2.4B). The zeta potential of the 
formulation with the highest transfection efficiency, 16-7N(G-K)-16 at N/P= 2.5, was +21 mV 
which is optimal for efficient cellular uptake and endosomal release.  
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Zeta potential is a pivotal parameter that influences the delivery of genetic materials both in vitro 
and in vivo. Similar to particle size, it affects cellular uptake, intracellular localization and 
cytotoxicity [34]. While positive charge is conducive to electrostatic interaction with anionic 
proteoglycans on the cell surface, a high charge density could cause cell membrane rupturing[34]. 
Thus the optimal surface charge needs to be determined for nanoparticle systems. All P/G/L 
nanoparticles showed a positive zeta potential of 10-21mV at the highest transfection efficiency, 
N/P of 2.5. Further increase of N/P ratios led to an increase in zeta potential, but did not translate 
into a higher transgene expression. From a pharmaceutical formulation development perspective, 
zeta potential is an important marker of the stability of a colloidal system indicating the net 
balance between the attractive and the repulsive forces among the nanoparticles, DLVO theory 
[35]. For example, having a large positive or negative zeta potential indicates high repulsive forces 
between particles in the system; as a result, the probability for flocculation to occur is minimal. 
Conversely, if the particles have low zeta potential values, the attractive forces due to van der 
Waals interactions dominate and cause  particles to cluster and flocculate [35].  
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Figure 2.4. (A) Particle size and (B) Zeta potential results comparing the three different P/G/L 
nanoparticles vary in their tail length and degree of saturation at six N/P ratios. Results are 
shown as mean (n=3) ± standard deviation. N/D: not detectable; outside the measurable range. 
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2.4.3.3. Influence of pH on size and ζ-potential 
pH sensitivity can be utilized to design intelligent nanoparticles that respond to variation in pH 
of the environment in order to avoid intracellular degradation. In order to examine the impact of 
pH, size and zeta measurements were performed over a range of pH from the intrinsic pH of the 
formulation to acidic pH on the nanoparticles formulated with the best performing lipid, 16-
7N(G-K)-16 . The particle size of the nanoparticles showed an increase from 91 nm at pH= 6 to a 
maximum of 104 nm at pH 4, followed by a decrease at lower pH (Figure 2.5A). Zeta potential 
measurements showed a positive increase as a function of pH reduction from +48 to +65 mV 
(Figure 2.5B). This pH-induced particle size and zeta potential change indicates increased 
protonation of the terminal amines leads to an electrostatically induced expansion. The 
enlargement of the lipoplexes ruptures the membrane of the endocytotic vesicles releasing the 
cargo into the cytoplasm (proton sponge effect) [36]. In previous work, we found that both 
clathrin-mediated and caveolae-mediated pathways were utilized for the cellular uptake of 
lipoplexes formulated with 12-7N(G-K)-12[33]. In clathrin-mediated endocytosis, nanoparticles 
inside the endosomes experience a drop in pH  before merging with lysosomes where they can 
undergo degradation[37]. Thus, adopting a pH-induced structural change enables the nanoparticles 
to escape from endosomes, avoiding lysosomal degradation, and resulting in increased gene 
delivery. No significant differences were observed between formulations with 16-7N(G-K)-16 
and the previously studied 12-7N(G-K)-12, which also showed an expansion in size from 130 
nm at pH 6 to a maximum size of 140 nm at pH= 4 [33]. 
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Figure 2.5. pH dependence of (A) particle size and (B) zeta potential of the P/16-7N(G-K)-16/L 
nanoparticles at N/P ratio of 10. 
 
2.4.3.4. Determination of the lipid organization  
SAXS was employed to study the effect of the nature of the hydrocarbon tail of the glycyl-lysine 
modified gemini surfactants on the supramolecular assembly of the nanoparticles at six N/P 
ratios. In the first stage, the scattering profile of each component was evaluated. The diffraction 
pattern of the plasmid DNA was featureless, indicating no liquid crystalline structure. The helper 
lipid, DOPE showed Bragg peaks at q values of 0.1039, 0.178 and 0.206 with ratio of 1:√3:√4 
corresponding to the inverted hexagonal (HII) phase 
[38]. The gemini surfactants alone showed 
diffused scattering at low q values of 0.12-0.18 indicating micellar organization (Figure 2.6).  
The diffraction pattern resulted from the shell-like structure of the chloride counter-ion cloud 
around the micelles corresponding to a micellar diameter of 5.2-3.4 nm, in agreement with 
values for a similar micelle solution of gemini surfactant [39]. Mixing the three components: 
DNA, gemini lipid and DOPE (P/G/L) led to a marked increase of the intensity at low q 
suggesting the formation of larger scattering objects in the solution and the appearance of Bragg 
peaks at higher q indicating internal ordering of the newly formed aggregates.  
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An inverted hexagonal phase was adopted in all P/G/Ls at their lower N/P ratios (Figure 2.7). 
Inverted hexagonal phase (HII) is known to be responsible for high transfection efficiency due to 
its ability to facilitate fusion with the cell membrane and cytoplasmic release of the DNA into the 
cytosol [40]. The position of the scattering peaks and the corresponding unit cell spacings (a = 
4π/√3 q10) (where q10 is the first Bragg peak) are listed in Table SI, Apendix I. The best 
performing formulation, 16-7N(G-K)-16 at 2.5 N/P, revealed an inverted hexagonal morphology 
with peak positions at q = 0.102, 0.177 and 0.203 corresponding to a unit cell spacing a = 71.129 
Å. At the same N/P ratio, the repeat distance increased by increasing the length of the 
hydrophobic tail, in agreement with previously reported behaviour of cationic surfactant-nucleic 
acid lipoplexes [41-43]. Langevin et al. reported a linear relationship between the number of 
carbons in the surfactant tails and the d-spacing [43].   
Upon increasing the N/P ratios from 1 up to 5, there was a slight shift in peaks towards lower q 
values, indicating a slight increase in the size of the unit cell as the interacting components are 
less closely packed and the system is more hydrated [41]. Interestingly, further increase of the N/P 
ratio between 10 and 20 (increasing the amount of gemini surfactant) was accompanied by 
significant changes in the scattering pattern. In P/G/Ls formulated with 12-7N(G-K)-12 and 16-
7N(G-K)-16, there was a sign of interaction between the helper lipid and the excess gemini 
surfactants at N/P ratios of 5 (red arrows Figure 2.7) which led to the increase in the diffuse 
scattering that eventually overshadowed the Bragg peaks above the N/P ratio of 5.  
 In order to evaluate the possible interaction between the helper lipid and the free gemini 
surfactants micelles, SAXS measurements for formulations containing helper lipid and gemini 
surfactants in the absence of DNA were conducted. The scattering profile of the DOPE/gemini 
surfactants was similar to that of the corresponding P/G/L lipoplexes above the N/P ratio of 5 
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(Figure 2.8). These results are in accord with other studies [22, 23] suggesting that after 
neutralizing the DNA with cationic surfactants no more surfactant will bind to the lipoplexes and 
the excess surfactant will remain in the supernatant as free micelles,  explaining the high toxicity 
trend above N/P ratios of 5 (Figure 2.3). It is worth noting that nanoparticles formulated with 
18:1-7N(G-K)-18:1 gemini surfactant did not follow that trend and the inverted hexagonal phase 
was preserved upon increasing the gemini surfactant content and even this was the case when no 
DNA was added (Figure 2.7C and 2.8). This difference in behaviour could be attributed to the 
presence of the double bond (cis isomer) that might bring the compound’s geometry closer to the 
shape of the DOPE compound (Figure 2.1). Further discussion on this issue is provided below in 
the lipid packing parameter section.   
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Figure 2.6. SAXS scattering profile of gemini surfactant solutions of (A) 12-7N(G-K)-12 ,(B) 
16-7N(G-K)-16 and (C) 18:1-7N(G-K)-18:1. 
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Figure 2.7. SAXS scattering profile of nanoparticles prepared with (A) P/12-7N(G-K)-12/L ,(B) 
P/16-7N(G-K)-16/L and (C) P/18:1-7N(G-K)-18:1/L. 
 
 
 
Figure 2.8. SAXS scattering profile of DOPE and gemini surfactant mixtures at quantities 
corresponding to an N/P ratio of 10.  
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2.4.3.5. Determination of the molecular packaging parameter of the lipids 
In order to investigate the effect of structural differences on the preferred curvature of self-
aggregates of the three gemini surfactants, the molecular packing parameter was estimated using 
values of parameters based on the behaviour of the gemini surfactant at the air-water interface. 
The molecular packing parameter P  is a concept  developed by Israelachvili et al. to describe the 
shape of aggregates formed by surface active compounds in aqueous solution [44]. It is defined as  
𝑃 = Ѵ/𝚊₀ɭ          (1) 
where Ѵ is the volume of the hydrophobic tails, ɭ is the length of the hydrocarbon tails, and 𝚊₀ is 
the head group area per molecule at the aggregate surface.  
A specific value of P can be translated into a particular geometrical shape [44, 45]. It has been 
stated in the literature that the 𝚊₀  value is the main determinant of the P value since Ѵ/ɭ ratio is 
fixed for common surfactants regardless of the tail length [46, 47]. However, Nagarajan showed 
that the tail has an explicit or an implicit impact on the P values[47]. While the volume and the 
length of hydrocarbon chains are simple geometrical properties which can be calculated from the 
chemical structure, evaluation of the head group area is more complicated [47].  It is an 
equilibrium parameter that is determined by a balance between both the attractive forces of the 
hydrophobic chains and the repulsive force of the adjacent head groups [48]. This work aims at 
exploring the effect of tail length and geometry on the head group area and the packing 
parameter.  
The gemini surfactant 12-7N(G-K)-12 showed the smallest mean molecular area of 𝚊₀ = 52 Å2, 
as a result, the largest molecular packing parameter (1.17). In agreement with previously 
reported trend of cationic gemini surfactants [49], the mean molecular area expanded with 
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increasing length of the alkyl tail. The gemini surfactant having hexadecyl tails showed a mean 
molecular area of 60 Å2 and a P value of 0.84.  The 18:1-7N(G-K)-18:1 gemini surfactant had an 
𝚊₀ = 70 Å2 and a P value of 0.67 which were the closest to the value of the DOPE head group 
area 𝚊₀  =  75 Å2  and P of 0.63. The pressure-area isotherms are shown in Figure S2, Apendix I.  
The similarity in the head group area between the 18:1-7N(G-K)-18:1 gemini surfactant  and 
DOPE might be the reason for the preservation of the hexagonal arrangement of the P/G/Ls at all 
N/P ratios  (Figure 2.7C), while the other two gemini surfactants, with head group areas 
markedly different from DOPE induced structural changes in the P/G/Ls at high N/Ps (Figure 
2.7A and 7B). Based on these findings, we constructed a model of hexagonal arrangement of all 
P/G/Ls (Figure 2.9A) and a schematic representation of the lipid assembly (Figure 2.9B). As 
mentioned earlier, the presence of the double bond in the 18:1-7N(G-K)-18:1 confers this gemini 
surfactant similar nature to the helper lipid, DOPE amenable to maintain the organization 
through a wide range of molar ratios, whereas, the 12-7N(G-K)-12 and 16-7N(G-K)-16 are 
disruptive for organization. The variation in the mean molecular area among the gemini 
surfactants, with the same chemical composition of the head group, underlines the role of the 
alkyl tail in the interaction among the different molecules of the delivery system and genetic 
material, ultimately impacting on the condensation of the DNA.  
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Figure 2.9. Schematic representation of (A) inverted hexagonal phase adopted by all lipoplexes 
at their optimal N/P ratios and (B) the variation in the lipid packing resulted from the variation in 
the gemini surfactants geometry. 
 
2.5. Conclusion  
A new generation of peptide-substituted gemini surfactants was synthesized to evaluate the 
impact of varying the length of the hydophobic tail on the lipoplex morphology, transfection 
efficiency and cytotoxicity. Three glycyl-lysine substituted compounds having dodecyl, 
hexadecyl and oleyl tails were tested. The results indicated that the transfection efficiency was 
highly dependent on both the length of the alkyl tail and gemini surfactant to plasmid DNA (N/P) 
charge ratio, moreover, it correlated with physicochemical properties of the lipoplexes. By 
selecting a suitable alkyl tail length, the level of gene expression could increase 5 to10 folds. On 
balance, the results indicate that the structure of the gemini surfactants play an important role in 
determining the transgene efficiency of the delivery system and suggests that it is an essential 
factor in the rational design of effective gemini vectors for gene delivery systems.  
  
A B 
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Transitioning rationale: 
The incorporation of the amino acids into the gemini surfactants’ spacer region caused a 
significant increase in their transfection efficiency and reduced cytotoxicity. In the previous 
chapter, we assessed the impact of altering the alkyl tails on the efficiency of the delivery 
system. In this chapter, we introduce a new series of peptide-modified gemini surfactants with 
various alkyl tails and peptides spacer modifications. The aim is to elucidate their structure 
activity relationship and to identify the fundamental architectural requirements for efficient gene 
delivery systems. 
Contribution statement: 
Mays Al-Dulaymi contributed to this manuscript by designing the study, performing 
experiments, data acquisition, data analysis and manuscript writing. Dr. Jackson Chitanda 
synthesized the gemini surfactants utilized in this work. Ms. Deborah Michel and Dr. Ildiko 
Badea performed the onsite SAXS measurements. Surface tension data acquisition was 
conducted by Dr. Shawn Wettig lab.  
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3.1. Abstract 
Diquaternary ammonium gemini surfactants are an emerging class of non-viral gene 
delivery vectors. Their unique molecular structure impart preferable characteristics such as 
enhanced nucleic acid complexation ability, bottom-up design flexibility and relatively low 
cytotoxicity. To capitalize on the potential of gemini surfactants as effective gene delivery 
vectors, novel structural modifications should be explored. In this work, a series of novel 22 
peptide-modified gemini surfactants was introduced with various alkyl tails and peptide spacer 
modifications. To the best of our knowledge, this work represents the first report of dendrimer-
like gemini surfactants and first evaluation of the impact of incorporating a hydrocarbon linker 
into the peptide chain. The aim of this work was to assess the structure activity relationship of 
the novel peptide modified gemini surfactants and to identify the fundamental architectural 
requirements needed in designing the ultimate gene delivery systems.  
Transfection efficiency and cytotoxicity were evaluated in PAM 212 murine keratinocyte 
and COS-7 African green monkey kidney fibroblast cell lines. Physicochemical properties of the 
nanoparticles were systematically investigated by evaluating the particle size and surface charge 
using dynamic light scattering and laser Doppler velocimetry, respectively. In addition, surface 
tension measurements were used to assess the critical micelle concentration (CMC) and lipid 
packing parameters. Morphological characteristics were studied by small-angle X-ray scattering 
(SAXS). 
Results revealed that the highest transfection efficiency and the lowest cytotoxicity were 
associated with the glycyl-lysine modified gemini surfactants having the hexadecyl tail, 16-
7N(G-K)-16. In fact, it showed an 8-fold increase in secreted protein with 20% increase in cell 
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viability relative to the first-generation unsubstituted gemini surfactants. Further increase in the 
size of the attached peptides resulted in a decrease in the transfection efficiency and cell 
viability. Whereas the incorporation of a hydrocarbon linker into the peptide chain decreased the 
transfection efficiency of compounds with di-peptides, it increased the transfection efficiency of 
compounds with larger peptide chains. Such an increase was more prominent with incorporation 
of a longer hydrocarbon linker. We conclude that a balance between the hydrophilic and 
hydrophobic characteristics of the compound is necessary since it results in physicochemical 
parameters conducive to the gene delivery process.  
Keywords: structure activity relationship; non-viral vectors; cationic surfactants; dendrimer-
like; small angle x-ray scattering 
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3.2. Introduction 
The wealth of information gained upon completion of the human genome project has 
accelerated the discovery of the genetic basis of many disorders and the development of novel 
gene-editing technologies, presenting gene therapy as an approach that could revolutionize 
medicine [1, 2]. However, the success in delivering genes into the target site has not kept pace with 
the advancements in gene discovery and editing. This is mainly due to the lack of delivery 
vectors capable of overcoming various biological barriers and delivering the therapeutic DNA 
into the target site efficiently and safely. Over the past 30 years, both viral and non-viral vectors 
have been evaluated for their efficiency to deliver genetic material in clinical trials [3, 4]. While 
viruses have naturally evolved to deliver their genetic materials into the cells, they suffer from 
several inherent shortcomings such as immunogenicity, tumorigenicity, limited DNA packaging 
capacity and high cost [5]. Non-viral methods, on the other hand, have the potential to address 
many of these limitations, particularly safety concerns. 
Among the various non-viral gene delivery modalities currently being explored, lipid-
based delivery vectors are at the forefront [6]. In fact, there are more than 115 clinical trials that 
have investigated the feasibility of lipid-mediated transfection [7]. Diquaternary ammonium 
gemini surfactants are a unique class of the lipid-based delivery vectors that show promising 
results in delivering genetic materials [8]. They are composed of dimeric surfactants that retain 
positively charged head groups and hydrocarbon tails linked by a spacer chain [9].  The dicationic 
head groups and the hydrocarbon chains collectively offer a preferable nucleic acid complexation 
ability, resulting in the formation of nano-sized lipoplexes that favor cellular internalization [10]. 
In addition, the unique structure of gemini surfactants has imparted superior characteristics 
compared to their monomeric counterparts, particularly lower critical micelle concentration 
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(CMC) and Krafft temperature, which encourage the spontaneous formation of nanoparticles at 
very low concentrations [9]. Most importantly,  the structural versatility of gemini surfactants 
have allowed for bottom-up design flexibility to modulate the physicochemical properties of the 
delivery system toward the enhancement of transfection efficiency [10]. 
Research efforts have focused on the design and advancement of novel gemini surfactants 
aiming at improving their transfection efficiency and reducing cytotoxicity [11-13]. The most 
extensively studied group is the classical N, N-bis(dimethylalkyl)-α, ω-alkane-diammonium 
gemini surfactants represented as m-s-m where m is the number of carbon atoms in the alkyl tails 
and s is the number of carbon atoms in the spacer. They have showed promising results in 
delivering genetic material both in vitro and in vivo [14, 15]. The potential of  lipoplexes composed 
of N,N'-bis(dimethylhexadecyl)-1,3-propanediammonium dibromide gemini surfactant, 
designated as 16-3-16, was evaluated as a non-invasive topical gene delivery system for the 
treatment of localized scleroderma in normal, knock out and diseased animal models [14-16]. A 
significant elevation was observed in the level of transgene expression in both normal and knock 
out animal models upon treatment with gemini surfactant-based lipoplexes compared to 
treatment with naked DNA[14, 15]. Moreover, collagen production in diseased mice was decreased 
by 70%, suggesting the efficiency of the non-invasive delivery system [16]. 
Despite the success of the classical gemini surfactants, translation into clinical 
applications is delayed, mainly because their transfection efficiencies still lag behind those of 
viral vectors. In addition, some concerns regarding their toxicity profile have recently arisen [17]. 
Thus, the incorporation of biofunctional and biodegradable structural motifs were explored in an 
attempt to ameliorate their transfection efficiency and safety profile [18, 19]. For instance, amino 
acids are naturally occurring biocompatible and biodegradable materials that can be incorporated 
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into the gemini surfactants at low cost [20, 21]. They possess different functionalities, particularly 
pH sensitivity and chirality, which allow for the formation of a wide variety of aggregate 
structures. Furthermore, they mimic cell penetrating peptides located on viral capsids that are 
believed to be responsible for the viruses’ high infection capacity [22]. Accordingly, a new series 
of gemini surfactants was introduced by coupling mono and di- amino acids moieties into their 
spacer region [23-25].  They demonstrated a superior in vitro transfection efficiency and safety 
compared to the previously developed classical gemini surfactants [23-25]. In addition, topical 
application of lipoplexes composed of glycyl-lysine modified gemini surfactants, designated as 
12-7N(G-K)-12, into rabbit vaginal cavities exhibited higher gene expression compared to the 
unsubstituted parent compound without evidence of visible toxicity [26].  
The enhanced activity associated with the incorporation of amino acids into the gemini 
surfactants spacer region was attributed to the balanced binding with the nucleic acid facilitating 
both processes of genetic material compaction and subsequent release [24]. In addition, the amino 
acids high buffering capacity endowed a pH-dependent increase in particle size and zeta 
potential which gave rise to “intelligent” nanoparticles that respond to endosomal acidification to 
avoid lysosomal degradation [25, 27]. The conjugation of amino acids also resulted in decreasing 
the amount of gemini surfactant required to neutralize and compact the DNA due to the presence 
of terminal amino groups that imparted a higher positive charge [25].  
Further modification of the lead compound, 12-7N(G-K)-12,  resulted in more than 5-fold 
increase in the level of gene expression only by optimizing its hydrophobic domain, emphasizing 
the importance additional structural modification in augmenting the efficiency of the delivery 
system [25]. In light of the apparent importance of fine-tuning, this work introduces a new series 
of peptide modified gemini surfactants and evaluates for the first time the impact of inserting a 
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hydrocarbon linker within the peptide chain (Figure 3.1). The transfection efficiency, 
cytotoxicity and physicochemical properties of these compounds were systematically 
investigated aiming at elucidating their structure activity relationship. Such knowledge will 
address fundamental questions about the architectural requirements needed for efficient gene 
delivery systems and it will feed into the design of novel carriers with higher activity and 
reduced toxicity. 
 
Figure 3.1. Schematic representation of gemini surfactants showing the two ionic head groups, 
hydrocarbon tails, spacer, hydrocarbon linker and the attached peptides.  
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3.3. Materials and methods  
3.3.1. Materials 
Twenty two peptide-modified cationic gemini surfactants, designated as m-7N(R)-m 
where m is the alkyl tail carbon chain length, m= 12, 16 or 18:1 (18:1 is a mono-unsaturated 
oleyl chain), and R is the peptide chain: R = glycyl-lysine, glycyl-trilysine, glycyl-heptalysine, 
glycyl-hexyl-lysine, glycyl-hexyl-trilysine, glycyl-undecyl-lysine, glycyl-undecyl-trilysine, 
hexyl-trilysine, undecyl-trilysine, hexyl-heptalysine and undecyl-heptalysine (Figure 3.2), were 
synthesized similar to previously reported procedures [25]. The plasmid pGThCMV.IFNGFP 
(pDNA), encoding for murine interferon gamma (IFN-γ) and green fluorescent protein (GFP) 
was utilized in this work [14]. QIAGEN Plasmid Giga Kit (Mississauga, ON, Canada) was used to 
isolate and purify the plasmid DNA according to the manufacturer’s instructions. 1,2-dioleoyl-
sn-glycerol-3-phosphoethanolamine (DOPE), used as a helper lipid, was purchased from Avanti 
Polar Lipids Inc. (Alabaster, AL, USA). Sucrose, used as a stabilizing, agent was purchased from 
Sigma Aldrich (Oakville, ON, Canada).  
Minimal Eagle’s Medium (MEM) and Dulbecco's modified Eagle's medium (DMEM) 
were obtained from ATCC (Manassas, VA, USA). Tissue culture plates were purchased from 
Falcon, BD (Mississauga, ON, Canada). Lipofectamine Plus TM reagent and MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) were obtained from Invitrogen 
(Mississauga, ON, Canada). Recombinant mouse IFN-γ standard was attained from BD 
Biosciences (Mississauga, ON, Canada). Dimethyl sulfoxide (DMSO), ACS spectrophotometric 
grade, was purchased from Sigma-Aldrich (Mississauga, ON, Canada) 
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3.3.2. Formulations  
The gemini surfactants were combined with pDNA at three different nitrogen (cationic) 
to phosphate (anionic) charge ratios (N/P) of 2.5, 5, and 10 in the presence of a fixed amount of a 
helper lipid, DOPE, to create pDNA / gemini surfactants / helper lipid (P/G/L) nanoparticles. An 
appropriate amount of 3mM aqueous solution of gemini surfactant was added to 200 µg/mL 
pDNA and incubated for 20 minutes at room temperature (P/G complex). DOPE at a final 
concentration of 1mM was prepared as described previously [28] and added to P/G complexes to 
form the final nanoparticles (P/G/L).   
3.3.3. Cell culture and in vitro transfection study  
PAM 212 murine keratinocyte and COS-7 african green monkey kidney fibroblast cell 
lines (ATCC, CRL-1651) were grown to 80% confluency in 75-cm2 tissue culture flasks in 
MEM and DMEM supplemented with 10% (vol/vol) fetal bovine serum and 1% (vol/vol) 
antibiotic/antimycotic agents and incubated at 37 °C with 5% CO2. One day prior to transfection, 
96-well tissue culture plates were seeded with the cells at a density of 15×103 and 1×104 
cells/well for PAM 212 and COS-7 cell lines, respectively. The supplemented medium was 
replaced with FBS-free medium one hour prior to transfection. Cells were transfected with 0.2 
μg/well pDNA and incubated at 37 °C in CO2 for 5 h. Lipofectamine Plus reagent TM was used as 
a positive control according to the manufacturer’s protocol. The transfection mixture was 
replaced by supplemented medium after 5 h. Supernatants were collected and replaced with fresh 
medium at 24, 48 and 72 h. The collected supernatants were stored at - 20 °C. The results 
presented are the average of three independent plates of quadruplicate wells. 
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3.3.4. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was carried out to measure the level of secreted interferon gamma using flat 
bottom 96-well plates according to the BD Pharmingen protocol. A standard IFN-γ curve was 
created using recombinant mouse IFN-γ standard to calculate the concentration of the secreted 
IFN-γ.  
3.3.5. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
MTT assay was performed to examine the cytotoxicity of the peptide-modified gemini 
surfactants in both PAM 212 and COS-7 cell-lines. Three 96-well cell culture plates were seeded 
with the optimal cell density for each cell line and treated with the P/G/L nanoparticles. Plates 
were incubated for 5 h at 37 °C with 5% CO2 before replacing the old media with fresh media as 
described in the transfection section. Cell toxicity was evaluated 72 h after treatment in PAM212 
and 48 h in Cos-7. Lipofectamine, a commercial transfection agent, was used as a positive 
control. A sterile solution of 5 mg/mL of MTT (Invitrogen, U.S.A.) in phosphate buffered saline 
(PBS) was prepared, mixed with supplemented media, then added to the cells and incubated for 3 
h. The supplemented media was removed, then the formed, purple formazan crystal was 
dissolved in dimethyl sulfoxide and the plates incubated at 37 °C for 10 m. Absorbance was 
measured at 550 nm using a microplate reader (BioTek® Microplate Synergy HT, VT, U.S.A.). 
The results are the average of three plates (treated with individually prepared formulations of 
quadruplicate wells) and the cytotoxicity is expressed as a percentage of the non-transfected 
control cells ± standard deviation. 
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3.3.6. Size and ζ-potential measurements 
Size and ζ-potential measurements for the tested lipids at three N/P ratios were performed 
by using a Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK). Samples 
were prepared as described in the formulation section and each sample was measured three times 
and the results reported are the average of the three readings ± standard deviation. 
3.3.7. Small-angle X-ray scattering measurements (SAXS) 
The formulations were prepared as in the transfection study using ten times higher 
concentrations. The SAXS experiments were performed at the BL4-2 beam line at Stanford 
Synchrotron Radiation Lightsource (SSRL, Stanford, USA) using a wavelength of 1.1271 Å 
(11KeV energy). The scattered X-ray was detected on MAR225-HE (225 mm x 225 mm (3072 x 
3072 pixels, pixel size 73.24 μm) at sample to detector distance of 1.1m with exposure time of 
20s. The SAXS detector was calibrated with silver behenate. GSASII software was used to plot 
diffraction intensity versus 2θ (where θ is the diffraction angle) or the scattering vector (𝑞 =
4𝜋
𝜆
sin 𝜃 ) by radial integration of the 2D patterns.  
3.3.8. Surface Tension Measurements  
Surface tension measurements were performed using a Lauda model TE3 automated 
tensiometer (Lauda, Germany) by applying the du Nouy ring technique. The measured surface 
tension values (γ) were corrected using the method of Harkins and Jordan [29]. Experimental 
temperatures were maintained at 45.0 ºC using a circulating water bath. The stock gemini 
surfactant solutions were titrated into 15 mL of water and the surface tension was measured after 
each addition. The critical micelle concentration (CMC) values were obtained from the linear 
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fitting of the pre-micellar and post-micellar regions of the surface tension vs. logarithmic 
concentration plot. 
3.3.9. Molecular packing parameter  
Molecular packing parameter (P) was obtained according to the following equation.   
𝑃 = Ѵ/𝚊₀ɭ   (1) 
 where Ѵ is the volume of the hydrophobic tails, ɭ is the length of the hydrocarbon tails, and 𝚊₀ is 
the head group area per molecule at the aggregate surface. The volume and length of the 
hydrophobic tail can be estimated from knowledge about the gemini surfactant’s structure as will 
be discussed in the structure calculation section. Estimation of the head group area is rather 
complex since it is an equilibrium parameter that is determined by a balance between the several 
attractive and repulsive forces acting simultaneously to determine the preferred curvature of the 
gemini aggregates.  As such, it was obtained from calculating the surface excess concentration 
according to the relation:  
𝑎0 = (𝑁𝐴Γ)
−1    (2) 
where NA is the Avogadro number, and Γ is surface excess concentration derived from the Gibbs 
adsorption isotherm as shown in the equation below: 
Γ = −
1
2.303𝑛 RT
(
dγ
d log C
)
T
   (3) 
where R is the gas constant ,T is the absolute temperature and n is the number of species at the 
interface resulting from the dissociation of the surfactants, which for gemini surfactants it is 
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equal to 3 [30]. The value for the premicellar slope, (dγ/ d log C) T, is obtained from the surface 
tension measurements. 
3.3.10. Structure calculations  
An estimate of the length of the hydrocarbon tails was attained by using Avogadro 
software [31]. Volume calculations were conducted with Gaussian09 software, revision C.01 [32]. 
The geometry was optimized on the B3LYP level of theory with 6-311+G(d,p) basis set. 
Optimized structures were confirmed using harmonic frequency calculations. Volumes for the 
optimized structure were calculated using united atom radii. 
Calculated partition coefficient (clog P) values were estimated using ACD/Physchem 
Profiler 2016 [33] (Advanced Chemistry Development, Inc., Toronto, ON, Canada). 
3.3.11. Statistical analysis 
Statistical analyses were performed using SPSS software (Version 23.0). Results 
expressed as the average of n ≥ 3 ± SD. One-way analysis of variance (ANOVA, 
Scheffé/Dunnett’s post hoc tests) and Pearson’s correlation were used for statistical analyses. 
Significant differences were considered at p<0.05 level. 
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3.4. Results and discussion 
3.4.1. Molecular design of peptide-modified gemini surfactants  
The high performance and low cytotoxicity of the previously evaluated amino acid-
conjugated gemini surfactants have motivated the design of a novel series of 22 peptide-modified 
gemini surfactants (Figure 3.2) [23-25]. The aim of this work was (i) to produce compounds with 
higher transfection efficiencies, (ii) lower toxicity and (iii) to develop a better understanding of 
the impact of structural modification on the physicochemical characteristics and biological 
activity of the newly developed peptide-modified gemini surfactants, i.e., structure-activity 
relationship. The designed compounds are based on the m-7N(R)-m general structure, where m = 
the number of carbon atoms in the alkyl tails, R = the amino acid group coupled onto the N 
position of the spacer region as shown in Figure 3.2. The structural modification focused on 
altering the conjugated amino acid group grafted into the spacer and varying the hydrophobic 
tails.  
In light of the important role of the terminal lysine moiety in the interaction with the 
nucleic acid and the production of intelligent nanoparticles that respond to environmental stimuli 
[24, 25, 27], we investigated the impact of increasing the number of terminal lysine moieties on the 
efficiency of the delivery system. Accordingly, compounds with tri- and hepta- lysine residues 
were designed to create dendrimer-like gemini surfactants (Figure 3.2, compounds 2-3).  
Furthermore, the impact of incorporating an hydrocarbon linker between the amino acids and 
spacer group was evaluated. The rationale was that a distance between the quaternary ammonium 
head group and the amino acid substituent might be required for efficient gene delivery. Hexyl 
and undecyl chains were tested to assess the effect of linker length on the gene delivery system 
(Figure 3.2, compounds 4-7).  Eliminating the glycine residue and coupling of the hydrocarbon 
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linker directly into the spacer was also investigated to evaluate the role of the glycine in 
determining the transgene efficiency and physicochemical characteristics (Figure 3.2, 
compounds 8-11).  
In addition to the assessment of various structural substituents into the spacer region, 
modifications to the hydrophobic tails were also conducted. In earlier studies, it was found that 
the length and the degree of unsaturation of the alkyl tail have a significant effect on the 
physicochemical properties of gemini surfactants, thereby affecting their efficiency to deliver the 
genetic material [25]. As such, this work evaluates three types of hydrophobic tails that are 
commonly reported in the literature for their high efficiency, namely dodecyl, hexadecyl and 
oleyl (Figure 3.2).  Generally, compounds with hexadecyl tails demonstrated higher or very 
similar transfection efficiency compared to their structural analogues with dodecyl and oleyl 
chain in all compounds. This was in alignment with our previous report that specifically assessed 
the role of the alkyl tail on the transfection efficiency of di-amino acid-modified gemini 
surfactants [25]. Therefore, this manuscript focuses on compounds with hexadecyl alkyl tails with 
less emphasis on the dodecyl and oleyl chains.  
To the best of our knowledge, this is the first report that describes the design of 
dendrimer-like gemini surfactants and incorporation of hydrocarbon linkers into the spacer 
region. By evaluating the structure-activity relationship of such model compounds, we believe 
that this study could provide a framework for the future development of peptide-based gemini 
surfactants.   
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Figure 3.2. Chemical structure of the evaluated peptide-modified gemini surfactants where m is 
the alkyl tail carbon chain length, G is a glycine and K is a lysine residue.   
127 
 
3.4.2. Physicochemical characterization of the lipid-based gene delivery system 
3.4.2.1. Determination of critical micelle concentration  
The critical micelle concentration (CMC) is an important interfacial property that 
quantitatively describes the propensity of an amphiphile to assemble. It could give an indication 
of the ability of gemini surfactants to form stable complexes with the nucleic acid [34]. The self-
assembly process is governed by a balance between attractive forces resulting from both 
hydrophobic interactions as well as hydrogen bonding, and repulsive forces caused by the 
electrostatic repulsion [35]. As such, all the structural elements of the gemini surfactants act 
simultaneously to determine micelle formation.  
Peptide-modified gemini surfactants displayed a wide range of CMC values between 35 
to 106 µM (Table 3.1). This could be rationalised by the diverse molecular structure of the 
peptides incorporated into the spacer region. In general, increasing the number of terminal lysine 
moieties within the structure was associated with an increase in the CMC value (Table 3.1). For 
example, CMC values increased from 83 to 93 then to 107 µM when the number of lysine 
moieties increased from one in 16-7N(G-K)-16 to three in 16-7N(G-K3)-16 then to a sequence of 
seven residues in 16-7N(G-K7)-16. This was negatively correlated (Pearson’s correlation 
coefficient = -0.997, p<0.05) with the compounds lipophilicity where clog p values decreased 
from 2.80, to 0.98 then to -2.04 for 16-7N(G-K)-16, 16-7N(G-K3)-16 and 16-7N(G-K7)-16, 
respectively (Table 3.1). The same trend was followed across all evaluated structural analogs 
such as 16-7N(G-C6-K)-16 compared to 16-7N(C6-K3)-16 and 16-7N(G-C11-K)-16 relative to 
16-7N(G-C11-K3)-16 as shown in Table 3.1. Such a trend is in agreement with the reported 
pattern in the literature that the CMC in aqueous solution usually decreases upon increasing 
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hydrophobicity of the amphiphile as a result of strong hydrophobic interactions that induce 
micelle formation [36]. In addition, increasing the number of lysine moieties causes an increase of 
the charge density due to the high pKa (≈ 10.5) value of the primary amines of the terminal lysine 
residues, which is 99% ionized at the formulation intrinsic pH (≈ 6). Increasing the charge 
density will contribute to the Coulombic repulsion between the adjacent molecules of gemini 
surfactants [37]. Consequently, more surfactants are needed to form micelles. 
Furthermore, the incorporation of a hydrophobic linker into the spacer region resulted in 
a significant decrease in the CMC values (Table 3.1). This was also attributed to the overall 
increase in the compounds’ hydrophobicity which ultimately impacted the self-assembly process 
[36]. For example, while the attachment of an hexyl linker into 16-7N(G-K)-16 resulted in 
decreasing the CMC from 83 to 45 µM as in 16-7N(G-C6-K)-16, the incorporation of undecyl 
linker lowered CMC to 36 for 16-7N(G-C11-K)-16. Moreover, incorporation of the hydrophobic 
linker increased the distance between the quaternary ammonium and the charged atoms on the 
peptide chain which could minimize the repulsive forces, favoring surfactant aggregation at 
lower concentrations. As such, longer linkers (i.e., undecyl linker over hexyl linker) imparted 
lower CMC values (Table 3.1). 
Conversely, removing the glycine residue and coupling the hydrocarbon linker directly 
into the spacer region, 16-7N(C11-K3)-16 and 16-7N(C6-K3)-16, resulted in higher CMC values 
compared to the compounds that contained glycine (16-7N(G-C11-K3)-16 and 16-7N(G-C6-K3)-
16) despite the higher lipophilicity of the former compared to the latter. For instance, although 
compound 16-7N(G-C6-K3)-16 had lower lipophilicity than 16-7N(C6-K3)-16 (clog P values of 
1.28 and 1.98, respectively), it exhibited a lower CMC value of 67 µM compared to 86 µM for 
the latter (Table 3.1). This could be explained by the tendency of the glycine moiety to form 
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hydrogen bonding with the neighbouring head groups which could minimize the electrostatic 
repulsion. As a result, fewer building blocks are needed to form a micelle. These findings are 
consistent with reports that the incorporation of a small hydrophilic moiety into the spacer 
provides a more water-compatible interface that results in a lower CMC compared to an 
unsubstituted compound [38]. 
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Table 3.1. Hydrophobicity and micellization parameters of the peptide-modified gemini surfactants.   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Gemini surfactants clog P 
CMC 
(µM) 
Head group 
area (Å2) 
Molecular 
packing 
parameter 
Molecule shape Micelle shape 
16-7N(G-K)-16 2.80 83 40 1.26 Inverted truncated cone Inverted micelles 
16-7N(G-K3)-16 0.98 93 123 0.41 Truncated cone Cylindrical micelles 
16-7N(G-K7)-16 -2.04 107 190 0.27 Cone Spherical micelles 
16-7N(G-C6-K)-16 3.77 45 115 0.44 Truncated cone Cylindrical micelles 
16-7N(G-C11-K)-16 4.81 36 241 0.21 Cone Spherical micelles 
16-7N(G-C6-K3)-16 1.28 67 151 0.33 Truncated cone Cylindrical micelles 
16-7N(G-C11-K3)-16 3.27 57 257 0.20 Cone Spherical micelles 
16-7N(C6-K3)-16 1.98 86 79 0.64 Truncated cone 
Flexible bilayers, 
vesicles 
16-7N(C11-K3)-16 3.98 63 102 0.50 Truncated cone 
Flexible bilayers, 
vesicles 
16-7N(C6-K7)-16 -1.45 98 178 0.29 Cone Spherical micelles 
16-7N(C11-K7)-16 0.58 81 130 0.39 Truncated cone Cylindrical micelles 
1
3
0
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3.4.2.2. Determination of the molecular packaging parameter  
 The shape of the gemini surfactant molecules plays an important role in determining their 
ability to form a supramolecular assembly with the DNA; hence, it impacts the performance of 
the gene delivery system [39]. Accordingly, understanding how the molecular structure of the 
gemini surfactant controls the shape of the resulting aggregate is an essential step in the rational 
design process. The shape of the aggregates can be obtained from estimating the molecular 
packing parameter (P) based on the behaviour of the gemini surfactant at the air-water interface 
[40]. This concept was introduced by Israelachvili et al. to relate the geometrical shape of the 
surfactants to the preferred curvature of its aggregates [40].  
A specific value of P can be connected via geometrical relationship to a particular micelle  
shape [40, 41]. For example, a P values of less than 0.33 tend to form spherical micelles, whereas 
cylindrical or rod-like aggregates are observed with P values between 0.33 and 0.5. The 
formation of vesicles occurs for P values between 0.5 and 1.0.  When P =1 bilayers with zero 
curvature are formed and a P value greater than 1 favours the formation of reversed structures.     
Increasing number of the lysine moieties in compounds 16-7N(G-K)-16, 16-7N(G-K3)-16 
and 16-7N(G-K7)-16 resulted in a significant enlargement in the head group areas from 40 to 123 
to 190 Å2, respectively (Table 3.1 and Figure 3.3). Such an increase was expected due to the 
bulkiness of the functional groups incorporated into the spacer (Figure 3.3). This in turn gave 
rise to diverse aggregate shapes across the three compounds, namely the 16-7N(G-K)-16 
compound favoured the formation of inverted micelles, 16-7N(G-K3)-16 formed cylindrical 
micelles while 16-7N(G-K7)-16 gemini surfactants resulted in spherical micelles (Table 3.1). 
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Figure 3.3. Schematic representation of peptide-modified gemini surfactant molecular shapes 
shows the impact of increasing the number of terminal lysine moieties on the molecular packing 
parameter (P), preferred curvature and transfection efficiency.  
 
The incorporation of an hydrocarbon linker between the glycine and lysine residue(s) in 
compound 16-7N(G-K)-16 also induced a significant increase in the gemini surfactant head 
group areas (Table 3.1). For example, attachment of an undecyl linker in compound 16-7N(G-
C11-K)-16 gave rise to a head group areas twice as large as that of the hexyl linker in 16-7N(G-
C6-K)-16 (241 and 115 Å
2 , respectively) (Table 3.1). In fact, the head group area resulting from 
the incorporation of undecyl linker in 16-7N(G-C11-K)-16 was greater than that of compound 16-
7N(G-K7)-16 (241 and 190 Å
2, respectively) (Table 3.1). This could be explained by the greater 
tendency of 16-7N(G-K7)-16 to form intramolecular hydrogen bonding than in 16-7N(G-C11-K)-
16 causing compaction of the head group. The insertion of chemical motifs that permit 
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intramolecular hydrogen bonding encourages interaction within the head group area, giving rise 
to a smaller cross sectional area and larger packing parameter [42, 43].  
A similar trend was observed in compounds coupled with three lysine residues where the 
addition of the undecyl linker (16-7N(G-C11-K3)-16) resulted in an head group area 1.6-fold 
larger than that of the hexyl linker (16-7N(G-C6-K3)-16, Table 3.1). Contrary to the expectation 
that the addition of the hydrophobic linker (hexyl or undecyl) leads to a linear increase in the 
head group areas of gemini surfactants, regardless of the number of terminal lysine moieties, we 
observed that the expansion in the head group area was more prominent in the series that 
contained only one terminal lysine moiety. For example, while there was a 6-fold increase in the 
head group area of 16-7N(G-C11-K)-16 compared to 16-7N(G-K)-16, the head group area of 16-
7N(G-C11-K3)-16 increased by only 2-fold relative to 16-7N(G-K3)-16 compound (Table 3.1). 
We also attribute this to the stronger intramolecular bonding in the dendrimer-like modified 
surfactants that minimize the cross sectional area [42, 43].  
Removing the glycine moiety and conjugating the hexyl and undecyl linker directly into 
the spacer resulted in smaller head group areas compared to their analogs having the glycine. For 
example, 16-7N(C6-K3)-16 exhibited an head group area of 79 Å
2 whereas the 16-7N(G-C6-K3)-
16 head group area is 151 Å2 (Table 3.1). Surprisingly, the head group areas of compounds that 
had the linker directly incorporated into the spacer were even smaller than the compound without 
the linker as illustrated by compounds 16-7N(C6-K3)-16, 16-7N(C11-K3)-16 and 16-7N(G-K3)-16 
with head group areas of 79, 102 and 123 Å2, respectively. A similar trend was observed for 
compounds with seven lysine moieties where compound 16-7N(G-K7)-16 had a head group area 
of 190 Å2 while compounds 16-7N(C6-K7)-16 and 16-7N(C11-K7)-16 exhibited areas of 178 and 
130 Å2, respectively (Table 3.1). This could be attributed to the increased distance between the 
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positively charged quaternary ammonium head group and the charged functional groups in lysine 
residues induced upon the incorporation of the linkers, which could minimize the repulsion 
between the positively charged entities within the molecules (Figure 3.4). In fact, unlike 
compounds having tri-lysine moieties, compounds with an hexyl linker had a larger head group 
than the undecyl linker analogues in series with hepta lysine residues (Table 3.1 and Figure 3.4). 
The higher charge density of the hepta-lysine moieties compared to the tri-lysine moieties 
probably requires a longer distance to be separated from the positively charged quaternary amine 
head groups, hence, smaller head group area. Finally, the alternation of hydrophobic and 
hydrophilic regions of the compounds containing the hydrophobic linker imparted a complexity 
to their aggregation behaviours. This is caused by the several intramolecular forces, i.e., 
attractive forces and repulsive forces, which are acting simultaneously on different parts of the 
molecule to determine their preferred curvature at the air-water interface. 
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Figure 3.4. Schematic representation of peptide-modified gemini surfactant molecular shapes 
shows the impact of removing the glycine and incorporating an hydrocarbon linker on the 
molecular packing parameter (P) and head group area (𝚊₀) of 16-7N(G-K3)-16 and 16-7N(G-K7)-
16 series.    
3.4.2.3. Determination of size and ζ-potential 
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Size and surface charge of gene delivery nanoparticles are important parameters that can 
affect the efficiency of the delivery system by impacting their stability, efficiency of cellular 
uptake, route of cellular entry, intracellular fate, and cytotoxicity [44-46]. Therefore, size and zeta 
potential measurements of the peptide-modified gemini surfactants P/L/G lipoplexes at three N/P 
ratios of 2.5, 5 and 10 were evaluated and correlated with the transgene efficiency of the delivery 
system. In agreement with our previous results, increasing the N/P ratio caused a gradual 
decrease in particle size and increase in zeta potential [25]. In addition, the impact of varying the 
alkyl tail on the particle size and zeta potential was also in alignment with our recent report that 
investigated the role of the alkyl tail [25]. As such, this section only discusses the average particle 
size and zeta potential of P/L/G lipoplexes with hexadecyl tails at N/P of 2.5, so that the impact 
of the peptides modifications is evaluated. 
Lipoplexes at an N/P ratio of 2.5 showed a range of particle sizes between 72 and 107 
nm. In general, increasing the number of lysine residues resulted in an enlargement in the 
average particle size of lipoplexes (Table 3.2).  For compounds 16-7N(G-K)-16, 16-7N(G-K3)-
16 and 16-7N(G-K7)-16, the particle size increased from 80 ± 1 to 95 ± 4 to 107 ± 3 nm, 
respectively. A similar trend was also observed within the structural analogues that contain the 
hydrophobic linker e.g., 16-7N(G-C6-K)-16 compared to 16-7N(G-C6-K3)-16 and 16-7N(C11-
K3)-16 compared to 16-7N(C11-K7)-16 (Table 3.2). The increase in size was expected since 
increasing the number of lysine moieties from mono- to di- then to hepta-conjugates added a 
larger steric demand onto the compounds, hence, increased the overall size of the aggregates. 
However, the increase in particle size was not as significant as the increase in the head group 
area as shown in Table 3.2. This could be attributed to the tighter compaction of the DNA 
molecule by the hepta-derivatives, due to the involvement of the terminal lysine residues in the 
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interaction with the phosphate groups. In fact, several reports indicated that amino acids such as 
lysine can interact with the DNA by forming hydrogen bonds and by van der Waals forces [47, 48].  
Table 3.2. Particle size and zeta potential measurements of the peptide modified gemini 
surfactant lipoplexes with C16 tails at N/P of 2.5. Results are shown as mean (n=3) ± standard 
deviation. PDI is the polydispersity index.  
Gemini surfactants 
Average size 
(nm) ± STD 
PDI 
Average zeta (mV) 
± STD 
16-7N(G-K)-16  80 ± 1 0.23 24 ± 2 
16-7N(G-K3)-16  95± 4 0.25 38 ± 0.5 
16-7N(G-K7)-16  107 ± 3 0.24 48 ± 0.8 
16-7N(G-C6-K)-16  76 ± 1 0.22 21 ± 2 
16-7N(G-C11-K)-16  72 ± 2 0.11 19 ± 2 
16-7N(G-C6-K3)-16  89 ± 2 0.25 32 ± 0.4 
16-7N(G-C11-K3)-16  85 ± 1 0.26 29 ± 1 
16-7N(C6-K3)-16  88 ± 2 0.20 29± 1 
16-7N(C11-K3)-16  86 ± 0.8 0.19 34± 0.9 
16-7N(C6-K7)-16  94 ± 0.4 0.23 42 ± 1 
16-7N(C11-K7)-16  90 ± 0.5 0.22 39 ± 0.4 
 
The incorporation of the hydrocarbon linker between the glycine and lysine residues or 
grafted directly into the spacer resulted in a decrease in the particle size (Table 3.2). This could 
be explained by the involvement of the hydrocarbon linker in the compaction of the DNA 
through hydrophobic interactions [49, 50]. This hypothesis is supported by the fact that smaller 
particle size was observed in lipoplexes formulated with gemini surfactants having an undecyl 
linker compared to an hexyl linker. For example, the presence of the undecyl linker in compound 
16-7N(G-C11-K)-16 reduced the particle size to 72 ± 2 nm from 80 ± 1 nm for the parent 
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compound 16-7N(G-K)-16 whereas the addition of the hexyl linker resulted in an intermediate 
particle size of 76 ± 1 nm (Table 3.2). Removing the glycine and conjugating the hydrocarbon 
linker directly into the spacer also resulted in minor changes in the particle size of 88 ± 2 nm for  
16-7N(C6-K3)-16 compared to 89 ± 2 nm for 16-7N(G-C6-K3)-16  or 86 ± 0.8 nm for 16-7N(C11-
K3)-16  compared to 85 ± 1 nm for16-7N(G-C6-K3)-16  (Table 3.2). While smaller particle size 
should result from the removal of the glycine moiety due to the less steric demand, this effect 
was offset by the weaker interactions with DNA caused by fewer hydrogen bond and van der 
Waals forces between the gemini surfactants and DNA [49]. Thus, there is interplay between the 
physical size of the head group of the gemini surfactant and potential interactions with the DNA 
molecule contributing to the overall size of the P/L/G lipoplexes. 
Similar to the particle size, the P/L/G lipoplexes revealed a wide range of zeta potential 
values between +19 and +48 mV (Table 3.2). Increasing the number of lysine residues resulted 
in an increase in the zeta potential of nanoparticles. For instance, the zeta potential increased 
from 24 ± 2 mV to 38 ± 1 mV to 48 ± 1 mV upon increasing the number of lysine moieties from 
one to three to seven in 16-7N(G-K)-16, 16-7N(G-K3)-16 and 16-7N(G-K7)-16 molecules, 
respectively (Table 3.2). A higher number of lysine moieties implies more epsilon primary 
amines protonated at the intrinsic pH (≈ 6) of the formulation, leading to greater positively 
charged nanoparticles [51]. On the other hand, the insertion of the hydrocarbon linker resulted in a 
decrease in the zeta potential (Table 3.2). This effect could be a result of shielding of the charges 
with the hydrophobic linker. In fact, a longer linker rendered a lower zeta potential of 39 ± 1 mV 
in 16-7N(C11-K7)-16 compared to 16-7N(C6-K7)-16 that exhibited surface charge of 42 ± 1 mV 
(Table 3.2).  
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3.4.2.4. Determination of the lipid organization 
The effect of structural differences of the peptide-modified gemini surfactants on the 
supramolecular assembly of the lipoplexes at three N/P ratios was evaluated using SAXS. 
Scattering profile of each individual constituent of the P/G/L nanoparticle was assessed 
separately as a reference. The plasmid DNA did not show any diffraction peaks, suggesting the 
absence of any crystalline structure. DOPE showed Bragg peaks at q values of 0.1039, 0.178 and 
0.206 with ratio of 1:√3:√4 corresponding to the inverted hexagonal (HII) phase [52]. In general, 
the gemini surfactants alone showed diffused scattering at low q values of 0.12-0.17 indicating 
micellar organization. Such a diffraction pattern resulted from the shell-like structure of the 
chloride counter-ion cloud around the micelles corresponding to a micellar diameter of 3.6-5.2 
nm (Figure 3.5). 
 
Figure 3.5. SAXS scattering profile of 30 mM solutions of the peptide modified gemini 
surfactants show a diffused scattering at low q values (~ 0.13) suggesting the formation of 
micellar structures. 
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The complexation of gemini surfactants with the DNA led to an increase of the intensity 
at q ~0.113 values with respect to plateau at higher q, indicative of larger scattering objects in the 
solution (Figure 3.6). Mixing DNA to 16-7N(G-K)-16 revealed the most prominent peak among 
tested compounds at q= 0.100 especially at N/P ratio of 10 (Figure 3.6A). However, the absence 
of a second peak prevented the identification of the phase. The incorporation of an hexyl linker 
between the glycine and lysine, 16-7N(G-C6-K)-16, resulted in the formation of a small peak at 
q= 0. 110 and signs of a second diffraction peak at q= 0.22 at both N/P ratio of 2.5 and 5 (Figure 
3.6D). This could be an indication of the presence of the multilamellar phase Lα
c; however, a 
third peak would have been necessary for confirmation. Moreover, both peak signals were 
weakened upon further increase in the amount of gemini surfactant, N/P =10 (Figure 3.6D). On 
the other hand, the incorporation of an undecyl linker gave rise to three diffraction peaks at q= 
0.09, 0.180 and 0.268 in the ratio of 1:2:3 (Figure 3.6E), which correspond to peak positions of 
the multilamellar phase Lα
c [53]. However, the intensity of the peaks did not follow the 
conventional pattern of the previously reported multilamellar phases [53]. This could be due to the 
co-existence of another phase, albeit we were unable to assign this to the previously reported 
phases. Further increase in the ratio of gemini surfactants resulted in diffuse scattering that 
masked the second diffraction peak and minimized the intensity of the first and last peak.  
P/G complexes of both 16-7N(G-K3)-16 and 16-7N(G-K7)-16 exhibited a small peak at q= 0.112 
and 0.102, respectively, followed by diffuse scattering as indicated by the red arrows (Figure 
3.6B and C). The diffused scattering was more intense in compound 16-7N(G-K7)-16 which 
could be linked to its higher charge density compared to compounds with tri-lysine residues.  In 
fact, the same effect was noticed upon increasing the N/P ratio (Figure 3.6B and C, at N/P = 10). 
Unlike compounds with mono lysine head groups, the addition of hydrocarbon linker with or 
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without the glycine moiety resulted in decreased intensity of both the smaller peak and the 
diffused scattering (Figure 3.6F-K).  Overall, SAXS data revealed a complex behaviour of the 
P/G complex that is greatly affected by the molecular structure and valence of the spacer 
moieties. 
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Figure 3.6. SAXS scattering profile of DNA and gemini surfactants (P/G) complexes of the 
peptide modified gemini surfactants at N/P ratios of 2.5, 5 and 10. Black arrows represent a sign 
of phase formation. A diffuse scattering peak (red arrows) indicate complexity of structures and 
might correspond to high charge density. 
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Combining the three components: DNA, gemini lipid and DOPE (P/G/L) led to a marked 
increase of the intensity at low q and the appearance of Bragg peaks at higher q values indicating 
internal ordering of the newly formed aggregates (Figure 3.7). An inverted hexagonal phase was 
adopted in all P/G/Ls at their optimal N/P ratios of 2.5. In cationic gene delivery systems, the 
inverted hexagonal phase (HII) is known to be responsible for high transfection efficiency due to 
its ability to facilitate fusion with the cell membrane and cytoplasmic release of the DNA into the 
cytosol [54]. The position of the scattering peaks and the corresponding unit cell spacing (a = 
4π/√3 q10, where q10 is the first Bragg peak) are listed in Table S1, Appendix II.  At N/P ratio of 
2.5, no significant differences were observed in the repeated distances and corresponding unit 
cell spacing despite the variation in the molecular structure among the compounds. This could be 
mainly attributed to the low molar ratio of the gemini surfactants to the DOPE (1:33) at this 
charge ratio. The effect of structural modifications became more prominent in lipoplexes with 
N/P ratios of 5 and 10 (Figure 3.7), corresponding to gemini surfactant to DOPE mole ratios of 
1:16 and 1:8, respectively.  
Lipoplexes of 16-7N(G-K)-16 maintained the HII phase at N/P ratio of 2.5 and 5 (Figure 
3.7A). Increasing the charge ratio of N/P to 10 resulted in diffuse scattering that overshadowed 
Bragg peaks. Such behaviour was reported by us and others and it is believed to be caused by the 
interaction of the excess gemini surfactants with the helper lipid [25, 55]. Both DOPE and 16-
7N(G-K)-16 have an inverted truncated cone molecular shape which favour a negative 
membrane curvature giving raise to the HII phase (Table 3.1) 
[56]. However, the difference in the 
molecular size between DOPE and 16-7N(G-K)-16 might cause the distortion of the HII phase 
upon further increase in the amount of gemini surfactant at N/P of 10 (Figure 3.7A).  
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On the contrary, lipoplexes prepared from 16-7N(G-K3)-16 or 16-7N(G-K7)-16 exhibited 
the HII phase only at an N/P ratio of 2.5 while a broad peak was observed at N/P ratios of 5 and 
10 (Figure 3.7B and C).  It is noteworthy that gemini surfactants 16-7N(G-K3)-16 and 16-7N(G-
K7)-16 gave rise to truncated cone and cone molecular shapes which favour the formation of a 
positive spontaneous membrane curvature (Table 3.1). Therefore, it is possible that combining 
16-7N(G-K3)-16 or 16-7N(G-K7)-16 with DOPE causes higher interference to the HII phase than 
16-7N(G-K)-16. Furthermore, 16-7N(G-K3)-16 and 16-7N(G-K7)-16 have a higher charge 
density than 16-7N(G-K)-16, hence they promote transitions towards less negatively curved 
phases than the HII phase 
[57]. In fact, we think that the broad peak observed at N/P of 10 could be 
a sign of phase transition as previously reported in dendrimer like lipids [55]. 
The scattering pattern resulting from the incorporation of the hexyl linker into the 
compound with mono-lysine moiety (compound 16-7N(G-C6-K)-16, Figure 3.7D) did not differ 
from the scattering pattern of compound 16-7N(G-K)-16 (Figure 3.7A). However, the 
incorporation of the undecyl linker caused a loss in the HII phase at N/P =5 (compound 16-7N(G-
C11-K)-16, Figure 3.7E). A similar trend occurred upon the addition of hydrocarbon linkers to 
compounds with tri-lysine moieties in which lipoplexes of 16-7N(G-C6-K3)-16 maintained the 
HII phase up to an N/P ratio of 5 while 16-7N(G-C11-K3)-16 lost the phase by N/P of 5 (Figure 
3.7F and G).  On the contrary, the length of the hydrocarbon linker in compounds modified with 
tri-lysine moieties without the presence of glycine residues, 16-7N(C6-K3)-16 and 16-7N(C11-
K3)-16, did not interfere with the scattering profile of their lipoplexes (Figure 3.7H and I). In 
compounds with hepta-lysine residues the addition of an hexyl linker in 16-7N(C6-K7)-16 
resulted in the formation of the diffuse scattering at an N/P ratio of 5 while the incorporation of 
an undecyl linker prompt the formation of the diffuse scattering at an N/P ratio of 10 (Figure 3.7J 
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and K). We believe that the scattering profile is affected by the overall geometrical shape of the 
molecules rather than the length of the hydrophobic linker. In particular, there is a tendency of 
the surfactant to support or disturb the formation of a liquid crystalline phase with negative 
curvature of HII phase formed by DOPE. For example, all lipoplexes with cone-shaped gemini 
surfactants formed HII phase only at an N/P ratio of 2.5 and diffuse scattering arose upon further 
increase in the amount of gemini surfactant (Table 3.1, Figure 3.7). On the other hand, 
compounds with truncated cone molecular structure caused less interference to the HII phase, 
maintaining the phase up to N/P of 5 (Table 3.1, Figure 3.7). This was applicable to all truncated 
cone-shaped compounds except 16-7N(G-K3)-16 (Figure 3.7B).  We hypothesize that the 
interplay between the highly charged head of 16-7N(G-K3)-16 and the lack of an hydrophobic 
linker to shield those charges could be the reason for the greater interference with the HII phase 
formed by DOPE. 
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Figure 3.7. SAXS scattering profile of the P/G/L lipoplexes of the peptide modified gemini 
surfactants at N/P ratios of 2.5, 5 and 10. Black arrows indicate the position of Bragg peaks. q 
values with ratio of 1: √3: √4 correspond to the inverted hexagonal (HII) phase. 
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3.4.3. Evaluation of the in vitro transfection activity 
The transfection efficiency of the 22 peptide-modified gemini surfactants was evaluated 
in murine keratinocytes (PAM 212) since the ultimate goal of this research was to a develop 
topical gene delivery system that expands the treatment arsenal of fibrotic skin conditions 
(Figure S1, Appendix II). In addition, the compounds were evaluated in COS-7, a transfection 
cell-line commonly used to evaluate new transfection agents (Figure S2, Appendix II). Three 
N/P ratios of 2.5, 5 and 10 were assessed for all P/G/L lipoplexes. The most efficient N/P ratio 
was at 2.5 for all compounds in both cell lines (Figure S1 and S2, Appendix II). Increasing the 
N/P ratio above 2.5 was associated with a decreasing trend in the level of secreted protein. In 
PAM 212, this decrease was more prominent within the series that had seven terminal lysine 
moieties: m-7N(G-K7)-m, m-7N(C11-K7)-m and m-7N(C6-K7)-m (Figure S1, Appendix II). In 
both cell lines, lipoplexes of gemini surfactants with hexadecyl tail; C16, showed the highest 
transfection efficiency compared to their analogs with dodecyl; C12, and oleyl chain; C18:1 
(Figure S1 and S2, Appendix II). As such, in order to compare between the different subfamilies 
and assess the impact of various structural modifications into the spacer, the discussion will be 
mainly focused on compounds with a 16-carbon tail at the optimal charge ratio (N/P 2.5) (Figure 
3.8). 
P/G/Ls of gemini surfactant 16-7N(G-K)-16 exhibited the highest transfection efficiency 
among the tested compounds showing a protein level of 2.82± 0.2 ng INF-γ /15x103 cells in 
PAM 212 (Figure 3.8) and of 13.7± 0.8 ng INF-γ /104 cells in Cos-7 cell line (Figure S2, 
Appendix II). In fact, it showed more than 8-fold increase in the level of secreted protein, at four 
times lower concentration compared to the first-generation gemini surfactants [14]. Further 
increase in the number of terminal lysine moieties incorporated into the spacer of gemini 
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surfactants was associated with lower protein levels in both cell lines. P/G/Ls of gemini 
surfactants 16-7N(G-K3)-16 and 16-7N(G-K7)-16 showed about 2.5- and 3.5-fold reduction in 
the level of secreted protein, respectively, compared to 16-7N(G-K)-16 lipoplexes in PAM 212 
(Figure 3.8). Such a drop was even more detrimental in the COS-7 cell line where it led to more 
that a 7-10 folds reduction in the level of secreted protein (Figure S2, Appendix II).  
 
Figure 3.8. In vitro transfection of PAM 212 cells comparing the level of IFN-γ expression 
across the different subfamilies of the peptide-modified gemini surfactants. Results are the 
average of three plates of quadruplicate wells, error bars represent standard deviation. * Indicates 
significant at p < 0.05. 
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The reduction in transfection efficiency associated with increasing the number of lysine 
moieties could be attributed to several factors. First of all, 16-7N(G-K)-16 gemini surfactant had 
a packing parameter of 1.26 which favours the formation of inverted hexagonal phase (Table 
3.1). On the contrary, 16-7N(G-K3)-16 and 16-7N(G-K7)-16 exhibited a packing parameter of 
0.41 and 0.27, giving rise to truncated cone and cone-shaped molecules, respectively (Table 3.1). 
Such molecular shapes increase the preference for supramolecular assemblies with positive 
interfacial curvature. In fact, this was apparent in the SAXS data of the P/G/L lipoplexes where 
the HII phase in 16-7N(G-K3)-16 and 16-7N(G-K7)-16 was only seen at a N/P ratio of 2.5. 
Conversely, 16-7N(G-K)-16 maintained the inverted hexagonal phase up to a N/P ratio of  5 
(Figure 3.7A-C). Moreover, SAXS of the P/G of the lead compound 16-7N(G-K)-16 revealed the 
most prominent peak among all compounds suggesting a superior ability to form ordered 
structure even in the absence of the helper lipid, DOPE (Figure 3.6A-C). In addition, increasing 
the number of lysine moieties was associated with an increase in both the size and zeta potential 
which might hinder electrostatic attachment to the negatively charged cell surface and impede 
cellular uptake (Table 3.2). For example, D,L-lactide-coglycolide-based lipoplexes of 70 nm 
demonstrated a 27-fold higher transfection efficiency relative to larger-sized nanoparticles of 200 
nm in COS-7 cells [45], indicating the importance of optimal particle size in the gene delivery 
process. As such, this could be, in part, the reasons for the higher transfection efficiency of 16-
7N(G-K)-16 compared to 16-7N(G-K3)-16 and 16-7N(G-K7)-16 lipoplexes. Furthermore, 16-
7N(G-K)-16 exhibited the lowest CMC value relative to 16-7N(G-K3)-16 and 16-7N(G-K7)-16 
(Table 3.1), which could indicate a higher stability of the lipoplexes during the delivery process 
[34]. Higher charge density of compounds with tri- and hepta-lysine groups, 16-7N(G-K3)-16 and 
16-7N(G-K7)-16, showed lower efficiency relative to 16-7N(G-K)-16. A high charge density 
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indicates a stronger interaction with the pDNA which hinder subsequent release, limiting nuclear 
localization of the genetic material [58]. 
The attachment of an hydrocarbon linker in compounds with the mono-lysine moiety led 
to a decrease in the level of secreted protein in both cell lines (Figure 3.8 and S2, Appendix II). 
In fact, a longer hydrophobic linker was associated with lower efficiency. For example, protein 
secretion of 16-7N(G-C6-K)-16 and 16-7N(G-C11-K)-16 based lipoplexes were 3-fold and 4-fold 
lower than the compound without the linker, respectively (Figure 3.8). This could be attributed to 
the higher hydrophobicity of compounds 16-7N(G-C6-K)-16 and 16-7N(G-C11-K)-16 relative to 
16-7N(G-K)-16, resulting in stronger interaction with the pDNA which could hamper its 
subsequent release (Table 3.1). Manifestation of stronger pDNA-gemini surfactant interaction 
was also suggested by the smaller particle size of the lipoplexes formed with gemini surfactants 
with C6 and C11 linker (Table 3.2).  
Unlike compounds with a mono lysine moiety, the incorporation of an hydrocarbon 
linker between the amino acids in compounds with tri-lysine residues resulted in an increase in 
their transfection efficiency (Figures 3.8 and S2, Appendix II).  While the attachment of an hexyl 
linker (16-7N(G-C6-K3)-16) did not translate into significant elevation in the secreted protein in 
either cell lines, the addition of an undecyl linker (16-7N(G-C11-K3)-16) led to about 1.5-fold 
increase in the level of secreted INF-γ in PAM 212 and 2.3-fold in Cos-7 cell lines relative to 
compound 16-7N(G-K3)-16 (Figures 3.8 and S2, Appendix II).  The incorporation of the linker, 
especially the undecyl chain, gave rise to more hydrophobic compounds with lower CMC values 
which might confer a balanced binding with the plasmid DNA and better stability of the 
lipoplexes during the delivery process (Table 3.1). Although increasing the hydrophobicity in 
compounds with a mono-lysine moiety possibly hindered the release of the DNA, the higher 
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charge density of compounds with tri-lysine residues particularly upon acidification, might have 
balanced the DNA release process.  
Eliminating the glycine moiety and connecting the hydrocarbon linker directly to the 
spacer as in compounds 16-7N(C6-K3)-16 and 16-7N(C11-K3)-16 did not cause any significant 
differences in the transfection efficiency compared to the corresponding analogues containing 
the glycine residues i.e., 16-7N(G-C6-K3)-16 and 16-7N(G-C11-K3)-16 in PAM 212 cell-line 
(Figure 3.8). However, it resulted in a decrease in the transfection efficiency in Cos-7 (Figure S2, 
Appendix II). Such a variation in the transfection efficiency was in agreement with the 
previously reported behaviour of mono- and di-amino acid-modified gemini surfactant. In 
particular, coupling lysine residue directly on the spacer in compound 12-7N(K)-12 reduced the 
transfection efficiency compared to the analogue containing the glycine moiety, 12-7N(G-K)-12, 
only in Cos-7 without showing any significant differences in PAM 212 cell-line [24].  
In compounds with hepta-lysine moieties, incorporating the hydrocarbon linker resulted 
in significant increase in the transfection efficiency compared to compounds without the 
hydrocarbon linker in both cell-lines (Figures 3.8 and S2, Appendix II). While the addition of an 
hexyl linker increased the INF-γ secretion by 1.2-fold relative to 16-7N(G-K7)-16, conjugating 
the undecyl linker resulted in 2.5-fold increase in the protein secretion (Figure 3.8). Similarly to 
compounds with tri-lysine groups, the addition of an hydrocarbon linker elevated the 
hydrophobicity (clog P) and lowered CMC values (Table 3.1), contributing to balanced binding 
properties with the DNA.  
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3.4.4. Assessment of cell viability 
The toxicity of the P/G/L nanoparticles prepared with peptide-modified gemini 
surfactants at N/P ratios of 2.5, 5 and 10 were evaluated in PAM 212 and COS-7 cell lines after 
72 h and 48 h from the treatment, respectively (Figures 3.9 and S3, Appendix II). In both cell 
lines, P/G/Ls of the 16-7N(G-K)-16 exhibited the highest cell viability, 89% in PAM 212 and 
83% in COS-7 cell line, demonstrating a 20% improvement in cell viability relative to first-
generation unsubstituted gemini surfactants [14]. No significant differences were observed 
between the lead compounds at their optimal charge ratio (Figures 3.9 and S3, Appendix II).  At 
the optimal ratio, P/G/Ls of all compounds showed a significantly lower toxicity compared to a 
commercially available transfection agent (approximately 50 % viability) in both PAM212 and 
Cos-7 cells [14, 25]. Increasing the N/P ratio in all compounds was accompanied by a dose-
dependent cytotoxicity trend. However, the dose-dependent cytotoxicity was more prominent in 
m-7N(G-K7)-m series (Figures 3.9 and S3, Appendix II). For example, increasing the N/P ratio 
from 2.5 to 10 in compound 16-7N(G-K7)-16 resulted in about a 5-fold increase in the 
cytotoxicity (Figure 3.9). This could be attributed to their higher charge density caused by the 
high number of terminal amino groups that undergo protonation at the formulation intrinsic pH 
(≈ 6), leading to an increase in the overall positive charge of the lipoplexes as it was observed in 
the zeta potential measurements (Table 3.2). This was in agreement with a previously reported 
trend in literature where higher cationic charges were associated with higher tendency to rupture 
cell membrane, causing cell death [46].  
The incorporation of the hydrophobic linkers, especially in compounds with tri- and 
hepta-lysine moieties, reduced the cytotoxicity of the lipoplexes. Such an increase in cell 
viability was more prominent upon the incorporation of the undecyl linker as in 16-7N(C11-K7)-
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16 which has a cell viability of 62 % at an N/P ratio of 10 compared to the corresponding 15% 
for compound 16-7N(G-K7)-16 (Figure 3.9). This supports our hypothesis that the hydrophobic 
linker in shielding the positive charges of the terminal lysine residues, which is also supported by 
the lower zeta potential of the lipoplexes (Table 3.2). On the other hand, the addition of the 
hydrophobic linker plays a role in compounds with mono-lysine residues caused an increase in 
the cytotoxicity. In particular, both compounds 16-7N(G-C6-K)-16 and 16-7N(G-C11-K)-16 
showed a cell viability in the range of 75-78% while 16-7N(G-K)-16 exhibited cell viability of ≈ 
89% (Figure 3.9). The addition of the hydrophobic linker in compounds with a mono-lysine 
moiety caused an unfavorable increase in their hydrophobicity, leading to a higher cytotoxicity 
[59].  
Figure 3.9. Evaluation of PAM 212 cell viability of the peptide-modified gemini surfactants at 
three N/P ratios. Results are the average of three plates of quadruplicate wells, error bars 
represent standard deviation. 
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3.5. Conclusions   
In this work, a new series of peptide-modified gemini surfactants was introduced, 
reporting for the first time the design of dendrimers-like gemini surfactants. In addition, it 
evaluated the impact of incorporating a hydrocarbon linker of different length into the peptide 
chain. Our aim was to investigate the structure-activity relationship of the new compounds and 
identify the essential architectural requirements of efficient gene delivery system. The 
attachment of the peptide into the spacer region resulted in enhanced transfection efficiency and 
reduced cytotoxicity. In particular, lipoplexes composed of the lead compound, 16-7N(G-K)-16, 
demonstrated an 8-fold elevation in the level of protein secretion in PAM 212 and 20% increase 
in cell viability relative to the first-generation unsubstituted gemini surfactants. Such results 
suggest the potential of peptide-modified gemini surfactants as effective gene delivery systems 
for the treatment of fibrotic skin conditions. Further increase in the size of the incorporated 
peptide resulted in a decrease in the transfection efficiency. The impact of incorporating a 
hydrocarbon linker, on the other hand, was governed by the size of the peptide chain. In 
agreement with our recent report, peptide-modified gemini surfactants with hexadecyl alkyl tail 
exhibited the highest transfection efficiency compared to compounds with dodecyl and oleyl 
tails.  
Assessment of physicochemical characteristics suggested that the molecular shape of the 
gemini surfactants plays an important role in determining the transfection efficiency of the 
compound. In particular, molecular shapes that support the formation of a negative interfacial 
curvature resulted in higher transfection efficiency due to the higher tendency to maintain the HII 
assembly. Moreover, charge density of the gemini surfactants was associated with both 
transfection efficiency and cell viability wherein compounds with high charge density 
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demonstrated lower INF-γ secretion and higher cytotoxicity. Most importantly, a balance 
between the hydrophilic and hydrophobic characteristics of the gemini surfactants is an essential 
factor in determining the assembly, efficiency and safety profile of the peptide-modified gemini 
surfactants. Selected peptide-modified gemini surfactant-based gene delivery systems, including 
the lead compound will be further evaluated in animal models to assess the correlation between 
in vitro and in vivo gene delivery efficiency. The long-term goal is to develop a model that could 
be used to predict the in vivo efficiency of the gene delivery nanoparticles based on structural 
information.  
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Transitioning rationale: 
The importance of structural modifications of the gene delivery vectors in enhancing their 
transfection efficiency and safety profile was established in the previous chapters (Chapters 2 
and 3). The behavior of gemini surfactants in complex biological systems may ultimately 
determine their performance and the cytotoxicity. Accordingly, correlating the biodistribution 
and biological fate of the gemini surfactants to their chemical structure and physicochemical 
properties could provide insights into the rational design process, bridging the gap between 
empirical and rational design. As such, there is a need for an analytical approach to identify and 
quantify gemini surfactants in complex biological samples. Mass spectrometry (MS) was 
selected as the analytical technique of choice. This chapter aims at elucidating the tandem mass 
spectrometric (MS/MS) dissociation behaviour of peptides-modified gemini surfactants 
introduced in Chapter 3. The data from this study will be used for developing multiple reaction 
monitoring (MRM) quantification methods to probe the fate and the biodistribution of topically 
applied therapeutic gemini surfactant formulations (Chapter 5). 
 
Contribution statement: 
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4.1. Abstract 
Diquaternary ammonium gemini Surfactants have emerged as effective gene delivery 
vectors. A novel series of eleven peptide-modified compounds was synthesized, showing 
promising results in delivering genetic materials. The purpose of this work is to elucidate the 
tandem mass spectrometric (MS/MS) dissociation behaviour of these novel molecules 
establishing a generalized MS/MS fingerprint.  
Exact mass measurements were achieved using a hybrid quadrupole orthogonal time-of-
flight mass spectrometer (QqToF-MS) and a multi-stage tandem mass spectrometric analysis was 
conducted using a triple quadrupole-linear ion trap mass spectrometer (QqQLIT-MS). Both 
instruments were operated in the positive ionization mode and are equipped with electrospray 
ionization (ESI). Abundant triply charged [M+H]3+ species were observed in the single stage 
analysis of all the evaluated compounds with mass accuracies of less than 8 ppm in mass error. 
MS/MS analysis showed that the evaluated gemini surfactants exhibited peptide-related 
dissociation characteristics due to the presence of amino acids within the compounds’ spacer 
region. In particular, diagnostic product ions were originated from the neutral loss of ammonia 
from the amino acids’ side chain resulting in the formation of pipecolic acid at the N-terminus 
part of the gemini surfactants. In addition, a charge directed amide bond cleavage was initiated 
by the amino acids’ side chain producing a protonated α-amino-ε-caprolactam ion and its 
complimentary c-terminus ion that contains quaternary amines. MS/MS and MS3 analysis 
revealed common fragmentation behaviour among all tested compounds, resulting in the 
production of a universal MS/MS fragmentation pathway.  
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4.2. Introduction  
Gene therapy has emerged as a promising therapeutic approach for the treatment of 
inherited and acquired genetic disorders. The last few decades have witnessed unprecedented 
interest in developing efficient vectors able to compact, protect and deliver genetic material into 
targeted cells [1, 2]. One particular group is diquaternary ammonium gemini surfactants that have 
been extensively used as non-viral gene delivery vectors [3]. They have the ability to package and 
compact the negatively charged nucleic acids through electrostatic and hydrophobic interactions 
forming nano-sized lipoplexes [4]. Gemini surfactants are composed of two ionic head groups 
attached to their hydrocarbon tails and connected by a spacer (Figure 4.1A) [5]. The unique 
structure of gemini surfactants resulted in superior characteristics compared to their monomeric 
counterparts, such as their greater ability in reducing surface tension, lower critical micelle 
concentration (CMC) and lower Krafft temperature (critical micelle temperature) [6]. Owing to 
these enhanced characteristics, lower concentration of gemini surfactants is required for gene 
delivery compared to their monomeric counterparts, thus, they possess lower cytotoxicity profile 
[4]. In addition, gemini surfactants’ distinctive structure offers virtually various possibilities for 
structural modification, allowing for the production of compounds specifically designed to 
overcome delivery barriers. For example, the insertion of pH-sensitive moieties resulted in the 
production of “intelligent” delivery vehicles that respond to the surrounding stimuli [7].  
The most widely used group of gemini surfactants is the cationic N, N-
bis(dimethylalkyl)-α,ω-alkane-diammonium surfactants (Figure 4.1). They were successfully 
utilized in delivering genetic materials both in vitro and in vivo [8, 9]. In fact, Badea et al. reported 
three-fold increase in topical transgene expression in animals treated with N,N'-
bis(dimethylhexadecyl)-1,3-propanediammonium dibromide (designated as 16-3-16) gemini 
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surfactant-based nanoparticles compared to animals treated with naked DNA [9]. Despite the 
success of the traditional gemini surfactants, concerns regarding their toxicity have arisen [10]. 
Several approaches have been undertaken to address this problem, including the insertion of 
biocompatible and biodegradable moieties such as sugars, lipids, and amino acids [11-13]. For 
example, glycyl-lysine substituted gemini surfactants exhibited significantly higher gene 
expression in vitro and lower cytotoxicity compared to the unsubstituted parent compound [14-16]. 
Moreover, in vivo topical application of the glycyl-lysine substituted gemini surfactant-based 
lipoplexes into the rabbit vaginal cavities demonstrated higher transgene efficiency compared to 
the parent compound without visible toxicity [17].  
Although extensive research was focused on the design of new gemini surfactants and 
optimizing their physicochemical properties to increase efficiency and reduce side effects [3, 16, 
18], little is known about their post transfection fate. Many questions remain unanswered 
regarding the degradation profile of nanoparticles after releasing their therapeutic cargo 
including the formation of metabolic by-products, some of which can theoretically be toxic. 
Correlating the biodistribution and the biological fate of the nanoparticles to their chemical 
structure and physicochemical properties can provide insights into the rational design process to 
produce gene carriers with higher efficiency and reduced toxicity. Such knowledge will bridge 
the gap between empirical and rational design. As such, there is a need to develop analytical 
techniques that could identify and quantify gemini surfactants within complex biological 
samples. 
Mass spectrometry (MS) is routinely used for both the quantitative and qualitative 
analysis of pharmaceuticals [19-22]. In our group, we investigated the fragmentation pathways of 
different structural families of gemini surfactants establishing collision induced dissociation-
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tandem mass spectrometric (CID-MS/MS) fingerprints for accurate identification of gemini 
surfactants [23-26]. This data was subsequently utilized to develop MS-based methods for the 
quantification of conventional un-substituted gemini surfactants within cells to determine the rate 
of cellular uptake and removal [27-29]. Ongoing research, employs the use of these methods to 
investigate subcellular localization and to identify any potential metabolites.  
Recently, a new generation of peptide modified gemini surfactants was introduced 
demonstrating a superior in vitro transfection efficiency compared to the traditional unsubstituted 
gemini surfactants (Figure 4.1B) [30]. Herein, we aim to evaluate the CID-MS/MS fragmentation 
behaviour of eleven novel peptide modified gemini surfactants. The peptides are attached to the 
spacer region via an amide bond with variable hydrocarbon linkages that may affect the 
efficiency of the developed nano-formulations.  The data from this study will be needed for 
developing multiple reaction monitoring (MRM) quantification MS/MS methods to probe the 
fate and the biodistribution of topically applied therapeutic gemini surfactant formulations.  
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 Figure 4.1. (A) Prototype of gemini surfactants showing the two ionic head groups, 
hydrocarbon tails and the spacer and (B) schematic representation of the general structure of the 
tested peptide modified gemini surfactants.  
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4.3. Material and methods  
4.3.1. Material  
Eleven novel peptide modified gemini surfactants were synthesized using previously 
reported synthetic methods [16]. Tested compounds were designated as m-7N(R)-m where m is 
the alkyl tail carbon chain length, m = 12 or 16 and R is a chain of hydrocarbon linkers attached 
to amino acids: R = Glycyl-Hexyl-lysine, Glycyl-Hexyl-Trilysine, Glycyl-Undecyl-lysine, 
Glycyl-Undecyl-Trilysine, Hexyl-Trilysine and Undecyl-Trilysine. The general chemical 
structure of these gemini surfactants is shown in Figure 4.1B. Methanol (HPLC grade purity, 
Fisher Scientific, Nepean, ON, Canada), Water (HPLC grade purity, Fisher Scientific, Nepean, 
ON, Canada), and formic acid (purity 90%, EMD Chemicals Inc., Merck KGaA, Darmstadt, 
Germany) were used as solvents. 
4.3.2.  Sample preparation  
Stock solutions of 3 mM gemini surfactant were prepared in methanol/water (50:50 v: 
v) containing 0.1% formic acid and stored at −20 ◦C. Each sample was further diluted 1000 X at 
the time of analysis using the same solvent. 
4.3.3. Mass spectrometric analysis 
4.3.3.1.Single stage MS analysis 
Gemini surfactants were analyzed using an AB SCIEX QSTAR® XL quadrupole 
orthogonal time of-flight hybrid mass spectrometer (QqToF-MS) equipped with an electrospray 
ionization (ESI) source (AB SCIEX, Redwood City, CA, USA). The instrument was operated in 
the positive ion mode with declustering potential of 100 V and focusing potential of 290 V. 
Sample aliquots were infused into the mass spectrometer at flow rate of 10 μL/min using an 
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integrated Harvard syringe pump through a Turbo Ionspray Source, having a needle voltage of 
5500 V and a temperature of 80 °C. Nitrogen was used as the drying gas and ESI nebulizing gas. 
A two-point external calibration was performed prior to the analysis of gemini surfactants using 
two singly charged calibration standards: cesium iodide (CsI, m/z 132.9055, Sigma-Aldrich, 
Oakville, ON, Canada) and sex pheromone inhibitor (iPD1, m/z 829.5320, Bachem Bioscience 
Inc., PA, USA). 
4.3.3.2.Tandem mass spectrometric analysis 
Tandem mass spectrometric analysis of the tested gemini surfactants was performed 
using an AB SCIEX QTRAP® 4000 hybrid triple quadrupole–linear ion trap mass spectrometer 
(QqLIT-MS) equipped with a “Turbo V Ion Spray” ESI source (AB SCIEX, Redwood City, CA, 
USA).  Collision-induced dissociation (CID) was conducted using nitrogen as the collision gas. 
The instrument was operated in the positive ion mode with declustering potential in the range of 
45–100 (optimized for each compound). Collision energy (CE) was also optimized for the range 
20–40 eV to induce fragmentation while maintaining the abundance of the precursor ion. 
Samples were infused into the instrument at flow rate of 10 μL/min by using a model 11 Plus 
syringe pump (Harvard Apparatus, Holliston, MA, USA). Ionspray voltage was set at 5500 V 
with source temperature of 300°C. 
It is noteworthy that the MS/MS analysis of the all tested peptide-modified gemini 
surfactants was also conducted using the QSTAR®. It generated similar MS/MS spectra to that 
produced by the QTRAP®, confirming the elemental compositions of the projected product ions 
(Figure S1, Supplementary Material). However, MS/MS spectra acquired by the QTRAP® were 
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more informative due to the ability of the linear ion trap to accumulate ions when performing the 
enhanced product ion scan. 
4.3.3.3.Multi-stage MS3 analysis 
MS3 analysis of the selected second-generation ions was conducted on the AB SCIEX 
QTRAP® 4000 instrument under the same optimized conditions mentioned above.  Excitation 
energy (AF2) was set at the range of 20–100 to obtain abundant fragments of the selected 
second-generation ions. 
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4.4. Results and discussion 
4.4.1. Single-stage MS analysis 
Full scan ESI-QqToF-MS analysis of all tested peptide-modified gemini surfactants 
showed an abundant triply charged [M+H]3+ species (Table S1, Appendix III). In addition, some 
compounds with three terminal residues of amino acids showed a minor quadruply charged 
[M+2H]4+ species. The exact masses were assessed showing mass accuracies of less than 8 parts 
per million (ppm) mass error confirming the projected molecular structure of the tested gemini 
surfactants (Table S1, Appendix III). This mass accuracy was achieved by employing two-point 
external calibration prior to the analysis of the gemini surfactants. In fact, the accuracy of these 
measurements was similar to a recent work by our group which utilized internal calibration to 
assess mono-amino acid and di-amino acids substituted gemini surfactants [25]. 
4.4.2. Tandem mass spectrometric analysis 
The fragmentation behavior of peptide modified gemini surfactants was evaluated using 
low-energy CID-MS/MS employing ESI-QqLIT-MS instrument. Structural variation within the 
tested gemini surfactants, namely the number of amino acid residues, the length of the 
hydrocarbon tails and the length of the incorporated hydrocarbon linker drove the MS/MS 
dissociation behavior. In addition, MS/MS experiments yielded compound-specific product ions 
which authenticate the molecular structure of their precursor ions. Such product ions could be 
utilized as diagnostic ions for the qualitative and quantitative analysis of the evaluated gemini 
surfactants. 
 The MS/MS fragmentation behavior of peptide modified gemini surfactants showed 
remarkable differences compared to traditional gemini surfactants [23, 24]. This is mainly due to 
172 
 
the insertion of peptide segments within the gemini surfactant spacer region, resulting in the 
formation of peptide-related dissociation characteristics. The number of terminal amino acid 
residues in the spacer seems to play a major role in determining the MS/MS fragmentation 
pattern; hence, MS/MS analysis will be discussed based on the number of terminal amino acids 
residues. The following sections include detailed discussion of the fragmentation patterns of the  
16-7N(C11-K3)-16 gemini surfactant as an illustrative example of compounds with the tri-
terminal amino acids residues as it has the most complex MS/MS spectra among all tested 
compounds. In addition, the MS/MS dissociation behaviour of 16-7N(G-C11-K)-16 is briefly 
discussed to highlight the fragmentation of gemini surfactants with a mono-terminal amino acid 
moiety. The major product ions for peptide modified gemini surfactants with tri-terminal amino 
acids residues and mono-terminal amino acid moiety are displayed in Tables 4.1 and 4.2 
respectively. 
4.4.2.1. MS/MS fragmentation pathway of the peptide modified gemini surfactants with tri-
terminal lysine moieties  
The fragmentation of the triply charged precursor ion of 16-7N(C11-K3)-16 gemini 
surfactant resulted in the formation of three initial diagnostic product ions that have their unique 
subsequent dissociation pathways (Figure 4.2, Table 4.1). Two initial product ions arise from the 
loss of one of the terminal lysine moieties producing either a doubly charged product ion (A) 
observed at m/z 538.54 or a triply charged product ion (B) observed at m/z 359.36. The third 
initial product ion results from the loss of a NH3 moiety generating a triply charged product ion 
(C) observed at m/z 396.38. The coexistence of the three initial product ions suggests a 
competition between different fragmentation mechanisms. While both ions (A) and (B) are 
formed by losing one of the terminal lysine residues from the precursor ion, they have different 
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charge status implying the presence of different fragmentation mechanism for cleaving the amide 
bond.  
As indicated earlier, the presence of peptides within the gemini surfactants offered the 
compound protonated peptide characteristics, unlike conventional gemini surfactants [23, 24]. The 
dissociation of protonated peptides can be explained by the ‘mobile proton’ model: a 
comprehensive model that suggests a competition between charge-remote and charge-directed 
reactions to predict the fragmentation process [31-33]. Under low-energy conditions such as CID, 
charge-directed reactions are believed to be the major pathway for peptide dissociation in which 
bond cleavage is initiated by active involvement of the ionizing proton [34]. Thus, the location of 
the ionizing proton on the peptide chain could determine the fragmentation mechanism [33]. As 
such, the composition of the amino acids (the presence or absence of a basic residue), the 
sequence, size and charge state of the investigated peptide will play a crucial role in determining 
the MS/MS fragmentation pattern.  
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Figure 4.2. The ESI-QqLIT-MS/MS spectrum of 16-7N(C11-K3)-16 as a representative example of gemini surfactants with tri-terminal 
lysine moieties. Ions were labelled as designated in Figures 5-7. Strcture of the three initial product ions are shown as an insert (top).
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Table 4.1. Product ions observed during MS/MS analysis of [M+H] 3+ ions of the peptide modified gemini surfactants with tri-
terminal lysine moieties.  
 
 Gemini surfactants  12-7N(G-
C11-K3)-
12 
16-7N(G-
C11-K3)-16 
12-7N(G-
C6-K3)-12 
16-7N(G-
C6-K3)-16 
12-7N(C11-
K3)-12 
16-7N(C11-
K3)-16 
12-7N(C6-
K3)-12 
16-7N(C6-
K3)-16 
Ion # Product ions m/z m/z m/z m/z m/z m/z m/z m/z 
A [M–C6H13N2O]2+ 510.98 567.04 475.94 532.37 482.47 538.54 447.43 503.50 
B 
(y2) 
[M–C6H12N2O]3+ 340.99 378.37                                                                                                                                                       321.98 359.36
C [M–NH3]3+ 378.01 415.39 354.65 392.03 359.01 396.38 335.65 373.02 
bx C6H13N2O 129.10 129.10 129.10 129.10 129.10 129.10 129.10 129.10 
a1 C5H13N2 101.10 101.10     101.10 101.10     
1 Dimethylalkenaminium 214.25 270.31 214.25 270.31 214.25 270.31 214.25 270.31 
2 [M–(bx)-ion(1)]2+ 404.36 432.39 369.32 397.35 375.85 403.88 340.81 368.84 
2` [M–(bx)-ion(1)]+ 807.71 863.78 737.63 793.70 750.69 806.76 680.62 736.68 
3 [M–(bx)-2 ion(1)]+ 594.47 594.47 524.40 524.40 537.44 537.44 467.37 467.37 
3` [M–(bx)-2 ion(1)] 2+ 297.74 297.74 262.70 262.70 269.23 269.23 234.19 234.19 
4 [M– 2(bx)-ion(1)]+ 679.62 735.68 609.54 665.59 622.60 678.66 552.52 608.58 
4` [M– 2(bx)-ion(1)] 2+ 340.31 368.19 305.27 333.30 311.80 339.83 276.76 304.80 
5 [M–(bx)-(NH3)-2 ion(1)]+ 577.44 577.44 507.36 507.36 520.42 520.42 450.34 450.34 
5` [M–(bx)-(NH3)-2 ion(1)]2+ 289.22 289.22 254.18 254.18 260.71 260.71 225.67 225.67 
6 [M– 2(bx)-2 ion(1)] + 446.94 446.94 396.30 396.30 409.35 409.35 339.27 339.27 
6` [M– 2(bx)- 2 ion(1)]2+ 233.69 233.69   205.18 205.18   
 
1
7
5
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7 [M–2(bx)-(NH3)-2ion(1)] 
2+ 
225.18 225.18 190.14 190.14 196.67 196.67 161.63 161.63 
8 [M–3(bx)- 2 ion(1)] + 338.27 338.27 268.19 268.19 281.26 281.26 211.18 211.18 
9 [M–(bx)-(NH3)] 3+ 335.31 372.69 311.96 349.33 316.31 353.68 292.95 330.32 
9` [M–(bx)-(NH3)] 2+ 502.47 558.53 467.43 523.49 473.96 530.02 438.92 494.98 
10 [M–2(bx)] 2+ 446.94 503.00 411.90 467.96 418.43 474.49 383.39 439.45 
11 [M–3(bx)] 2+ 382.89 438.95 347.85 403.91 354.38 410.44 319.34 375.40 
12 [M–3(bx)- ion(1)] + 551.52 607.59 481.44 537.51  494.50 550.57 424.43  480.49 
12` [M–3(bx)- ion(1)] 2+ 276.27 304.30 241.23 269.26 247.75 275.79 212.71  240.75 
13 [M–2(NH3)] 3+ 372.34 409.71 348.97 386.62 353.33 390.70 329.97 367.35 
14 [M–(NH3)-ion(1)] 3+ 306.93 325.62 283.57 302.26 287.92 306.61 264.57 283.25 
15 [M–(NH3)-2 ion(1)]2+ 353.27 353.27 318.23 318.23 324.76 324.76 289.723 289.72 
15` [M–(NH3)-2 ion(1)] 3+ 235.85 235.85 212.49 212.49 216.84 216.84 193.48 193.48 
16 [M–2(NH3)-ion(1)] 3+ 301.26 319.94 277.90 296.58 282.25 300.94 258.89 277.58 
17 [M–2(NH3)-2 ion(1)] 2+ 344.76 344.76 309.72 309.72 316.25 316.25 281.21 281.21 
17` [M–2(NH3)-2 ion(1)] 3+ 230.17 230.17 206.82 206.82 211.17 211.17 187.81 187.81 
18 [M–(bx)-(NH3)- ion(1)] + 790.69 846.75  720.61                                                                                                                                                                                                                                                                                                                            776.67 733.67 789.73 663.59 719.65
 
18` [M–(bx)-(NH3)- ion(1)] 2+ 395.85 423.87 360.81 388.84 367.33 395.37 332.30 360.33 
18`` [M–(bx)-(NH3)- ion(1)] 3+ 264.23 282.92 240.87 259.56 245.23 263.91 221.87 240.55 
1
7
6
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The gemini surfactant 16-7N(C11-K3)-16 has a chain of three branched lysine moieties. 
Lysine is a basic amino acid that is most probably protonated at the ε-amino group of the side 
chain. Amide bond cleavage is initiated by nucleophilic attack by the lysine side chain on the 
amide bond [35, 36]. The first step of the reaction involves mobilization of the proton of the lysine 
side chain to the nitrogen of the C-terminal neighboring amide bond (Figure 4.3). Subsequently, 
nucleophilic attack by the lysine side chain on the carbon of the protonated amide bond leading 
to the cleavage of the amide bond and the formation of a protonated α-amino-ε-caprolactam ion 
observed at m/z 129.10 (b1) (Figure 4.3). A complementary ion at m/z 538.5 (product ion A) is 
formed rather than a neutral species as in the case of peptides due to the presence of quaternary 
amines that exist within the structure of gemini surfactants (Figure 4.1B, Figure 4.3).  
In fact, the formation of the product ion at m/z 129.10 is a characteristic of lysine 
containing peptides [35-37]. The loss of lysine through this mechanism explains the formation of 
product ion (A) the doubly charge compound, however, it does not explain the formation of 
product ion (B), the triply charged species of the same structure (Figure 4.2), suggesting the 
presence of alternative MS/MS dissociation mechanism.   
Two mechanisms can be proposed for the formation of the product ion (B) observed at 
m/z 359.36. The first could be explained by the  established fragmentation mechanism termed (ax 
- yx) which leads to integrated formation of ax and yx ions 
[38, 39]. This dissociation is focused on 
the cleavage of the amide bond and Cα –C amide bond resulting in the formation of protonated 
imine, carbon monoxide and product ion B (i.e., protonated C-terminal fragment) (Figure 4.4) 
[38]. Following the expulsion of the weakly bound carbon monoxide, a proton-bound dimer 
between the N terminal and the C-terminal fragments is formed. Under low-energy CID 
conditions, the formed dimer has a long lifetime allowing for numerous proton transfers among 
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product ions to occur. As a result, the dimer is dissociated to form either product ion B (i.e., the 
y2 ion based on Roepstorff nomenclature for peptide fragmentation
[40]) or ion a1 which is 
observed at m/z 101.10 (Figure 4.4). It should be noted that ions B and a1 were only observed in 
gemini surfactants with longer hydrophobic linker chain (C11) and not in shorter linker (C6) 
(Table 4.1). This is in agreement with previously reported behavior of mono and di- amino acid 
substituted gemini surfactants in which no ion B analogues was observed [25]. 
Alternative mechanism that could lead to the formation of product ion (B) is simply the 
same as that of product ion (A) (Figure 4.3), however; a proton transfer from the amide-nitrogen 
of the protonated α-amino-ε-caprolactam to the ε-amino group of the remaining lysine (c-
terminus) is required. Csonka et al. indicated the possibility of such a dissociation to occur 
especially when the c-terminal part of the compound has high enough proton affinity to compete 
with the α-amino-ε-caprolactam [36]. In the tested compound, the ε-amino group of the c- 
terminal has a higher pKa value than the amide-nitrogen, thus it has higher proton affinity raising 
the possibility for the ion transfer to take place. As such, it is possible that two mechanisms are 
simultaneously involved in the formation of product ion (B).     
In addition to product ions A and B, Product ion (C) at m/z 396.38 results from the 
neutral loss of a (NH3) moiety (Figure S1, Appendix III; Figure 4.2). This is expected as 
protonated peptides under low-energy CID conditions often undergo neutral losses of small 
molecules such as water or ammonia [34]. The loss of ammonia has been reported mainly in basic 
amino acid residues such as lysine, arginine, asparagine and glutamine [34]. A charge-directed 
fragmentation mechanism has been proposed for the elimination of ammonia from the lysine side 
chain [35]. As such, protonation of the side chain is required. Since ε-amino group is the most 
favored protonation site in lysine, mobilization of protons is not needed. Dookeran et al. 
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demonstrated utilizing an α-15N protonated lysine that the loss of the NH3 moiety involves in 
particular the nitrogen of the side chain [37]. When lysine is located at the peptide N-terminus, 
like in the tested gemini surfactants, the loss of ammonia occurs via nucleophilic attack by the N-
terminal amino group resulting in the formation of pipecolic acid (Figure S2, Appendix III) [36].  
It is noteworthy that the proposed fragmentation pathways forming the three initial product ions 
could involve either one of the two N-terminal lysine moieties, leading to identical product ions. 
In fact, the various observed ions could be a mixture of two species losing either lysine moiety 
terminal. Both losses will not affect the produced product ions that can still efficiently be used 
for both qualitative and quantitative applications. 
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Dissociation of product ion A  
The dissociation of product ion (A) starts with the loss of the quaternary ammonium head 
group and the attached aliphatic tail resulting in the formation of two complementary ions: 
product ion (1) at m/z 270.31 a singly charged ion and a minor singly charged product ion (2) 
observed at m/z 806.76 (Figure 4.5, Table 4.1). In addition, a doubly charged species was 
observed at m/z 403.88 (2`) which shares the same molecular structure of product ion (2) albeit 
doubly charged. This suggests the existence of an alternative ion formation mechanism. It could 
be explained by a homolytic cleavage of the N-C bond between the quaternary ammonium head 
group and the hydrocarbon tail resulting in the neutral loss of the aliphatic tail (hexadec-1-ene) 
and the formation of a doubly charged minor product ion at m/z 426.41(2*) (Figure 4.5).  In 
agreement with the previously observed behavior of mono and di- amino acid substituted gemini 
surfactants [25], the close proximity of the two positively charged head groups of  ions such as 
(2*) could make the ion relatively unstable which easily fragments by the subsequent loss of a 
head group as dimethylamine leading to the formation of (2`) ion at m/z 403.88. Such a behavior 
was consistent among all the evaluated gemini surfactants. In fact, in some cases the intermediate 
ion (i.e., 2*) was abundant enough to enable for MS3 analysis that supported the projected 
molecular structure of this ion (2*) (Table S2, Appendix III). The formation of such unstable 
intermediate ions and their subsequent stable product ions (i.e., ion 2` in this case) was 
commonly noticeable in the various tested gemini surfactants. It will be referenced frequently in 
the text as an intermediate ion. 
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Figure 4.5. Proposed MS/MS product ions generated form product ion (A) at m/z 538.54 of 16-
7N(C11-K3)-16 gemini surfactant. Product ion 2* is a transient ion.  
 
Product ion (2`) subsequently yields the formation of four product ions (Figure 4.5). The 
first involves the loss of the head group and the attached aliphatic tail (ion 1) at m/z 270.31 
producing a singly charged product ion (3) at m/z 537.44. A second ion is formed via the neutral 
loss of the aliphatic chain and the formation of intermediate doubly charged ion, as discussed 
above, at m/z 291.75 (ion structure is not shown) which easily loses the dimethylamine head 
group generating a doubly charged species (3`) at m/z 269.23. The third and fourth ions are 
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formed as a result of eliminating the terminal lysine moiety leading to the formation of a singly 
charged ion (4) at m/z 678.66 and the corresponding doubly charged ion (4`) at m/z 339.83 
(dotted arrows originating from ion 403.8).  As shown in Figure 4.3, this cleavage is usually 
initiated by nucleophilic attack of the lysine side chain on the amide bond releasing m/z 129.10 
ion (b2) as a protonated α-amino-ε-caprolactam and forming product ion (4). Ion (4`) on the other 
hand could either result from the same mechanism as ion (4) but it requires a proton transfer 
from the protonated α-amino-ε-caprolactam to the complementary c-terminal ion or through the 
(ax - yx) peptide fragmentation mechanism (Figure 4.4). Unlike product ion (2`), fragmentation of 
the singly charged ion (2) produces only two product ions: ions (3) and (4) (Figure 4.5). 
Ion (3`) at m/z 269.23 undergoes neutral loss of ammonia forming pipecolic acid 
derivative compound at m/z 260.71 (5`) (Figure 4.5). Furthermore, (3`) loses another terminal 
lysine moiety forming a single-charged ion (6) at m/z 409.35 and a double-charged ion (6`) at 
m/z 205.18. Similar to ion (3`), ion (3) also eliminates an ammonia group producing ion (5) at 
m/z 520.42 and loses a lysine moiety to produce ion (6). Ion (6) can also be formed via the loss 
of alkyl tail from ion (4) as well as ion (4`); the latter can additionally yield ion (6`) as shown in 
Figure 4.5. Finally, ions (5) and (5`) can also yield the formation of product ion (6) through the 
loss of the pipecolic acid ring (Figure 4.5). It can be speculated that this loss occurred by the 
mobilization of the proton from the pipecolic acid ring to the nitrogen of the amide bond 
followed by nucleophilic attack either by the carbonyl group releasing pipecolic acid which was 
observed at m/z 112.07 or by the pipecolic acid ring’s amine resulting in opening the ring and 
forming caprolactam ion which was also observed at m/z 114.09 (Figure 4.5).  
Product ion (6`) experiences loss of ammonia group forming ion (7) at m/z 196.67 and 
eliminates the last lysine moiety forming ion (8) at m/z 281.26. It should be noted that ion (8) at 
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m/z 281.26 was also produced by ion (6); however, MS3 analysis did not show any second 
generation product ions at m/z 129.10, which corresponds to the elimination of lysine as a 
protonated α-amino-ε-caprolactam (Table S2, Appendix III). This finding supports the theory of 
the proton transfer from the protonated α-amino-ε-caprolactam to the c-terminal fragment ion 
that we proposed earlier as a possible mechanism to justify the formation of product ion B.  
Dissociation of product ion B  
Product ion (B) dissociates via two fragmentation pathways; firstly by the loss of an 
NH3 moiety from the terminal lysine producing pipecolic acid derivative, product ion (9) at m/z 
353.68 (Figure 4.6, Table 4.1). The second product ion results from the loss of the terminal 
lysine amino acid residue (observed at m/z 129.10 [b2]) by amide bond cleavage forming a 
doubly charged product ion (10) at m/z 474.49.  Elimination of the pipecolic acid part of ion (9) 
also leads to the formation of ion (10) which subsequently dissociates by eliminating the last 
terminal lysine, forming ion (11) observed at m/z 410.44.  Furthermore, ion (10) loses the tail 
region and the attached head forming the previously mentioned singly and doubly charged ions 
designated as (4) and (4`). As it can be seen, the complexity of the MS/MS spectra supports the 
notion that some ions may be formed from various product ions as in the case of the product ions 
(4) and (4`). Such observation is supported by second generation MS3 analysis (Table S2, 
Appendix III). Both of these ions further dissociate as shown in Figure 4.6. Ion (11) also loses 
the aliphatic tail and the attached head group yielding ion (12) and (12`) at m/z 550.57 and m/z 
275.79 respectively supported by second generation MS3 analysis (Table S2, Appendix III). Both 
ions subsequently eliminate the remaining dimethylalkenammonium ion forming the product ion 
(8) at m/z 281.26 (Figure 4.6).  
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Figure 4.6. Proposed MS/MS product ions generated form product ion (B) at m/z 359.36 of 16-
7N(C11-K3)-16 gemini surfactant. 
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Dissociation of product ion C  
Product ion (C) was the source of six product ions (Figure 4.7) which is much more 
complex than product ions A or B. This is expected since product ion C retains the same 
structural backbone of the precursor ion with the simple loss of NH3 moiety. The first two 
product ions arise from the loss of pipecolic acid re-forming product ions (A) or (B) which was 
confirmed by MS3 analysis (Table S2, Figure S3, Appendix III). On the other hand, cleavage of 
the peptide bond of the lysine with intact side chain resulted in the formation of ions 9 and 9` 
observed at m/z 353.68 and m/z 530.02 (Figure 4.7, Table 4.1) respectively which differs only in 
the charge state due to variations in the formation mechanisms as disused earlier in details in the 
section entitled “Dissociation of product ion A”. Interestingly, MS3 analysis of ion (C) revealed 
that product ions (A) and (B) were of lower abundance than product ions 9 and 9` (Figure S3, 
Appendix III). This could be attributed to the ease of the cleavage of the amide bond linked to 
the lysine side chain ε-amino group in comparison to the loss of pipecolic acid.  
Product ion (C) can also eliminates another ammonia group from the second terminal 
lysine producing a triply charge ion (13) observed at m/z at 390.70 (Figure 4.7, Table 4.1). Since 
the elimination of the ammonia is charge-directed, mobilization of the proton from the pipecolic 
acid ring to the lysine ε-amino group is required. Ion (13) subsequently loses one of the pipecolic 
acids yielding the previously mentioned ions (9) and (9`) which was confirmed by second 
generation MS3 analysis (Table S2, Appendix III). Finally, product ion C undergoes a neutral 
loss of the aliphatic tail forming an unstable intermediate at m/z 321.63 (not shown) which easily 
loses dimethylamine group forming a triply charged ion (14) at m/z 306.61. Similar to past 
observation, such an intermediate ion was occasionally observed and its genesis was confirmed 
by MS3 analysis. 
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Ion (14) eliminates the remaining ammonium head group and the associated aliphatic 
tail producing the product ion (15) at m/z 324.76. It also undergoes neutral loss of the tail 
through hemolytic cleavage of the N-C bond forming, as above, unstable intermediate at m/z 
231.86 that subsequently losses the head group yielding ion (15`) at m/z 216.84. Ion (16) 
observed at m/z 300.94 is also produced from ion (13) after losing the dimethylalkenammonium 
ion and from ion (14) after the neutral loss of ammonia which was confirmed by MS3 analysis 
(Figure 4.7, Table S2, Appendix III). Ion (16) follows same pathway as ion 14 forming ion (17) 
at m/z 316.25 and ion (17`) at m/z 211.17. Both ion 17 and 17` was generated by loss of ammonia 
from ions 15 and 15`. Ions 15, 15`, 17 and 17` further cleaved various amid bonds producing 
smaller structures product ions as illustrated in Figure 4.7. 
 Ions 9 and 9` follow similar fragmentation pattern as ion (13), firstly by losing one of 
the dimethylalkenammonium ions then by eliminating the second one (Figure 4.7, Table 4.1).The 
produced product ions later fragmented to smaller ions in a similar fashion by cleaving the amide 
bond and/or ejecting lysine moieties as illustrated in Figure 4.7. 
In order to support the proposed fragmentation pathways of the peptide-modified 
gemini surfactants with tri-terminal lysine moieties, isotopically labeled analogues were 
evaluated. This include compounds 16-7N(G-C11-KD-K2)-16 and 16-7N(G-C6-KD-K2)-16 where 
KD is a deuterated lysine moiety bearing four deuterium atoms. The MS/MS analysis revealed an 
increased m/z values in the product ions containing the deuterated lysine such as product ions 
(A), (B) and (C) (Figure S4, Appendix III). Moreover, fragment ions (8), (11), (12) and (12`) that 
bear no deuterated region showed identical m/z values, confirming the proposed fragmentation 
pathway (Figure S4, Appendix III). 
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Figure 4.7. Proposed MS/MS product ions generated form product ion (C) at m/z 396.38 of 16-7N(C11-K3)-16 gemini surfactant.  
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4.4.2.2. MS/MS fragmentation pathway of the peptide modified gemini surfactants with mono-
terminal lysine moiety 
Gemini surfactant 16-7N(G-C11-K)-16 is used as an illustrative example of peptide 
modified gemini surfactants functionalized with single terminal lysine moiety (Figure 4.8). 
Similar to the fragmentation pathway of 16-7N(C11-K3)-16 gemini surfactant, dissociation of 16-
7N(G-C11-K)-16 compound started with either the elimination of the lysine moiety and/or the 
neutral loss of amino group. Elimination of the lysine residue through the cleavage of the amide 
bond produced ion (A), a doubly charged product ion observed at m/z 438.95, and released its 
complimentary ion (b1) at m/z 129.10 as a protonated α-amino-ε-caprolactam (Figure 4.8, Table 
4.2). Unlike 16-7N(C11-K3)-16 gemini surfactants, the formation of a triply charged product ion 
after the elimination of the lysine residues from 16-7N(G-C11-K)-16 was not observed. This is 
possibly due to the higher proton affinity of the α-amino-ε-caprolactam compared to the c-
terminal product ions. A charge-directed loss of the lysine ε-amino group from the precursor ion 
resulted in the formation of pipecolic acid derivative product ion (B) at m/z 329.99 which can 
subsequently eradicate the pipecolic acid ring forming ion (A) (Figure 4.8). 
As indicated earlier, product ion (A) undergoes the loss of the dimethylalkenammonium 
ion (1) generating both a single-charged product ion (2) at m/z 607.59 and a double-charged 
product ion (2`) at m/z 304.30 (Figure 4.8, Table 4.2). Both product ions experience a loss of the 
last dimethylalkenammonium ion producing product ion (3) at m/z 338.28. In addition, ion (2`) 
produced ion (3`), the doubly charged analog of ion (3).  
Ion (B) also loses ion (1) producing ion (4) at m/z 240.22 which either eliminates the 
last dimethylalkenammonium ion generating ion (5) at m/z 225.18 and/or removes the pipecolic 
191 
 
acid ring resulting in the formation of ion (2`) (Figure 4.8, Table 4.2). Further dissociations of 
ion (5) are self-explanatory resulting in the production of ion (3) and (3`). Similar to other 
compounds, the genesis and structures of all ions observed in Figure 4.8 were confirmed by MS3 
analysis (data not shown).   
 
Table 4.2. Product ions observed during MS/MS analysis of [M+H] 3+ ions of the peptide 
modified gemini surfactants with mono-terminal lysine moiety.  
 
 
 
  
 Gemini surfactants 16-7N(G-C11-K)-16 12-7N(G-C6-K)-12 16-7N(G-C6-K)-16 
Ion # Product ions m/z m/z m/z 
A [M–C6H13N2O]2+ 438.95 347.85 403.91 
B [M–NH3]3+ 329.99 269.26 306.63 
b1 C6H13N2O 129.1 129.1 129.1 
1 Dimethylalkenaminium 270.31 214.25 270.31 
2 [M–( b1 )- ion(1)] + 607.59 481.44 537.51 
2` [M–( b1 )- ion(1)] 2+ 304.3 241.23 269.26 
3 [M–( b1 )-2 ion(1)] + 338.28 268.2 268.2 
3` [M–( b1)-2 ion(1)] 2+ 169.64 134.6 134.6 
4 [M–(NH3)- ion(1)] 3+ 240.22 198.18 216.86 
5 [M–(NH3)- 2 ion(1)] 2+ 225.18 190.14 190.14 
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Figure 4.8. (A) The ESI-QqLIT MS/MS spectrum of 16-7N(G-C11-k)-16 as a representative 
example of gemini surfactants with mono-terminal lysine moiety and (B) the proposed MS/MS 
fragmentation pattern. 
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4.4.2.3. Universal MS/MS fragmentation pattern of the novel peptide modified gemini surfactants 
Similarities in the fragmentation behaviour of the peptide modified gemini surfactants 
resulted in the establishment of a universal MS/MS fragmentation pattern (Figure 4.9) that can 
be applied to any related structure. The universal fragmentation pathway begins with both the 
cleavage of the peptide bond forming a doubly charged product ion (A) and the neutral loss of 
the lysine’s ε-amino group producing pipecolic acid derivative product ion (B).  
Two dissociation pathways are proposed for product ion (A). First, a loss of one 
quaternary ammonium head group and the attached aliphatic tail producing two complimentary 
ions: dimethylalkenammonium product ion (1) and the singly charged product ion (2). The 
second pathway occurs via homolytic cleavage of the N-C bond between the quaternary 
ammonium headgroup and the hydrocarbon tail resulting in the neutral loss of the aliphatic tail 
and the production of a doubly charged intermediate ion that easily eradicates the dimethylamine 
head group, probably due to the close proximity of the two positively charged head groups, 
generating product ion (2`). In some cases, the intermediate ion was abundant enough to conduct 
MS3 analysis to support proposition. Both ions (2) and (2`) also undergo subsequent loss of 
dimethylalkenammonium ion forming ions (3) and (3`) (Figure 4.9).  
On the other hand, ion (B) dissociates by the loss of dimethylalkenammonium  ion 
forming a triply charged ion (4) which subsequently eliminates another dimethylalken 
ammonium ion to produce ion (5). Product ions (B), (4) and (5) produced ions (A), (2`) and (3`) 
respectively through the removal of the pipecolic acid ring as illustrated in Figure 4.9. 
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Figure 4.9. Universal MS/MS fragmentation pattern for peptide modified gemini surfactants.  
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4.5. Conclusion  
In this work, we utilized ESI-QqToF-MS and ESI-QqLIT-MS to study the CID-MS/MS 
fragmentation behaviour of eleven novel peptide-modified gemini surfactants. Exact mass 
measurements confirmed the projected molecular composition of the evaluated compounds 
showing mass accuracies of less than 8 ppm. In addition, tandem mass spectrometric analysis 
generated compound-specific product ions authenticating the chemical structure of their 
precursor ions. The genesis of these product ions was further confirmed by MS3 analysis (Table 
S2, Appendix III), allowing for the development of fragmentation pattern that could be used as a 
fingerprint for accurate identification of the tested compounds.  
In general, the MS/MS dissociation was centered on the attached amino acids in which 
peptide bonds were cleaved for the generation of diagnostic product ions. Furthermore, neutral 
loss of an ammonia group from the amino acid side chain was dominant within the evaluated 
structures. Elimination of one or both of the quaternary ammonium head groups and the attached 
aliphatic tail was also observed. It should be noted that the number of terminal amino acid 
residues in the spacer and the length of the inserted hydrocarbon linker affected the dissociation 
behaviour. For example, the formation of the triply charged initial product ions after eliminating 
a terminal lysine residue was only observed in gemini surfactants with longer hydrophobic linker 
chain (C11) and with tri-terminal amino acids residues. Nevertheless, similarities in the 
fragmentation behaviour among all the tested gemini surfactants resulted in the production of a 
universal fragmentation pattern as illustrated in Figure 4.9. This universal fragmentation pattern 
can be utilized to predict the dissociation behaviour of new compounds with similar general 
structural features. In addition, it will be utilized for the development of qualitative and 
196 
 
quantitative MS-based methods to probe the fate and biodistribution of topically applied 
therapeutic gemini surfactant formulations. We are currently quantitatively evaluating the 
distribution of lead gemini surfactants within skin tissues for therapeutic applications. This data 
will be reported upon completion.  
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Transitioning rationale: 
Literature review provided evidence about the potential of gemini surfactants as a gene delivery 
carries for topical application. Peptide-modified gemini surfactants demonstrated promising 
results in transfecting keratinocytes (Chapter 3). The success of developing efficient and safe 
cutaneous gene delivery systems requires a thorough understanding of the vectors’ skin 
deposition and penetration behaviour. In the previous chapter, we evaluated the MS/MS 
dissociation behaviours of peptide-modified gemini surfactants. Herein, we aim at developing 
flow injection analysis tandem mass spectrometric methods (FIA)-MS/MS to assess the skin 
deposition and penetration behaviour of topically applied therapeutic gemini surfactant 
formulations.  
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5.1. Abstract 
Diquaternary ammonium gemini surfactants are a class of non-viral gene delivery 
vectors, primarily studied for their dermal applications. However, their biological fate has rarely 
been investigated. In this work, we developed simple flow injection analysis tandem mass 
spectrometric methods, (FIA)-MS/MS, to understand the fate and biodistribution of topically 
applied gemini surfactant-based therapeutics in an ex-vivo skin model.  
Three peptide-modified gemini surfactants with varied structures and transfection 
efficiencies were evaluated. For each compound, two methods were developed to quantify their 
presence in skin tissue and in phosphate buffered saline (PBS). The methods were developed 
using single-point calibration mode. Skin penetration was assessed on CD1 mice dorsal skin 
tissue mounted in a Franz diffusion cell after extraction. Amongst the five evaluated liquid-liquid 
extraction protocols, the Folch method provides the highest extraction efficiency for all 
compounds. Weak cationic exchange solid phase extraction was also used to further isolate 
gemini surfactants from endogenous skin lipids. FIA–MS/MS analysis of the skin revealed that 
all compounds were detected in the skin with minimal partition into the PBS compartment, 
which represents circulation. Interestingly, the detected amounts of gemini lipids in the skin were 
correlated with their transfection efficiencies, where the lead compound exhibited the highest 
skin concentration. The developed methods will be used, in the close future, to investigate the 
fate of topically applied gemini surfactant-based formulation in vivo.     
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5.2. Introduction  
Recent advances in discovering the genetic basis of many dermatological disorders have 
found cutaneous gene therapy to be a promising therapeutic option [1, 2]. Cutaneous delivery of 
genetic material offers numerous advantages over other routes of administration, such as 
minimizing systematic toxicity, bypassing first-pass metabolism, and avoiding rapid clearance 
from the systemic circulation [3]. Despite these advantages, skin is a formidable barrier to foreign 
materials, such as nanotechnology products [4]. Therefore, effective delivery systems capable of 
penetrating the cutaneous barrier and facilitating recombinant DNA uptake into the skin are 
needed to achieve gene expression – the ultimate goal of gene therapy. 
Among topical delivery modalities currently being explored, lipid-based delivery vectors 
are at the forefront [5, 6]. They have the ability to encapsulate, protect, and compact negatively 
charged nucleic acids, whereby forming nano-sized lipoplexes. Furthermore, the chemical 
composition of lipid-based nanocarriers bears some similarity to skin lipids, which enables them 
to fuse with the lipids in the stratum corneum, the outer layer of the skin; destabilizing the lipid 
matrix and enhancing drug penetration [6]. Diquaternary ammonium gemini surfactants are a 
class of lipid-based delivery systems that are composed of dimeric surfactants with positively 
charged head groups and hydrocarbon tails linked by a spacer chain (Figure 5.1) [7],[8]. The 
structure of gemini surfactants can be tailored to overcome skin barrier functions [9]. The topical 
application of gemini surfactant-based nanoparticles demonstrated a promising potential in the 
treatment of localized cutaneous scleroderma [9-11]. Nanoparticles of N,N'-
bis(dimethylhexadecyl)-1,3-propanediammonium dibromide gemini surfactant complexed with 
pDNA encoding for interferon gamma (INF-γ) showed a significant increase in the level of INF-
γ in mice [9-11].  
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Figure 5.1. Schematic representation of gemini surfactants showing the two ionic head groups, 
hydrocarbon tails and the spacer. 
 
Despite advances in the design of lipid-based nanocarriers, their biodistribution and 
biological fate have been less explored. Upon topical application, lipid-based nanoparticles 
distribute within various layers and cellular components. At present, the biodistribution, 
intracellular trafficking, and the ultimate fate of the lipid vector, after releasing its therapeutic 
cargo, are not fully understood. A fundamental understanding of the behavior of the lipid-based 
vectors in complex biological environments is essential in guiding the design of safer and more 
effective nanoparticles.  
To track the fate and distribution of lipid-based nanoparticles, fluorescently labeled and 
radiolabeled carriers are the most commonly used strategies. However, labeling techniques have 
drawbacks, particularly their tendency to alter the physicochemical properties of the delivery 
system. These modifications, in turn, change the pharmacokinetic profile of the nanocarriers [12]. 
Furthermore, they are unable to distinguish between the localization of a labeled molecule and 
the metabolites that retain the fluorescent or radioactive probes [13]. Therefore, a more robust and 
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sensitive analytical technique should be employed to identify and quantify gene-based carriers in 
complex biological samples. 
Mass spectrometry (MS) is an ideal technique to monitor the fate of gemini surfactants in 
the skin [14-16]. It is a label-free technique with a powerful chemical identification capability and 
is gaining popularity in pharmaceutical sciences due to its high selectivity and sensitivity [17, 18]. 
Coupling liquid chromatography to tandem mass spectrometry (LC–MS/MS) allows for reliable 
high throughput qualitative and quantitative analysis [19]. In fact, it is the gold standard 
technology for the quantification of pharmaceuticals in complex biological matrices [20, 21].  
In our laboratory, we developed two LC–MS/MS methods for the quantification of 
unsubstituted diquaternary ammoniums gemini surfactants (N, N-bis(dimethylalkyl)-α,ω-alkane-
diammonium), amine substituted diquaternary ammoniums compounds, and heterocyclic head 
group gemini surfactants (bis(alkyl-pyridinum) in epidermal keratinocytes [22, 23]. These methods 
provided essential information about the rate of cellular uptake and intracellular depletion of 
gemini surfactants [22, 23]. Currently, these methods are being employed to determine the 
subcellular localization of gemini surfactants and identify any potential metabolites. Recently, a 
new series of peptide modified diquaternary ammoniums gemini surfactants was found to exhibit 
superior transfection efficiency compared to previous generations of gemini surfactants [24]. Their 
collision-induced dissociation (CID)-MS/MS behaviour was evaluated, establishing a universal 
mass spectrometric fingerprint, essential for the development of targeted LC-MS qualitative and 
quantitative methods [14].  
Herein, we resolved a significant analytical challenge, the efficient extraction of gemini 
surfactants from lipid rich skin tissues. Efficient analytical platforms are needed to guide the 
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development of effective pharmaceutical formulations. Three representative compounds were 
selected with high, low, and moderate transfection efficiencies. Subsequently, rapid and simple 
flow injection analysis (FIA)-MS/MS methods were developed to detect and quantify peptide-
modified gemini surfactants in skin tissues as well as in phosphate buffered saline (PBS).  
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5.3. Materials and methods  
5.3.1. Materials  
The evaluated peptide-modified gemini surfactants, designated as 16-7N(R)-16 where 16 
is the alkyl chain length and R is the peptide-containing moiety: R= glycyl-lysine, glycyl-hexyl-
trilysine and glycyl-undecyl-trilysine (Figure 5.2), were synthesized using previously reported 
synthetic methods [24]. The corresponding internal standards were synthesized using the same 
synthetic procedure with the incorporation of deuterated lysine moiety bearing four deuterium 
atoms (Figure S1, Appendix IV). The plasmid pGThCMV.IFNGFP (pDNA), encoding for 
murine interferon gamma (IFN-γ) and green fluorescent protein (GFP) was utilized in this work 
[9].  
The helper lipid 1,2-dioleoyl-snglycerol-3-phosphoethanolamine (DOPE) was purchased 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Sucrose, used as a stabilizing agent, and 
phosphate buffered saline (PBS) were purchased from Sigma Aldrich (Oakville, ON, Canada). 
Mass spectrometry-grade methanol, water, and acetonitrile were purchased from Fisher 
Scientific (Nepean, ON, Canada). Formic acid (purity 90%) was obtained from EMD Chemicals 
Inc. (Merck KGaA, Darmstadt, Germany). Anhydrous chloroform and methyl tert-butyl ether 
(MTBE) used as extraction solvents were purchased from Sigma Aldrich (Oakville, ON, 
Canada). Solid phase extraction cartridges, Bond Elute® CBA, were obtained from Agilent 
Technologies (Mississauga, ON, Canada).  
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Figure 5.2. Chemical structure of gemini surfactants 16-7N(G-K)-16 (A), 16-7N(G-C6-K3)-16 
(B) and 16-7N(G-C11-K3)-16 surfactants showing their precursor ion and the monitored product 
ions.  
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5.3.2. Preparation of topical formulations  
Cationic gemini lipids were combined with pDNA at nitrogen (cationic) to phosphate 
(anionic) charge ratios (N/P) of 5 in the presence of a helper lipid DOPE to create pDNA/gemini 
lipid/helper lipid (P/G/L) nanoparticles. An appropriate amount of 30 mM aqueous solutions of 
gemini surfactant was added to 2 mg/mL pDNA solution and incubated for 20 minutes at room 
temperature (P/G complex). 2 mM DOPE was prepared as described previously [25] then 
concentrated to 10mM using Eppendorf concentrator 5301(Eppendorf, Hamburg, Germany). The 
concentrated DOPE was added to P/G complexes at a gemini surfactant to DOPE molar ratio of 
1:16 to form the final nanoparticles (P/G/L) and incubated at room temperature for 20 minutes.  
5.3.3. Ex vivo skin penetration study 
Dorsal skin tissues were collected from female CD1 mice (Charles River Laboratories, 
Saint-Constant, QC, Canada) weighing around 22-24 g. Approval for this study was granted by 
the University of Saskatchewan’s Animal Research Ethics Board in adherence to the Canadian 
Council on Animal Care guidelines for humane animal use (protocol # 20090081). The animals 
were shaved and the skin was collected and stored at -80 °C until use.  
Skin penetration was evaluated using multi-station Franz diffusion cell system with 64 
mm2 surface area (PermeGear Inc., Hellertown, PA, USA). The skin tissue was mounted between 
the donor and receptor compartments of the Franz cell with the stratum corneum facing the 
donor compartment. The receiving chamber was filled with 5 mL PBS, avoiding any air bubbles 
between the skin and the solution. The skin tissues were allowed to equilibrate for 10 minutes 
before applying any formulation. A total 200 µL of peptide modified gemini surfactant-based 
lipoplexes containing 16 µg pDNA was placed in the donor compartment and the chamber was 
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covered with parafilm. Throughout the experiment, the PBS in the receptor compartment was 
continuously stirred at 700 rpm using a magnetic stirrer bar and temperature was maintained at 
32 °C using a circulating water bath (Fisher Scientific, Nepean, ON, Canada).  
Aliquots of 200 µL were withdrawn from the receptor compartment at fixed intervals (2, 
4, 6, 8, 12, 18 and 24 h) and replaced with an equal volume of pre-warmed PBS. After 24 hours, 
any remaining formulation in the donor chamber was aspirated and the skin tissue was removed 
from the Franz cell. The skin was rinsed thoroughly with water, blotted with tissue paper, then 
stripped 10 times with Scotch adhesive tape. The collected skin tissues and PBS samples were 
stored at -80 °C prior to analyte extraction and FIA-MS/MS analysis. 
5.3.4. Sample preparation for FIA-MS/MS analysis 
Skin tissue (40 mg) was spiked with 200 µL of methanol containing 0.03 mM of the 
corresponding internal standards for 16-7N(G-Kd4)-16 as well as 16-7N(G-C11-Kd4-K2)-16  and 
0.015 mM of 16-7N(G-C6-Kd4-K2)-16. After adding the extraction solvent, the skin was 
homogenized using a probe homogenizer (PRO200 Homogenizer, PRO Scientific Inc., Oxford, 
Connecticut, USA). During homogenization, the sample was kept on ice to avoid overheating. 
Five extraction solvent protocols were evaluated as explained below.   
5.3.4.1. Liquid-liquid extraction protocols 
Modified Folch method  
The analytes were extracted as described in the Folch protocol [26] with some 
modifications by the addition of 200 µL methanol containing the internal standards, followed by 
the addition of 400 µL chloroform. Then, the skin sample was homogenized in the presence of 
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ice to avoid overheating. High purity water (150 µL) was added to the homogenate to induce 
phase separation followed by pulse vortexing for a few seconds. The sample was centrifuged at 
14,000 rpm for 10 min at room temperature to obtain separate aqueous and organic phases. The 
bottom organic phase was retrieved while the upper aqueous phase and the skin pellet were re-
extracted by the addition of 400 µL chloroform as described above. The upper phase was 
discarded and both organic phases were combined, dried using a centrifugal evaporator, and 
stored at -80°C until analysis. 
Modified Bligh and Dyer method (B&D)  
The analytes were extracted by employing the Bligh and Dyer method with some 
modifications [27], by adding 80 µL high purity water, 200 µL methanol containing the internal 
standards and 100 µL chloroform to the skin tissue. Additional 100 µL chloroform was added, 
followed by 100 µL water while the sample was homogenized. Subsequently, the homogenate 
was centrifuged at 14,000 rpm for 10 min at room temperature. Similar to the modified Folch 
protocol, the lower organic layer was collected while the upper aqueous layer and the skin pellet 
were re-extracted with additional 200 µL chloroform. Finally, the organic layers were combined, 
dried with a centrifugal evaporator, and stored at -80°C. 
Acidified/alkaline B&D method  
The analytes and internal standards were extracted as described in the Bligh and Dyer 
protocol, except that either 2 µL of 3M hydrochloric acid [28] or 0.3% 12 M ammonium 
hydroxide [29] was added to the pre-homogenization mixture.  
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Modified methyl-tert-butyl ether (MTBE) method 
The analytes were extracted as described [30], with modifications, by adding 200 µL 
methanol containing the internal standards, then 666 µL MTBE. Subsequently, the tissue sample 
was homogenized in the presence of ice to avoid overheating. Afterwards, phase separation was 
induced by adding 166 µL water followed by pulse vortexing for a few seconds. The 
homogenates were centrifuged for 10 min at 14,000 rpm then the upper organic layer was 
retrieved while the lower aqueous layer and the skin pellet were re-extracted by adding 666 µL 
MTBE. After final centrifugation, both organic phases were combined and dried before being 
stored at -80°C. Figure 5.3 summarizes the discussed liquid-liquid extraction protocols. 
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Figure 5.3. Flowchart summarizing the five evaluated liquid-liquid extraction methods.   
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5.3.4.2. Solid phase extraction (SPE) protocol  
Extracts from each solvent system were solubilized in 3 mL methanol-water (50:50, v/v). 
The CBA cartridges were activated by successive additions of 3 mL methanol, 3 mL water, and 
3mL methanol-water mixture (50:50, v/v). Subsequently, extracts were loaded into the cartridges 
followed by washing steps with 3 mL pure water and 3 mL methanol. Retained analytes and 
internal standards were eluted with 6 mL concentrated HCL-methanol (2:98, v/v). Finally, 
sample elutes were dried using a centrifugal evaporator and stored at -80°C.  
Prior to MS analysis, extracted analytes were reconstituted in 3 mL methanol with 0.1% 
formic acid. Same procedure was followed to extract the analytes of interest from the PBS used 
in Franz cell’s receptor compartment.   
5.3.5. FIA-MS/MS instrumentation 
FIA-MS/MS was performed on an Agilent 1290 infinity UHPLC (Agilent Technologies, 
Mississauga, ON, Canada) interfaced to an AB SCIEX QTRAP® 6500 triple quadrupole-linear 
ion trap mass spectrometer (QqLIT-MS) (AB SCIEX, Concord, ON, Canada). The mobile phase 
was optimized for each compound to achieve better ionization and peak shape. Isocratic mobile 
phase composed of acetonitrile/water mixture (50:50, v/v for 16-7N(G-K)-16 and 90:10, v/v for 
the rest of compounds) with 0.1% formic acid was delivered at a flow rate of 0.3 mL/min for a 
run time of 4 min. Sample aliquots of 1 µL were injected while maintaining the auto sampler 
temperature at 4 °C.  
The AB SCIEX QTRAP® 6500 is equipped with a “Turbo V Ion Spray” ESI source, 
operated in the positive ion mode and set at 5500 V ionspray voltage. Optimal detection 
parameters for each analyte are listed in Table 5.1. The MS/MS data were obtained by low 
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energy collision-induced dissociation (CID) employing nitrogen as the collision gas. Multiple 
reaction monitoring (MRM) was selected as the scan mode to monitor the analytes and internal 
standards precursor ions to product ions transitions. Dwell time for all transitions was 150 ms at 
unit resolution. The monitored transitions and their MRM conditions are listed in Table 5.2. The 
structures of the monitored transitions are shown in Figure 5.2 as well as Figure S1, Appendix 
IV.  
Table 5.1. Optimal detection parameters of the tested analytes on the AB SCIEX 6500 QTRAP® 
system.  
 
Gemini Surfactants 
Curtain gas, 
CUR (psi) 
Nebulizer gas, 
GS1 (psi) 
Heater gas, GS2 
(psi) 
Collision gas, 
CAD (psi) 
Source 
temperature 
(°C) 
16-7N(G-K)-16 45 50 80 10 700 
16-7N(G-C6-K3)-16 45 60 60 11 700 
16-7N(G-C11-K3)-16 45 70 90 10 600 
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Table 5.2. Conditions for MRM transitions of the gemini surfactants on AB SCIEX 6500 
QTRAP® System. 
 
Gemini surfactant Transition (m/z) DP (eV) CE (eV) CXE (eV) 
16-7N(G-K)-16 
411.4 → 276.9 151 27 10 
411.4→ 268.4 151 29 20 
16-7N(G-Kd4)-16 413.5 → 278.9 151 27 18 
16-7N(G-C6-K3)-16 
397.8 → 532.1 101 25 26 
397.8 → 268.2 101 33 10 
16-7N(G-C6-Kd4-K2)-16 399.2 → 534.2 101 23 26 
16-7N(G-C11-K3)-16 
421.2 → 338.3 141 35 18 
421.2 → 378.4 141 23 18 
16-7N(G-C11-Kd4-K2)-16 422.5 → 379.8 116 23 18 
 
5.3.6. Preparation of standard solutions  
In this work, two methods were developed for each gemini surfactant: method A to 
determine their presence in the skin tissues and method B to monitor their cumulative amount 
permeated into the PBS solution.  
Method A: 
Aqueous stock solutions of gemini surfactants and their internal standards were prepared 
at a concentration of 3mM and stored at -20 °C. Working stock solutions were prepared daily by 
serial dilution of the stock solutions in methanol to concentrations of 0.03 mM and 0.015 mM. 
One point calibration standards were prepared by adding 400 µL of 0.03 mM target analyte and 
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200 µL of 0.03 mM from the corresponding internal standards to 2.4 mL pooled blank skin tissue 
extract. The exception was with 16-7N(G-C6-K3)-16 gemini surfactants where 0.015 mM of the 
analyte and 0.015 mM IS were used, since the concentration of 16-7N(G-C6-K3)-16 in the skin 
was less than the other two compounds. The equivalent final mass concentration of the gemini 
surfactants and the corresponding internal standards are listed in Table S1, Supplementary 
Material.  
Method B: 
Aqueous stock solutions of gemini surfactants and their internal standards were prepared 
at a concentration of 3mM and stored at -20 °C. Working stock solutions were prepared daily by 
serial dilution of the stock solutions in methanol to concentrations of 3 µM and 1.5 µM. One 
point calibration standards were prepared by adding 60 µL of 3 µM target analyte (except for 16-
7N(G-C6-K3)-16 gemini surfactants where 1.5 µM was used) and 40 µL of 3 µM from the 
corresponding internal standards (except for 16-7N(G-C6-Kd4-K2)-16 where 1.5 µM was used) to 
200 µL blank PBS extract. The equivalent final mass concentration of the gemini surfactants and 
the corresponding internal standards are listed in Table S1, Appendix IV.  
5.3.7. Method validation  
The methods were partially validated with respect to selectivity, recovery, matrix effect, 
and process efficiency as recommended by the USFDA guidelines [31]. The performance of the 
methods was evaluated by statistically comparing the slope of the three-point calibration curves 
for three intra-run measurements.  
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5.3.8. Data analysis 
Data processing for quantitative analysis was conducted using Analyst® software 
(Version 1.6.0).  A sample concentration was obtained according to single point calibration mode 
using the following equation. 
𝐶𝑜𝑛𝑐 (𝑠𝑎𝑚𝑝𝑙𝑒)  =
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑅𝑎𝑡𝑖𝑜 (𝑠𝑎𝑚𝑝𝑙𝑒) × 𝐶𝑜𝑛𝑐(𝐶𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑)
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑅𝑎𝑡𝑖𝑜 (𝐶𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑)
   (1) 
The skin permeation parameters were calculated from the plot of cumulative amount of 
gemini surfactants permeated to the Franz diffusion cell’s receptor compartment divided by 0.64 
cm2 to correct for the exposed skin area as a function of time. Steady-state flux (Jss) was derived 
from the slope of the linear portion of the curve. The lag-time (tlag) was estimated from the 
intercept of the tangent to the linear part of the absorption profile on the time axis. The 
permeability coefficient Kp was calculated using the following equation 
[32]: 
𝐾𝑝 =
𝐽𝑠𝑠
𝐶𝑑𝑜𝑠𝑒
    (2) 
where C dose is the concentration of the applied dose.  
Consequently, diffusion coefficient Dm and skin partition coefficient Km could be 
calculated as follows: 
𝐷𝑚 =  
𝑑2
6×𝑡𝑙𝑎𝑔
    (3) 
𝐾𝑚 =
𝐾𝑝×𝑑
𝐷𝑚
    (4) 
where d is the measured skin thickness in cm.  
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5.3.9. Computational prediction 
The gemini surfactants partition coefficient (clog P), distribution coefficient (clog D) at 
varying pH, and aqueous solubility (clog S) were estimated using ACD/Physchem Profiler 2016 
[33] (Advanced Chemistry Development, Inc., Toronto, ON, Canada). 
5.3.10. Statistical analysis 
Statistical analyses were performed using SPSS software (Version 24.0). One-way 
analysis of variance (ANOVA, Scheffé/Dunnett’s post hoc tests) and Pearson’s correlation were 
used for statistical analyses. Significant differences were considered at p<0.05 level.   
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5.4. Results and discussion  
5.4.1. Method development  
The major purpose of this work is to overcome an analytical challenge by developing 
simple and rapid MS-based methods for the detection and relative quantification of peptide-
modified gemini surfactants in skin tissues as well as in PBS. Analytical strategies should meet 
the need of the experiment; in our work, a fit-for-the-purpose approach was adopted as it 
provides the needed data to drive future formulation decisions. The developed methods aim to 
track the distribution of topically applied gemini surfactant-based therapeutics and investigate 
the impact of structural variation on the efficiency of skin penetration.  
LC-MS/MS is the most widely used platform for the quantification of pharmaceuticals in 
complex biological matrices, offering analyte separation and matrix effect reduction capabilities 
[20, 21]. Despite these advantages, LC-MS/MS significantly increases the overall analysis time and 
associated costs [34]. The sensitivity and selectivity of modern MS instruments and the evolution 
of efficient sample preparation techniques allow the development of simple analytical procedures 
[35, 36]. Direct introduction of the sample into the MS using FIA (i.e., loop injection) has emerged 
as an effective approach that offers a rapid sample possessing rate, low cost, and method 
simplicity [37]. It has been successfully applied in the quantitation of several analytes, including 
pharmaceuticals, environmental contaminants, and endogenous compounds [38-41]. Therefore, 
FIA-MS/MS methods were developed removing the need for chromatographic separation while 
relying on the MS separation capabilities. For each gemini surfactant, two methods were 
developed: method A to determine their presence in the skin and method B to monitor their 
cumulative amount permeated into the PBS. 
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To ensure adequate selectivity and specificity of the developed method, we capitalized on 
the QTRAP capability in the MRM scan mode. The MS operational parameters such as 
declustering potential (DP), collision energy (CE), and collision exit potential (CXP) were 
optimized as shown in Table 5.2 to maintain ion abundance and stability. Two diagnostic MRM 
transitions with relatively high abundance, listed in Table 5.2, were selected for each compound. 
To improve accuracy and precision, an isotopically labelled internal standard bearing four 
deuterium atoms was used for each compound. The use of 4 mass unit difference between the 
analyte and its corresponding internal standard prevents any cross talk. The proposed structure of 
the monitored product ions for each gemini surfactant and their internal standards are shown in 
Figures 5.2 and S1 (Appendix IV), respectively.  
All tested compounds eluted before 0.8 min, as no column was used, with a total data 
acquisition time of 4 min (Figure 5.4A).  No carryover was observed under the experimental 
conditions. This was significantly faster than the elution time in the recently developed HILIC-
based LC-MS/MS quantification method in which second generation amine substituted gemini 
surfactants eluted at 7.12 min 30. It is noteworthy that peptide-modified gemini surfactants are 
more polar than amine substituted gemini surfactants, hence, longer elution times are expected 
for peptide-modified gemini surfactants if the HILIC-MS/MS method was applied.  
5.4.2. Selectivity 
Selectivity of the developed methods was assessed by monitoring the existence of 
interfering peaks of the evaluated analytes and their internal standards in murine skin tissue 
extracts as well as in PBS solution from 6 different sources (data not shown). As shown in Figure 
5.4 B and C, no interference from endogenous compounds against the selective bio-
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determination of the gemini surfactants was observed in both double blank skin tissue extracts 
and PBS. The ratio of the quantifier to the identifier transition ions were also monitored showing 
less than 9% variations, indicating peak purity. The relative standard deviation (RSD) of the 
qualifier to the quantifier ratios was used as the acceptance criterion (less than 15%).  
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Figure 5.4. Representative FIA‐MS/MS chromatograms of (A) skin tissue extract of 16-7N(G-
K)-16 gemini surfactants, (B) double blank skin tissue extract, and (C) double blank PBS extract.   
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5.4.3. Sample preparation  
Sample preparation represents one of the most critical steps for obtaining reliable and 
sensitive quantitative data [42]. As such, the ability to extract gemini surfactants from skin tissues 
was thoroughly assessed in this work using five common liquid-liquid extraction protocols, 
namely Folch [26], B&D [27], Acidified B&D [28], Alkaline B&D [29], and MTBE [30]. Extraction of 
gemini surfactants from skin tissues posed an analytical challenge due to the complexity of the 
skin matrix and the presence of a wide variety of interfering substances such as proteins, salts, 
and lipids [43]. In fact, the main challenge was the lipid-rich nature of skin tissues that caused 
significant matrix effects (data not shown) due to the high affinity of the endogenous lipids to the 
organic phase, similar to the target analyte, i.e., the gemini surfactants. Therefore, further 
purification was necessary to isolate gemini surfactants from the skin’s endogenous lipids.  
Since the skin is composed of a wide variety of lipid classes ranging from highly non-polar 
to polar lipids [44]; we capitalized on the gemini surfactants’ unique feature, namely the two 
permanently charged quaternary amines to efficiently isolate them. Therefore, Bond Elute® CBA 
weak cationic exchange solid phase extraction (SPE) was used to purify extracts obtained from 
the liquid-liquid extractions. Bond Elute® CBA is a silica-based sorbent with a weak anion, 
carboxylic acid group, bonded to the surface. The carboxylic acid functional group has a pKa of 
4.8 that is negatively charged at pH 6.8 and higher, allowing for strong ionic interaction with the 
positively charged nitrogen atoms of the gemini surfactants. Washing of the cartridges with non-
acidic methanol and water was used to remove non-bonded skin lipids and other interfering 
substances. Finally, elution of the gemini surfactants was achieved by neutralizing the carboxylic 
acid functional group using acidified methanol (pH 2.8 and lower).  
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Recovery, matrix effect, and process efficiency were evaluated across the five extraction 
protocol according to Matuszewski et al. [45] equations as follow:  
% 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒  𝑝𝑟𝑒−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑝𝑜𝑠𝑡−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒  
× 100    (5) 
% 𝑀𝑎𝑡𝑟𝑖𝑥 𝑒𝑓𝑓𝑒𝑐𝑡 =
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑝𝑜𝑠𝑡−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑛𝑜𝑛−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑛𝑒𝑎𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 
 × 100    (6) 
% 𝑃𝑟𝑜𝑐𝑒𝑠𝑠 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒  𝑝𝑟𝑒−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑛𝑜𝑛−𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑛𝑒𝑎𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 
× 100   (7) 
where the pre-extraction spiked sample refers to gemini surfactant standards added to the skin 
tissue before extraction and where samples were processed according to each liquid-liquid 
extraction procedure followed by purification with SPE. Response from the post-extraction 
spiked sample contains gemini surfactant standards added to the extracted blank tissues after 
passing through the SPE. The non-extracted neat sample contains the gemini surfactants added to 
the final reconstitution solvent (methanol with 0.1% formic acid). The determined value is the 
average for a set of triplicates. 
Table 5.3 displays the effect of the extraction protocols on the recovery, matrix effect, and 
process efficiency. The Folch method resulted in the highest extraction efficiency in all gemini 
surfactants while MTBE displayed the lowest efficiency. The higher extraction efficiency of 
Folch compared to B&D methods was in agreement with the notion that the Folch protocol is 
more suited for extracting lipids from tissues, whereas B&D is more successful for biological 
fluids [46, 47]. Although both Folch and B&D methods are based on the biphasic chloroform-
methanol-water mixtures, the Folch method uses a higher percentage of chloroform over 
methanol (Folch maintains the chloroform-methanol-water mixture at 8:4:3 while the B&D ratio 
is 2:2:1.8) [26, 27]. Chloroform is a widely used extraction reagent for analytes with intermediate 
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polarity such as gemini surfactants, while methanol is not an ideal extraction solvent since it is 
miscible with water. In fact, methanol is incorporated into the extraction mixture to disturb the 
interaction of the target analyte with the cellular biopolymers such as proteins, owing to its 
polarity and high dielectric constant [46]. Although methanol has recently been used as a 
monophasic extraction system for phospholipids in blood and polar lipids in the upper layer of 
human skin [48, 49], in our experiments, it showed no success in extracting gemini surfactants from 
the skin tissues (data not shown).  
Adjustment of the pH in the B&D method is viewed as an effective way to optimize the 
extraction efficiency of specific classes of lipids [28, 29, 50]. In the case of gemini surfactants, 
higher recovery and less ion suppression were reported with alkaline B&D compared to 
conventional B&D, however the differences were not statistically significant (Table 5.3). 
Alkaline medium caused an increase in logD values and a decrease in logS values of the tested 
gemini surfactants (Table 5.4), resulting in their higher partition into the organic layer. In 
addition, the alkaline medium increases the polarity of the phosphate moiety of the skin natural 
lipids, which might increase their partition into the aqueous layer, minimizing interference with 
gemini surfactants.  
Acidified B&D was the least effective method among the B&D methods; it exhibited the 
highest ion suppression. This could be attributed to the higher affinity of the endogenous lipids to 
the organic phase under acidic conditions resulting in significant ion suppression. The addition of 
HCl neutralizes the negatively charged skin lipids resulting in increased hydrophobicity, hence, 
higher unfavorable partition into the organic phase.  
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Extraction with MTBE was significantly the least effective among the evaluated extraction 
protocols (Table 5.3). This could be attributed to the lower polarity index of MTBE of 2.5 
compared to chloroform of 4.1 [51]. MTBE was introduced as an alternative solvent system to 
chloroform that offered simplified sample handling [30]. It has a lower density than water and 
methanol, thus, it forms the upper layer during the extraction allowing for easier analyte 
collection. While it was suggested that extraction with MTBE is effective for most major classes 
of lipids, including polar and neutral lipids [30, 52], contradictory reports indicate that MBTE was 
only able to extract 10% of major polar lipids [53].  
Comparison of the extraction efficiency among the three gemini surfactants revealed that 
16-7N(G-C11-K3)-16 exhibited the highest recovery in all extraction methods, followed by 16-
7N(G-K)-16, then 16-7N(G-C6-K3)-16 (Table 5.3). This trend was in accordance with the clog P 
values of the gemini surfactants in which the higher the compound hydrophobicity, the higher its 
affinity into the organic phase, hence the higher the extraction efficiency (Table 5.4). However, 
while there is a major difference in the clog P values between compound 16-7N(G-C11-K3)-16 
and 16-7N(G-K)-16 ( 3.27 and 2.8 respectively), the differences in the extraction efficiency is 
not as dramatic. This could be explained by the higher number of terminal lysine moieties in 
compound 16-7N(G-C11-K3)-16 compared to 16-7N(G-K)-16 which exhibit higher affinity to 
bind to the negatively charged constituents of the skin. In fact, such speculation could explain the 
substantially low extraction efficiency of compound 16-7N(G-C6-K3)-16, which has three polar 
lysine residues and shorter hydrophobic spacer, conferring low lipophilicity to the molecule.  
Since the modified Folch method demonstrated the highest process efficiency, it was 
selected as the liquid-liquid extraction method for the bioanalysis.  
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Table 5.3. Recovery, matrix effect, and process efficiency of the evaluated-peptide modified gemini surfactants using different liquid-
liquid extraction protocol.  
 
 Gemini surfactants 
 16-7N(G-K)-16 16-7N(G-C6-K3)-16 16-7N(G-C11-K3)-16 
Extraction 
Method 
% 
Recovery 
%Matrix 
effects 
%Process 
efficiency 
% 
Recovery 
%Matrix 
effects 
%Process 
efficiency 
% 
Recovery 
%Matrix 
effects 
%Process 
efficiency 
MTBE 51.80 ± 2 89.75± 6 56.67 ± 1 21.9 ± 3 75.29 ± 7 23.1 ± 5 53.98 ± 1 83.66±4 45.86 ± 0.8 
Folch 85.32 ± 7 71.48 ±6 75.06 ± 5 46.04 ± 7 71.8 ± 1 38.28 ± 0.3 93.82 ± 5 74.63 ±5 77.09 ± 3 
Blight&Dyer 74.18 ± 3 77.92± 4 
69.01 ± 
0.5 
30.7 ± 1 53.44 ± 3 30.1 ± 0.8 
76.57 ± 
0.8 
62.71± 2 60.88 ± 4 
Acidify B&D 60.17 ± 3 67.7 ± 6 60.81 ±5 28.37 ± 2 
46.09 ± 
0.9 
29.64 ± 1 63.65 ± 5 53.91 ± 8 55.97 ± 4 
Alkaline B&D 77.60 ± 2 88 ± 1 73.18 ± 2 39.9 ± 1 68.49 ± 4 31.2 ± 1 80.7 ± 6 67.24 ± 4 60.77 ± 0.5 
 
2
2
8
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Table 5.4. Physicochemical properties of the evaluated gemini surfactants estimated using 
ACD/Physchem Profiler.  
  
 Gemini surfactants 
Physicochemical 
properties 
16-7N(G-K)-16 16-7N(G-C6-K3)-16 16-7N(G-C11-K3)-16 
clog P 2.80 1.28 3.27 
clog D at pH= 4 0.8 -2.7 -0.7 
clog D at pH= 6 1.0 -2.6 -0.6 
clog D at pH= 10 2.3 0.3 2.3 
clog S at pH= 4 -9.2 -7.6 -9.1 
clog S at pH= 6 -9.4 -7.7 -9.2 
clog S at pH= 10 -10.7 -10.6 -12.1 
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5.4.4. Single point calibration 
Fully validated quantification methods are usually needed for preclinical and clinical 
analysis, however, they require considerable time, workload, and resources [54, 55]. In the case 
where full validation is not required, a “fit-for-the-purpose” approach is a more suited analytical 
strategy to obtain the needed data and is frequently used to answer predefined research questions 
[54], [56, 57]. One common quantification strategy is single-point calibration; considered a 
compromise between the rigor of the analytical method and the workload without sacrificing the 
accuracy of the results. In fact, several studies compared single point to conventional multi-point 
calibration showing the usefulness of single-point calibration in providing quantitative data with 
accuracy and precision that meet regulatory guidelines [58-60]. Since the scope of this work is to 
conduct a relative comparison among three gemini surfactants with varying transfection 
efficiencies; a one-point calibration quantitative strategy is deemed adequate to provide relative 
quantification data with acceptable accuracy and precision, effectively reducing the required 
time, resources, and cost of analysis.  
In single point calibration, one reference concentration is employed for the quantification 
of the analyte of interest. However, two conditions must be fulfilled: (i) the concentration-
response function is linear and (ii) the y-intercept is negligibly small [61]. In this work, a single 
concentration of gemini surfactants was selected to serve as a calibration standard for each 
method: method A and method B (Table S1, Appendix IV). The calibration standard was 
prepared in triplicate and the average response was used for quantification. The RSD values (i.e., 
precision) in all cases did not exceed 11%. The concentrations of selected calibration standards 
were relatively close to the concentration of the analytes in the skin tissue samples for method A 
and in the mid-range of the sample concentrations in the PBS solution (Table S1, Appendix IV). 
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The selection of each point was extrapolated from previous knowledge about the penetration 
behaviour of similar delivery vectors, which was then adjusted experimentally to best suit the 
method [62]. Although some studies suggest that the linearity condition for single point calibration 
can be avoided if the analyte amount in the evaluated samples is close to its amount in the 
calibration standard [61], the linearity over the samples’ concentrations range was verified by 
developing a three-point calibration curve in the range of 1 µg/mL to 7 µg/mL for method A and 
of 50 ng/mL to 3000 ng/mL for method B. In order to assess the reliability and reproducibility of 
the methods, the slope of the three-point calibration curve for each method was statistically 
compared across at least three intra-run measurements. One-way analysis of variance comparison 
suggested that the variations between the evaluated slopes were not significantly different 
(p<0.05), indicating the reproducibility and reliability of the generated quantitative data.  
5.4.5. Skin penetration study  
The developed methods were used to assess the cutaneous deposition and penetration 
behaviour of the three peptide-modified gemini surfactants after the topical application of P/G/L 
nanoparticles. The selection of gemini surfactants was based on: (i) the variation in their 
molecular structure and (ii) their differences in transfection efficiency profiles. Namely, 16-
7N(G-K)-16 was the lead compound with the highest transfection efficiency showing protein 
expression of 2.82 ±0.2 ng/ 15*103 in PAM 212 murine keratinocytes. On the other hand, 16-
7N(G-C11-K3)-16 demonstrated moderate transfection efficacy with protein expression of 1.73 
±0.2, while 16-7N(G-C6-K3)-16 had a low transfection ability of 1.09 ±0.1. The choice of the 
three compounds was based on a comprehensive evaluation of over 20 compounds (data not 
shown, manuscript in preparation). Table 5.5 displays the skin disposition and penetration 
parameters of the gemini surfactants obtained in accordance with the Organisation for Economic 
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Co-operation and Development (OECD) guideline for determining the dermal penetration of 
chemicals [32]. 
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Table 5.5. Skin disposition and penetration parameters of the evaluated peptide-modified gemini surfactants. Results are the average 
of five measurements. Abbreviations: Jss: the steady-state flux, tlag: the lag-time, Kp: the skin permeability coefficient, Dm: diffusion 
coefficient and Km: partition coefficient. 
 Skin tissues Skin penetration parameter (receptor compartment) 
Gemini 
Surfactants 
Applied 
dose 
(µg/cm2) 
Amount 
in skin 
(µg/cm2) 
± RSD 
(%) 
% 
Deposit-
ed in 
skin  
Total amount 
penetrated 
across skin 
(µg/cm2) ± 
RSD (%) 
% 
Penetrate
-d across 
skin 
Jss 
(ng/cm2/
h)  
t lag 
(h) 
Kp 
(cm/h) 
Dm 
(cm2/h) 
Km 
16-7N(G-K)-16 181.36 
 
20.30± 4 11.19 0.99± 0.01 0.55 50.59 5.0 2.79×10-4 2.70×10-4 0.93 
 
16-7N(G-C6-K3)-
16 
264.31 
 
10.45± 3 3.95 0.28±0.02  0.11 13.67 5.5 0.52×10-4 2.45×10-4 0.19 
16-7N(G-C11-
K3)-16 
277.46 
 
22.25 ± 5 8.02 0.86± 0.02 0.31 43.48 5.3 1.57×10-4 2.55×10-4 0.55 
 
2
3
3
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After 24 h of topical application, FIA–MS/MS analysis of the skin tissues revealed that 
3.95-11.19% of the applied dose of the three evaluated gemini surfactants was retained in the 
skin (Table 5.5). It is noteworthy that the detected amounts of gemini surfactants in the skin 
correlated with their transfection efficiency, where the lead compound 16-7N(G-K)-16 exhibited 
the highest skin deposition (11.19%) followed by 16-7N(G-C11-K3)-16 (8.02%) and the least 
performing compound 16-7N(G-K)-16 (3.95%). This could be explained by the gemini 
surfactants physicochemical properties, particularly lipophilicity and molecular size. In fact, it 
has been established in the literature that molecular size and hydrophobicity are the main 
determinants of dermal penetration suggesting that small hydrophobic compounds have a higher 
tendency to pass through the different layers of the skin [63, 64]. In the evaluated model 
compounds, the lead compound, 16-7N(G-K)-16, with the highest skin deposition had the 
smallest molecular size (M.Wt. 967.24 g/mol) among the tested compounds; in addition, it 
showed the highest lipophilicity (clog D= 1.0) at the intrinsic pH of the formulation (pH=6, Table 
5.4). However, while compound 16-7N(G-C6-K3)-16 has a smaller molecular size than 16-7N(G-
C11-K3)-16, it exhibited significantly less residence in the skin tissues (Table 5.5). This could be 
attributed to the significantly lower clog D value of the former (-2.7) compared to the latter (-0.6) 
at the formulation intrinsic pH of 6 (Table 5.4). This is in agreement with the reported trend in 
the literature where lower skin penetration is expected for compounds with higher molecular 
weight unless they have higher lipophilicity [65]. 
In addition to the lipophilicity and molecular size, several other parameters such as 
solubility might play a role in determining skin penetration ability. In the evaluated model 
compounds, skin penetration correlated negatively with the compounds’ aqueous solubility (clog 
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S at pH 6, Table 5.4). Lower aqueous solubility is usually associated with a higher ability to 
penetrate through the lipid-rich stratum corneum [66].  
Finally, the physicochemical parameters of the P/G/L nanoparticles could also affect the 
dermal delivery. For example, small particle size and lower surface charge usually translate into 
higher skin penetration due to their superior ability to move through the complex skin matrix [67, 
68]. Evaluation of the size and zeta potential of the P/G/L nanoparticles revealed that the lead 
compound, 16-7N(G-K)-16, exhibited the smallest particle size (85 ± 2 nm) and lowest zeta 
potential (34 ± 2 mV) among the tested compounds. On the other hand, compound 16-7N(G-C11-
K3)-16 had a particle size of 96 ± 1 nm and a zeta potential of 44± 1 mV while 16-7N(G-C6-K3)-
16 with the least skin disposition demonstrated the largest particle size and zeta potential, i.e., 
107 ± 3 nm and 52 mV, respectively.  
The cumulative amount of gemini surfactants that permeated across the skin into the 
receptor compartment increased progressively with time (Figure 5.5). After 24 h, only 0.11- 
0.55% of the applied dose was found in the Franz cell diffusion receptor compartment. This is an 
indication that the gemini surfactant-based gene delivery system could be suitable for the 
treatment of localized skin conditions like scleroderma or melanoma with minimum passing into 
the systematic circulation.  
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Figure 5.5: Cumulative amount of gemini surfactants (µg/cm2) penetrated across the skin into 
the Franz cell diffusion receptor compartment versus time curves. Results are the average of five 
measurements, error bars represent standard deviation. 
 
From the linear part of the curves plotted in Figure 5.5, the steady-state flux (Jss), the lag-
time (tlag), the skin permeability coefficient (Kp), diffusion coefficient (Dm) and partition 
coefficient (Km) were calculated (Table 5.5). The time required before the steady state absorption 
occurs denoted as tlag was around 5 - 5.5 h for all compounds. The compound with the highest 
skin penetration 16-7N(G-K)-16 demonstrated the shortest tlag of 5.0 h, followed by 16-7N(G-
C11-K3)-16 (tlag =5.3 h ), and 16-7N(G-C6-K3)-16, with tlag= 5.5 h (Table 5.5). Lag time is a 
reflection of the efficiency of the compound to pass through the different layers of the skin. 
Therefore, it is mainly influenced by the same parameters that determine skin permeability, 
namely lipophilicity, solubility, and molecular size [69]. While tlag inversely correlated with the 
clog D values at the formulation intrinsic pH, it directly correlated with clog S values (Table 5.4). 
The gemini surfactants’ net rate of transport, once equilibrium conditions have been reached, is 
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described by the steady-state flux (Jss). Similar to tlag, Jss is a representation of the efficiency of 
the compounds to penetrate the skin. As such, Jss is directly related to the total amount of gemini 
surfactants found in the Franz cell receptor compartment (Table 5.5).  
The permeability coefficient (Kp), which depicts the rate at which gemini surfactants 
penetrate the skin, diffusion coefficient (Dm), and partition coefficient (Km), are extracted from 
tlag and Jss (equations 2-4), thereby showing a direct relationship with the compounds’ 
hydrophobicity at the intrinsic pH, lipid solubility, and skin penetration ability (Table 5.4 and 
5.5). Reporting these parameters is not only valuable for drug delivery but it is also of significant 
interest for assessing the toxicity and occupational risk of the gemini surfactants [70]. 
5.5 Conclusion 
In this work, rapid and simple FIA‐MS/MS methods were developed for the relative 
quantification of three peptide-modified gemini surfactants in skin tissues as well as PBS 
solution. Combining the Folch liquid-liquid extraction protocol with weak cationic exchange 
SPE enhanced the extraction efficiency of gemini surfactants from the complex lipid-rich skin 
tissues. As such, proper sample preparation (i.e., clean extracts) eliminated the need for HPLC 
column, resulting in fast analysis in which all compounds eluted before 0.8 min with a total 
acquisition time of merely 4 min. In addition, single-point calibration was successfully 
employed, resulting in a significant reduction in the required time and resources for method 
development and sample analysis.  
The developed methods were applied to assess the skin deposition and skin penetration 
behavior of the evaluated gemini surfactants, generating data that could help in the design of 
more effective cutaneous lipid-based gene delivery vectors. The skin disposition and penetration 
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behavior of gemini surfactants heavily relied on their physicochemical properties, particularly 
their lipophilicity. Furthermore, it correlated with the transfection efficiency of the gemini 
surfactants. A favorable deposition in the skin with minimum escape into the PBS compartment 
(representing circulation) was observed, suggesting the feasibility of the delivery system in a 
topical application. The developed methods will be further utilized to probe the biodistribution 
and fate of topically applied therapeutic gemini surfactant formulations in animal models. Such 
knowledge is fundamental before any translation from laboratory to clinical evaluation.  
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CHAPTER 6 
General Discussions 
6.1. General discussion  
Gene therapy has emerged as a promising biotherapeutic approach aimed at improving 
health and combating diseases. In order to realize the full benefit of gene therapy, an effective 
gene delivery vector must overcome complex tissue and cellular barriers to deliver the 
therapeutic DNA into the targeted site efficiently without toxic side effects [1]. Gemini 
surfactants are entering the mainstream as an effective class of non-viral gene delivery carriers [2-
4]. Their unique molecular structure offer enhanced nucleic acid packaging abilities, promoting 
the assembly into nano-sized lipoplexes that favour cellular internalization [5]. Research efforts 
capitalized on bottom-up design flexibility of gemini surfactants to produce new compounds 
capable of conquering numerous biological barriers. Over the past two decades, several structural 
designs of gemini surfactants have emerged and were successfully utilized in the delivery of 
genetic materials both in vitro and in vivo [6-9].  
Despite their promising results [8-10], the transfection efficiency of gemini surfactants is 
still insufficient to encourage their translation into clinical applications. Moreover, concerns 
regarding the biocompatibility and biodegradability of gemini surfactants have recently been 
expressed [11]. Therefore, there is a need to design novel compounds capable of driving proficient 
expression of therapeutic genes without disrupting normal cell functions; such tasks can be 
achieved through rational modification of the basic structure of gemini surfactants. As such, my 
research evaluated, for the first time, a series of 22 peptide-modified gemini surfactants and 
conducted a systematic investigation of their physicochemical properties, cytotoxicity, 
transfection efficiencies, and tissue localization. My main goal was to assess the structure-
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activity relationship of the new compounds and to identify the fundamental architectural 
characteristics required for efficient and safe gene delivery.  
Cutaneous gene delivery is an attractive approach for treating various dermatological 
disorders with minimal systemic side effects [12]. The potential of gemini surfactant-based 
lipoplexes in delivering genetic material into the skin was previously evaluated, demonstrating 
their feasibility in overcoming skin barrier functions [6, 7, 13]. Upon topical application, gemini 
surfactants distribute within various skin layers and cellular compartments. While many studies 
focused on the development of new DNA carriers monitoring gene expression and overall 
toxicity, the fate and distribution of the delivery agent per se in the biological system has not 
been fully explored. In-depth understanding of the behavior of gemini surfactants in complex 
biological environments is essential for developing efficient and safe gene delivery systems. 
Therefore, my research also evaluated the skin deposition and penetration behaviour of three 
representative examples of the peptide-modified gemini surfactants. The selection of the 
representative compounds was based on variation in their chemical structure as well as 
differences in their transfection efficiency profiles. The purpose was to correlate the skin 
penetration efficiency to the compounds’ architectural characteristics, physicochemical 
properties and transfection efficiency profiles.   
In order to determine the skin deposition and penetration behaviour of the peptide-
modified gemini surfactants, a robust and sensitive bioanalytical method is required. The lack of 
any chromophore or fluorophore on the gemini surfactants and the existence of two permanently 
charged quaternary amine groups made mass spectrometry (MS) an ideal technique for the 
detection and quantification of gemini surfactants in complex biological matrices [14-17]. 
Therefore, understanding the collision induced dissociation-tandem mass spectrometric 
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behaviour (CID-MS/MS) of peptide-modified gemini surfactants is needed to ensure selective 
and specific identification of the gemini surfactants in the complex lipid-rich skin tissues. It also 
allows for the development of targeted quantification methods by choosing suitable diagnostic 
product ions. Accordingly, my research project assessed the MS/MS fragmentation behaviour of 
eleven compounds of the peptide-modified gemini surfactants. The generated data was later 
utilized to develop a multiple reaction monitoring (MRM) quantification method to assess the 
skin deposition and penetration behaviour of topically applied therapeutic gemini surfactant 
formulations. 
6.1.1. Molecular engineering of peptide-modified gemini surfactants  
The design of a new generation of peptide-modified gemini surfactants was motivated by 
the good transfection efficiency and relatively low cell toxicity of the previously developed 
amino acid-substituted gemini surfactant-based lipoplexes [18, 19]. Strategic modifications to the 
conjugated amino acid sequence grafted onto the spacer were carried out (Figure 3.2). Notably, 
we evaluated the impact of increasing the number of the terminal lysine moieties (Figure 3.2, 
compounds 1-3), considering the previous research findings that suggest the importance of  
terminal lysine moiety positioned on the spacer of gemini surfactant-based lipoplexes [19, 20]. To 
the best of our knowledge, such compounds represent the first dendrimer-like gemini surfactants. 
In addition, we evaluated the impact of altering the distance between the terminal lysine moieties 
and the quaternary ammonium head groups by incorporating a hydrocarbon linker of either a 
hexyl or undecyl chain (Figure 3.2, compounds 4-7). Finally, the effects of removing the glycine 
moiety grafted on the spacer while conjugating the hydrocarbon linker directly onto the spacer 
was investigated (Figure 3.2, compounds 8-11).  
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In general, the incorporation of peptides into the gemini surfactants spacer region 
improved transfection efficiency and reduced cytotoxicity. In particular, lipoplexes of the lead 
compound, 16-7N(G-K)-16, exhibited an 8-fold increase in the level of protein secretion in PAM 
212 and a 20% increase in cell viability compared to the first-generation unsubstituted gemini 
surfactants (Figures 3.8 and 3.9) [6]. Peptides are biocompatible and biodegradable structural 
motifs that render conformational flexibility to the gemini surfactants. They allow for a balanced 
binding properties with the nucleic acid which mediate both DNA compaction and subsequent 
release [19]. Moreover, the addition of peptides induced a pH-dependent increase in particle size 
and zeta potential (Figure 2.5), producing “intelligent” nanoparticles that respond to endosomal 
acidification to avoid lysosomal degradation [20]. Finally, the presence of terminal amino groups 
in the peptide backbone imparted a higher positive charge to the modified compounds, hence 
fewer gemini surfactant molecules are required to neutralize and compact the DNA. This was 
manifested by the lower optimal N/P ratio of 2.5 for peptide-modified gemini surfactants relative 
to N/P of 10 for first-generation unmodified gemini surfactants (Figure 2.2) [6]. 
Contrary to the theoretical expectations, increasing the number of terminal lysine 
moieties added into the spacer from mono- to tri- then to hepta-lysine residues resulted in 
reduction in the transfection efficiency and cell viability (Figure 3.8 and 3.9). Such observations 
are attributed to the collective effect of (i) increasing charge density, (ii) decreasing 
hydrophobicity and (iii) changing the compounds’ geometry. Both charge density and 
hydrophobicity play a role in the interaction with the DNA through the electrostatic and 
cooperative hydrophobic interactions [21]. Therefore, a balance between optimal charge density 
and hydrophobicity is needed to compact the DNA, maintain the stability of the complex during 
the delivery process, and facilitate the release of the DNA from the endosomal compartments. In 
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addition, a higher charge density of the compounds resulted in a higher zeta potential of the 
P/G/L nanoparticles (Table 3.2). Higher cationic charge is associated with greater tendency of 
rupturing the cell membrane and causing cell death [22].  
  With the increase in the number of amino acids in the peptide, the geometry of the gemini 
surfactants’ molecular shape transformed from compounds that prefer negative membrane 
curvature to compounds that favor positive curvature (Figure 3.3). This is mainly due to 
increasing the bulkiness of the functional groups incorporated into the spacer that caused an 
enlargement in the head group area of the compounds, altering their molecular packing 
parameter (Table 3.1).  The supramolecular assembly of the lipoplexes is highly dependent on 
the molecular packing parameter of its lipid components. In particular, compounds with 
molecular shapes that support the formation of a negative interfacial curvature exhibited greater 
tendency of maintaining the inverted hexagonal phase (H II) assembly (Figure 3.7), resulting in 
higher transfection efficiency (Figure 3.8). On the other hand, compounds that favor the 
formation of positive interfacial curvature distorted the HII phase at lower concentration of the 
gemini surfactants (N/P ≥ 5) and demonstrated lower transfection efficiency (Figures 3.7 and 
3.8).  
The impact of incorporating a hydrocarbon linker into the peptide chain on the 
transfection efficiency and cytotoxicity profile was dependant on the number of amino acids in 
the peptide chain. While the addition of a hydrocarbon linker reduced the transfection efficiency 
of compounds with di-peptides, it enhanced the transfection of those with greater number of 
amino acids (Figure 3.8). Furthermore, the incorporation of the hydrocarbon linker increased the 
cytotoxicity of compounds with di-peptides; however, the reverse was observed for compounds 
with hepta-lysine residues (Figure 3.9). Coupling hydrophobic linkers to compounds with a 
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mono-lysine moiety caused an unfavorable increase in their hydrophobicity, which resulted in 
higher cytotoxicity [23]. Vectors with high hydrophobicity could also cause a stronger interaction 
with the pDNA, hindering its subsequent release. On the contrary, the incorporation of a 
hydrocarbon linker to compounds with hepta-lysine residues resulted in favorable increases in 
hydrophobicity that prompted a balanced binding with the pDNA and better stability of the 
lipoplexes during the delivery process (Table 3.1). The decrease in cell toxicity is also attributed 
to the role of the hydrophobic linker in shielding the excess positive charges of the terminal 
lysine residues as attested by the lower zeta potential of the lipoplexes (Table 3.2). Removing the 
glycine moiety while incorporating a hydrocarbon linker directly into the spacer did not result in 
any obvious changes (Figure 3.8). This was in agreement with previously reported behaviors of 
mono- and di-amino acid-modified gemini surfactant-based lipoplexes [19]. 
The introduced series of peptide-modified gemini surfactants also examined the role of 
the alkyl tails on transfection efficiency. In particular, three hydrophobic tails that differ in their 
length and degree of unsaturation were evaluated; namely dodecyl, hexadecyl and oleyl (Figures 
2.1A and 3.2). In vitro evaluation revealed that the highest transgene activity was observed in 
compounds with hexadecyl tails (Figures 3.8). In fact, it showed a 5-10 fold increase in the level 
of reporter protein in compounds with di-peptides compared to its analogues with dodecyl and 
oleyl carbon-tail evaluated in a COS-7 cell-line (Figures 2.2). These observations are linked to 
the: (i) hydrophobicity of the compounds’ and (ii) geometry of the compounds’ tails relative to 
that of the helper lipid. Firstly, hexadecyl tails are more hydrophobic than dodecyl ones, 
rendering a lower CMC value that will increase the stability of the lipoplexes during the delivery 
process [24]. Secondly, the geometry of the alkyl tail controls the membrane fluidity of the 
nanoparticle, which impacts critical steps such as membrane fusion and endosomal escape [25]. 
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The geometry of unsaturated hydrophobic tails hampers the packing of lipids at the molecular 
level, conferring a higher membrane fluidity relative to saturated tails [151, 152]. Therefore, 
mixing unsaturated lipids with the helper lipid, DOPE, which is also composed of an unsaturated 
hydrophobic tail, might result in a loose packing arrangement of the P/G/L lipoplexes. 
Accordingly, formulations prepared by mixing a saturated and unsaturated lipid together resulted 
in the highest transfection efficiency compared to formulations prepared from mixing either two 
saturated or two unsaturated lipids [26]. 
In summary, a balance between the hydrophilic and hydrophobic features of the peptide-
modified gemini surfactants lead to parameters conducive to the gene delivery process. My work 
lays a foundation for the advancement of peptide-based gemini surfactants towards clinical 
applications.  
6.1.2. Mass spectrometric analysis of peptide-modified gemini surfactants 
Mass spectrometric analysis of the peptide-modified gemini surfactants was conducted to 
(i) confirm their projected molecular composition, (ii) assess their MS/MS dissociation 
behaviour and (iii) identify unique diagnostic product ions for each compound. This was 
achieved by using a combination of high-resolution single-stage (MS), tandem (MS/MS) and 
multi-stage (MS3) analysis.  While a hybrid quadrupole orthogonal time-of-flight mass 
spectrometer (QqToF-MS) was used to conduct single-stage MS analysis, a triple quadrupole-
linear ion trap mass spectrometer (QqQLIT-MS) was used to perform tandem and multi-stage 
MS analysis.  Both instruments were operated in the positive ionization mode and were equipped 
with electrospray ionization (ESI).   
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High-resolution single-stage MS analysis confirmed the projected molecular structure of 
the 11 evaluated peptide-modified gemini surfactants by assessing their exact masses (Table S1, 
Appendix III). Two-point external calibration prior to the analysis of the peptide-modified 
gemini surfactants produced mass accuracies of less than 8 ppm, which were comparable to 
those attained using internal calibration in a previous work by our group that assessed mono-
amino acid and di-amino acid-substituted gemini surfactants [27]. The generation of compound-
specific product ions upon MS/MS analysis authenticated the chemical structure of their 
precursor ions (Tables 4.1 and 4.2). Further confirmation of the genesis of the produced product 
ions was achieved by MS3 analysis (Table S2, Appendix III). Such a comprehensive analysis 
allowed for the development of compound-specific CID-MS/MS fingerprint for rapid and 
accurate identification of these compounds in complex matrices (Figure 4.2).  
MS/MS analysis of the peptide-modified gemini surfactants revealed that the presence of 
amino acids on the compounds structure defined peptide-related dissociation characteristics, 
which was remarkably different compared to traditional gemini surfactants [14, 28]. In particular, 
the formation of pipecolic acid at the N-terminus part of the gemini surfactants was a unique 
observation for these structural family.  It resulted from the neutral loss of ammonia on the 
amino acids’ side chain (Figure S1, Appendix III).  Furthermore, a protonated α-amino-ε-
caprolactam ion and its complimentary c-terminus ion was generated as a result of an amide 
bond cleavage initiated by a nucleophilic attack of the lysine side chain (Figure 4.3). The 
compounds also demonstrated a typical gemini surfactants dissociation pattern such as the 
elimination of one or both of the quaternary aminium head groups and the attached aliphatic tail 
(Figures 4.5- 4.7).  
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Structural features such as the length of the inserted hydrocarbon linker and the number of 
terminal amino acid residues determined the dissociation behaviour. For instance, gemini 
surfactants with a longer hydrophobic linker chain (C11) and with tri-terminal amino acids 
residues were the only compounds that produced the triply charged initial product ions after the 
elimination of a terminal lysine moiety (Figure 4.4). However, similarities in the dissociation 
behaviour of peptide-modified gemini surfactants allowed for the establishment of a universal 
MS/MS fragmentation pathway (Figure 4.9). Such a pathway could be applied to predict the 
dissociation behaviour of new families of compounds with similar general structural features. 
The generated MS/MS data was utilized for the development of targeted MRM quantification 
methods to probe the skin deposition and penetration behaviour of topically applied gemini 
surfactant-based formulations. 
6.1.3. Cutaneous distribution of peptide-modified gemini surfactants  
The success of developing efficient and safe gemini surfactant-based gene delivery 
systems for cutaneous application requires a thorough understanding of their skin deposition and 
penetration behaviour. Furthermore, correlating the behaviour of gemini surfactants in complex 
biological environments to their structural features and transfection efficiency is an essential 
aspect in guiding the design of future gemini surfactants. Therefore, skin penetration and 
deposition behaviour of three structurally distinct peptide-modified gemini surfactants (Figure 
5.2) with varying transfection efficiency profiles were evaluated on CD1 mice dorsal skin tissue 
mounted in a Franz diffusion cell. After 24 h of topical application, the remaining gemini 
surfactant-based formulation in the Franz cell’s donor chamber were discarded, while the skin 
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tissues and the PBS in the receptor compartment (mimicking blood circulation) were collected 
for MS analysis.  
The first step in the analysis process is the selection of an appropriate sample preparation 
approach to extract gemini surfactants from the skin tissues as well as the PBS. Skin as a matrix 
posed an analytical challenge due to the presence of a wide variety of interfering substances such 
as proteins, salts and skin endogenous lipids. The latter group, in particular, required careful 
consideration owing to the resemblance in their structure and physicochemical properties to the 
gemini surfactants. Such a challenge emphasized the importance of optimizing sample 
preparation to obtain reliable and reproducible data. Accordingly, extraction of the gemini 
surfactants from the skin followed three steps: (i) tissue homogenization, (ii) liquid-liquid 
extraction and (iii) purification using solid phase extraction (SPE).  
 I conducted systematic evaluation of extraction procedures for the gemini surfactants 
using five liquid-liquid extraction protocols (Figure 5.3): Folch [29], B&D [30], Acidified B&D [31], 
Alkaline B&D [32] and MTBE [33]. The Folch method achieved the highest extraction efficiency 
for all compounds (Table 5.3). This was attributed  to the presence of a higher ratio of 
chloroform in the Folch method that has an intermediate polarity (polarity index of 4.1), making 
it suitable to extract the gemini surfactants [34]. Extraction with MTBE was the least effective in 
all compounds (Table 5.3), probably due to  its low polarity index of 2.5 [34]. Finally, weak 
cationic exchange SPE was efficient in isolating the positively charged gemini surfactants from 
endogenous skin lipids, minimizing matrix effects. The same SPE procedure was used to extract 
gemini surfactants from the PBS solution.  
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The development of an efficient sample preparation strategy eliminated the need for 
chromatographic separation, allowing direct introduction of the sample into the MS using flow 
injection analysis (FIA). This offered simplicity and rapid sample processing in which the total 
acquisition time was merely 4 min (Figure 5.4A). The elution time at 0.8 min was about 9 times 
faster than even less polar compounds (amine substituted gemini surfactants) in the recently 
developed HILIC-based LC-MS/MS quantification method [17]. By selecting two diagnostic 
product ions with relatively high abundance (Table 5.2), we capitalized on the QTRAP capability 
in the MRM scan mode to achieve adequate selectivity and specificity (Figure 5.4 B and C). 
Furthermore, the use of an isotopically labelled internal standard bearing four deuterium atoms 
for each compound prevented any cross talk, improving accuracy and precision. Since the aim of 
this work is to conduct a relative comparison among three gemini surfactants, a single point 
calibration technique was selected to develop the quantitative approach. Such a strategy also 
reduced the required time and cost of analysis compared to the traditional multi-point calibration 
[35]. For each compound, two methods were developed for their detection and relative 
quantification in skin tissue and in PBS solution.  
FIA-MS/MS analysis revealed that the three assessed peptide-modified gemini 
surfactants were detected in the skin with minimal partition into the PBS compartment, 
suggesting the suitability of the delivery system to be used for topical application. (Table 5.5). 
Their skin deposition and penetration behaviour was dependent on the lipophilicity and 
molecular weight of the compounds. Furthermore, the physicochemical parameters of the P/G/L 
nanoparticle such as size and zeta potential affected the dermal penetration where smaller 
particle size and low zeta potential resulted in higher penetration.   
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6.2. Conclusion 
Peptide-modified gemini surfactants showed a potential as an effective gene delivery 
system for the treatment of fibrotic skin conditions. A balance between the hydrophilic and 
hydrophobic characteristics of the gemini surfactants is essential since it produces 
physicochemical parameters conducive to the gene delivery process. Furthermore, geometrical 
consideration of the compounds controls their transfection efficiency. The number of terminal 
amino acids and the length of the hydrocarbon linker drove the MS/MS dissociation behavior of 
the compounds. The lipophilicity and molecular weight of the compounds were the main 
determinants of their skin deposition and penetration behavior. My results indicated a direct 
correlation between the skin penetration ability and the transfection efficiency profile. This work 
identifies some of the fundamental structural requirements (mono lysine residue and absence of 
hydrocarbon linker) needed for efficient gene delivery vehicle, providing a framework for future 
development of peptide-modified gemini surfactant-based gene delivery system.  
6.3. Future directions 
The ultimate goal of my research is to develop a more efficient and less toxic gemini 
surfactant-based gene delivery system with potential application in the treatment of fibrotic skin 
conditions. The introduced peptide-modified gemini surfactant-based lipoplexes demonstrated an 
enhanced transfection efficiency and reduced cytotoxicity. In addition, gemini surfactants 
showed a favorable deposition in the skin with minimum penetration into the receptor chamber 
(representing circulation), suggesting the feasibility of the delivery system to be used for topical 
application. The promising results of my research lay a foundation for future research directions 
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to focus on translating the gemini surfactant-based gene delivery system into clinical 
applications.  
The extensive physicochemical characterization of the 22 peptide-modified gemini 
surfactant-based lipoplexes conducted in my research provided information about the 
fundamental requirements for efficient gene delivery system. However, further characterization 
could allow for the determination of other essential characteristics. This includes the use of 
circular dichroism and atomic force microscopy to assess the interaction of gemini surfactants 
with the pDNA and the shape of the lipoplexes. In addition, the use of grazing-incidence small-
angle scattering (GISAS) will evaluate the effects of structural variations on the interaction of the 
delivery system with a cell membrane model. The effect of structural variation of the peptide-
modified gene delivery system on the method of cellular entry should also be evaluated.  
Evaluation of the transfection efficiency of the gene delivery system in vitro represents 
an excellent start for the screening of novel vectors. However, it does not account for the 
complications associated with the in vivo environment. Therefore, the developed peptide-
modified gemini surfactant-based gene delivery systems should be further evaluated in an animal 
model to assess the correlation between in vitro and in vivo data. The long-term goal is to 
develop a structure-activity relationship model that could be used to predict the in vivo efficiency 
of the gene delivery nanoparticles based on structural information and physicochemical 
parameters.  
The next step is to evaluate the delivery system in a diseased animal model such as 
scleroderma to assess clinical relevance. Optimization of the treatment regimen should be 
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conducted to assess optimal dose, dose frequency and duration of the treatments. Toxicological 
studies should also be performed to evaluate the safety of the delivery system.  
The ex-vivo assessment of skin deposition and penetration behaviour conducted in my 
research provides basic evidence about the favorable deposition of gemini surfactants in skin 
tissues. However, tracking the fate and biodistribution of topically applied gemini surfactant-
based gene delivery systems in animal models is essential before any translation into clinical 
applications. Correlating the tissue distribution and degradation profile of gemini surfactants to 
their chemical structure and physicochemical characteristics will provide insights into the 
rational design process to produce compounds with higher efficiency and reduced toxicity. This 
will benefit from the extraction protocols and the FIA-MS/MS methods developed in my work 
(Chapter 5).  
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APPENDICES 
Appendix I 
  
Figure S1.  Evaluation of COS-7 cell viability of P/G/Ls formulated with 16-7N(G-K)-16 at N/P 
ratios of 2.5 and 5 using MTT assay  after 48 h of treatment compared to commercial 
transfection agent (lipofectamine). Results are the average of three plates of quadruplicate wells, 
error bars represent standard deviation. * Indicates significant at p < 0.05. 
 
Figure S2.  Pressure-area isotherms of the gemini surfactants and DOPE at 22°C, pH= 6.6.  
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Table SI. Scattering peak position and the corresponding a spacing for nanoparticles containing 
DNA/ gemini  surfactants/ DOPE, where gemini were either 12-7N(G-K)-12 or 16-7N(G-K)-16 
or 18:1-7N(G-K)-18:1 at six N/P ratios each. 
Gemini type N/P 
Ratio 
q10 (Å -1) q11 (Å -1) q20 (Å -1) a (Å ) 
12-7N(G-K)-12 
 
 
 
 
 
1 0.102 0.177 0.204 71.130 
2.5 0.101 0.174 0.200 71.833 
5 0.097 0.167 0.192 74.795 
10 0.101   NA 
15 0.100   NA 
20 0.099   NA 
16-7N(G-K)-16 
 
 
 
 
 
1 0.103 0.179 0.205 70.438 
2.5 0.102 0.177 0.203 71.129 
5 0.098 0.167 0.193 74.032 
10 0.100   NA 
15 0.099   NA 
20 0.099   NA 
18:1-7N(G-K)-18:1 
 
 
 
 
 
1 0.104 0.180 0.208 69.761 
2.5 0.102 0.177 0.205 71.129 
5 0.100 0.174 0.201 72.551 
10 0.098 0.169 0.194 74.03 
15 0.097 0.168 0.194 74.795 
20 0.097 0.167 0.193 74.795 
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Appendix II 
Table S1: Scattering peak position and the corresponding a spacing for P/L/G lipoplexes at three 
N/P ratios. 
 
 
Gemini type  N/P Ratio q10 (Å -1) q11 (Å -1) q20 (Å -1) a (Å ) 
16-7N(G-K)-16 
2.5 0.100 0.174 0.201 72.552 
5 0.098 0.169 0.205 74.033 
10 0.101    
16-7N(G-K3)-16 
2.5 0.099 0.171 0.199 73.285 
5 0.102    
10 0.103    
16-7N(G-K7)-16 
2.5 0.100 0.173 0.200 72.552 
5 0.103    
10 0.103    
16-7N(G-C6-K)-16 
2.5 0.102 0.177 0.204 71.130 
5 0.100 0.172 0.199 72.552 
10 0.100    
16-7N(G-C11-K)-16 
2.5 0.099 0.172 0.199 73.285 
5 0.097    
10 0.098    
16-7N(G-C6-K3)-16 
2.5 0.100 0.173 0.200 72.552 
5 0.100 0.172 0.199 72.552 
10 0.099    
16-7N(G-C11-K3)-16 
2.5 0.100 0.172 0.199 72.552 
5 0.102    
10 0.103    
16-7N(C6-K3)-16 
2.5 0.101 0.174 0.201 71.834 
5 0.100 0.176 0.199 72.552 
10 0.101    
16-7N(C11-K3)-16 
2.5 0.100 0.173 0.200 72.552 
5 0.100 0.172 0.199 72.552 
10 0.098    
16-7N(C6-K7)-16 
2.5 0.101 0.176 0.204 71.834 
5 0.101    
10 0.100    
16-7N(C11-K7)-16 
2.5 0.101 0.175 0.203 71.834 
5 0.101 0.176 0.202 71.834 
10 0.102    
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Figure S1: In vitro transfection of PAM 212 cells comparing the level of IFN-γ expression of the peptide-modified gemini surfactants 
after 72 h of treatment. Results are the average of three plates of quadruplicate wells, error bars represent standard deviation.  
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Figure S2: In vitro transfection of COS-7 cells comparing the level of IFN-γ expression of the three gemini surfactants after 48 h of 
treatment. Results are the average of three plates of quadruplicate wells, error bars represent standard deviation.  
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Figure S3: Evaluation of COS-7 cell viability at three different N/P ratios of the tested gemini surfactants using MTT assay after 48 h 
of treatment. Results are the average of three plates of quadruplicate wells, error bars represent standard deviation. 
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Appendix III 
Table S1. Mass accuracies of the triply charged ions [M+H] 3+ obtained during single stage ESI-
QqToF-MS. 
  
Gemini surfactants Molecular formula Theoretical, m/z Observed, m/z Mass accuracy (ppm)  
12-7N(G-C11-K3)-12 C65H136N11O5 383.6903 383.6895 2.124 
16-7N(G-C11-K3)-16 C73H152N11O5 421.0653 421.0633 4.945 
16-7N(G-C11-K)-16 C61H128N7O3 335.6687 335.6693 1.668 
12-7N(G-C6-K3)-12 C60H126N11O5 360.3308 360.3344 5.555 
16-7N(G-C6-K3)-16 C68H142N11O5 397.7059 397.7076 4.11 
12-7N(G-C6-K)-12 C48H101N7O3 274.9342 274.9356 4.887 
16-7N(G-C6-K)-16 C56H118N7O3 312.3093 312.3098 1.526 
12-7N(C11-K3)-12 C63H133N10O4 364.6831 364.6828 0.988 
16-7N(C11-K3)-16 C71H149N10O4 402.0582 402.0593 2.667 
12-7N(C6-K3)-12 C58H123N10O4 341.3237 341.3257 5.73 
16-7N(C6-K3)-16 C66H139N10O4 378.6988 378.7015 7.101 
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Figure S1. The ESI-QqToF MS/MS spectrum of 16-7N(C11-K3)-16 as a representative example 
of gemini surfactants with tri-terminal lysine moieties. Ions were labelled as designated in 
Figures 5-7.  
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Figure S2. The proposed mechanism for the formation of product ion (C): loss of ammonia 
group from the lysine side chain.  
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Table S2. Summary of MS3 analysis for 16-7N(C11-K3)-16 gemini surfactants. 
 
Precursor 
ion 
MS/MS product 
ions  
Ms3 product ions  
402.05 538.54 [A] 806.76 [2], 403.88 [2`], 270.31 [1], 537.44 [3], 269.23 [3`], 
129.10 [b1], 678.66 [4], 339.83 [4`], 520.42 [5], 260.71 [5`], 
409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8] 
 359.36 [B] 353.68 [9], 474.49 [10], 129.10 [b1], 678.66 [4], 339.83 [4`], 
270.31 [1], 410.44 [11], 550.57 [12], 275.79 [12`], 281.26 [8] , 
270.31 [1] 
 396.38 [C] 538.54 [A], 359.36 [B], 390.70 [13], 306.61 [14], 216.84 [15`], 
324.76 [15], 300.94 [16], 316.25 [17], 211.17 [17`], 353.68 
[9], 530.02 [9`], 789.73 [18], 395.37 [18`], 263.91 [18``], 
474.49 [10], 537.44 [3], 269.23 [3`],  520.42 [5], 260.71 [5`], 
270.31 [1], 129.10 [b1] 
 129.10 [b1]  
 270.31 [1]  
 806.76 [2] 537.44 [3], 678.66 [4], 129.10 [b1], 270.31 [1], 520.42 [5], 
409.35 [6], 281.26 [8] 
 403.88 [2`] 537.44 [3], 269.23 [3`],129.10 [b1], 678.66 [4], 339.83 [4`], 
270.31 [1], 520.42 [5], 260.71 [5`], 409.35 [6], 205.18 [6`], 
196.67 [7], 281.26 [8] 
 537.44 [3] 520.42 [5], 409.35 [6], 281.26 [8] 
 269.23 [3`] 260.71 [5`], 409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8], 
129.10 [b1] 
 678.66 [4] 409.35 [6], 281.26 [8], 129.10 [b1], 270.31 [1] 
 339.83 [4`] 409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8], 129.10 [b1], 
270.31 [1] 
 520.42 [5] 409.35 [6], 281.26 [8] 
 260.71 [5`] 409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8], 129.10 [b1] 
 409.35 [6] 281.26 [8] 
 205.18 [6`] 196.67 [7], 281.26 [8], 129.10 [b1] 
 196.67 [7] 281.26 [8] 
 281.26 [8]  
 353.68 [9] 474.49 [10], 678.66 [4], 339.83 [4`], 474.49 [10], 409.35 [6], 
205.18 [6`], 129.10 [b1], 270.31 [1], 196.67 [7], 281.26 [8], 
395.37 [18`], 263.91 [18``], 520.42 [5], 260.71 [5`] 
 530.02 [9`] 789.73 [18], 395.37 [18`], 520.42 [5], 260.71 [5`], 409.35 [6], 
205.18 [6`], 196.67 [7], 281.26 [8] 
 474.49 [10] 678.66 [4], 339.83 [4`], 270.31 [1], 410.44 [11] , 409.35 [6], 
205.18 [6`], 129.10 [b1], 550.57 [12], 275.79 [12`], 281.26 [8]  
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 410.44 [11] 550.57 [12], 275.79 [12`], 270.31 [1], 281.26 [8] 
 550.57 [12] 281.26 [8] 
 275.79 [12`] 281.26 [8] 
 390.70 [13] 300.94 [16], 316.25 [17], 211.17 [17`], 353.68 [9], 530.02 [9`], 
789.73 [18], 395.37 [18`], 263.91 [18``], 474.49 [10], 520.42 
[5], 260.71 [5`], 409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8], 
129.10 [b1], 270.31 [1] 
 306.61 [14] 216.84 [15`], 324.76 [15], 300.94 [16], 316.25 [17], 211.17 
[17`], 395.37 [18`], 263.91 [18``], 520.42 [5], 260.71 [5`], 
537.44 [3], 269.23 [3`],129.10 [b1], 270.31 [1] 
 324.76 [15] 316.25 [17], 537.44 [3], 520.42 [5], 409.35 [6], 281.26 [8] 
,129.10 [b1] 
 216.84 [15`] 211.17 [17`],269.23 [3`], 260.71 [5`], 129.10 [b1] 
 300.94 [16] 395.37 [18`], 263.91 [18``], 520.42 [5], 260.71 [5`], 409.35 [6], 
205.18 [6`], 196.67 [7], 281.26 [8], 129.10 [b1], 270.31 [1] 
 316.25 [17] 520.42 [5], 409.35 [6], 281.26 [8] 
 211.17 [17`] 260.71 [5`], 409.35 [6], 205.18 [6`], 196.67 [7], 281.26 [8], 
129.10 [b1] 
 789.73 [18] 520.42 [5], 409.35 [6], 281.26 [8], 
 395.37 [18`] 520.42 [5], 260.71 [5`], 409.35 [6], 205.18 [6`], 196.67 [7], 
281.26 [8], 129.10 [b1]  
 263.91 [18``] 260.71 [5`], 205.18 [6`], 196.67 [7], 281.26 [8], 129.10 [b1] 
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Figure S3. The ESI-QqLIT-MS3 spectrum of product ion (C) at m/z 396.38 of 16-7N(C11-K3)-
16 gemini surfactant. Ions were labelled as designated in Figures 7.  
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Figure S4. The ESI-QqLIT-MS/MS spectrum of (A) 16-7N(G-C11-K3)-16 and (B) its deuterated 
version 16-7N(G-C11-KD-K2)-16 showing the similarities in the fragmentation patterns. Ions 
were labelled as designated in Figures 5-7.  
A 
B 
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Appendix IV 
 
Table S1.  Equivalent analytes final mass concentrations in the single point calibration 
standards.  
 
 
 
 
 
 
 
 
 
 
 
Calibration standard final mass 
concentration 
Gemini surfactant 
Methods A’s 
(µg/mL) 
Methods B’s 
(ng/mL) 
16-7N(G-K)-16 3.86 580.34 
16-7N(G-C6-K3)-16 2.81 422.90 
16-7N(G-C11-K3)-16 5.91 887.87 
16-7N(G-Kd4)-16 1.94 388.47 
16-7N(G-C6-Kd4-K2)-16 1.4137 282.73 
16-7N(G-C11-Kd4-K2)-16 2.9676 593.52 
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Figure S1. Chemical structure of the internal standards’ precursor ion and the monitored product ion of 16-7N(G-Kd4)-16 (A), 16-
7N(G-C6-Kd4-K3)-16 (B) and 16-7N(G-C11-Kd4-K3)-16.  
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